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1 ERBB signaling
The ERBB family of receptor tyrosine kinases consists of four members denoted EGFR (also 
known as ERBB1), ERBB2, ERBB3 and ERBB4, which are able to form homo- and 
hetero-dimeric complexes upon ligand binding. ERBB2 is an orphan receptor, which 
functions by forming heterodimers with other ligand-activated ERBB receptors, including 
the catalytically inactive ERBB3 receptor (1, 2). There are multiple groups of ligands that 
bind the ERBB receptors. The first group of ligands includes EGF, TGFα and amphiregulin, 
which bind specifically to EGFR. The second group comprises betacellulin, HB-EGF and 
epiregulin, which show dual specificity towards EGFR and ERBB4. The third group is 
composed of the neuregulins (NRG) that can bind to ERBB3 and ERBB4 (NRG1 and NRG2) 
or to ERBB4 alone (NRG3 and NRG4) (3). Binding of ligand induces conformational changes, 
which facilitate receptor dimerization and enhanced tyrosine kinase activity. The resulting 
autophosphorylation of receptor intrinsic tyrosine residues forms the trigger for activation 
of downstream signal transduction cascades that couple ERBBs to cellular responses, such 
as proliferation, differentiation, migration, survival and tissue development in many 
different organs (1). While EGFR plays an essential role during epithelial-cell development 
(4, 5), ERBB2 has been demonstrated to be important in the development of the heart (6), 
central (7) and peripheral (8) nervous system and in mammary gland morphogenesis (9), 
while ERBB3 and ERBB4 are essential for cardiac and neural development (10, 11).
2 ERBBs in cancer
Apart from their role in normal physiology, EGFR, ERBB2 and ERBB3 are also frequently 
involved in the formation of solid tumors. Ectopic or overexpression of ERBB receptors or 
their ligands, as well as mutation or poor downregulation of these receptors, can lead to 
enhanced cellular proliferation, survival and migration, thereby resulting in a variety of 
human cancers (12, 13). Indeed, overexpression of EGFR is associated with breast-, bladder-, 
prostate- and non-small-cell lung cancers as well as brain tumors, of which gliomas are 
the most common. Moreover, overexpression of EGFR results in higher proliferation rates 
of tumor cells  and is often correlated with a higher grade of the tumor at diagnosis and a 
worse prognosis for patients (1, 14). ERBB2 overexpression is often observed in breast and 
ovarian cancers, where it is associated with increased tumor size, enhanced spreading of 
the tumor, resistance to anti-estrogen therapy and poor prognosis (15). ERBB2 
overexpression can trigger shedding of its extracellular domain resulting in ligand-inde-
pendent activation of the ERBB2 kinase domain (16). The catalytically inactive ERBB3 is 
expressed in several cancers and although overexpression of ERBB3 is not frequently 
observed, ERBB2-ERBB3 heterodimers appear to play an important role in oral squamous 
cell carcinoma (17). Relatively little is known about the cancer biology of ERBB4. Some 
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Accumulating evidence suggests that endosomal trafficking and lysosomal targeting are 
mediated in part by ERBB receptor (poly-)ubiquitination (2). The concerted action of E1 
ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases 
is responsible for the attachment of ubiquitin to activated ERBB receptors (see below). 
Apart from the role of ubiquitination in normal ERBB receptor physiology, various 
oncogenic mutations in the EGFR are associated with impaired recruitment of E3 ligases 
and, consequently, impaired ERBB receptor ubiquitination (30). Furthermore, enhanced 
ERBB ubiquitination is observed in association with various anti-ERBB receptor therapies. 
Indeed, the anti-tumor antibody  trastuzumab recruits E3 ligase C-CBL to ERBB2, leading to 
enhanced ubiquitination and degradation (31, 32). Furthermore, several tyrosine kinase 
inhibitors have been demonstrated to enhance ubiquituination and accelerate endo- 
cytosis and subsequent degradation of ERBB2 (14). Moreover, treatment of cells with the 
HSP-90 inhibitor 17-AAG recruits the E3-ligases CHIP to ERBB2, resulting in enhanced 
ubiquitination and degradation of ERBB2 (33). Thus, better understanding of the role of 
ERBB receptor ubiquitination in endosomal trafficking and normal physiology may lead to 
the development of improved or innovative anti-ERBB therapies. 
3 Ubiquitin-dependent degradation pathways
3.1 The ubiquitination cascade
Ubiquitination is a post-translational protein modification whereby lysine residues covalently 
bind the 76 amino acids polypeptide ubiquitin. Ubiquitin is attached via its C-terminal 
glycine residue to the e-NH2 lysine side chain of the substrate, resulting in an isopeptide 
bond or it can be attached to the a-NH2 group resulting in a peptide bond. This reaction is 
performed by a three-step enzymatic cascade. First, a ubiquitin-activating enzyme (E1) 
forms a thiol-ester bond with the carboxy-terminal glycine of ubiquitin in an ATP-dependent 
process. Then, the E1 transfers the ubiquitin C-terminus to the catalytic cysteine residue of a 
ubiquitin-conjugating enzyme (E2). Finally, a ubiquitin protein ligase (E3) catalyses the 
transfer of ubiquitin from the E2 enzyme to the lysine side chain of the substrate (figure 1). 
The human genome encodes two ubiquitin-activating E1 enzymes, 37 ubiquitin-conjugating 
E2 enzymes and over 600 E3 ubiquitin ligases (34). Mono-ubiquitination is the attachment 
of a single ubiquitin on a single lysine residue, whereas multi-ubiquitination is mono- 
ubiquitination on multiple lysine residues of a substrate protein. Poly-ubiquitin chains are 
formed when ubiquitin is attached to one of seven (K6, K11, K27, K29, K33, K48, K63) lysine 
residues of ubiquitin itself or when linear ubiquitin chains are formed via head-to-tail peptide 
bonds (35). All these different polyubiquitin chain linkages have been observed in vivo (36) 
and there is even evidence for the existence of mixed polyubiquitin chains (35, 37, 38). 
 Various forms of mono-, multi- and poly-ubiquitination are associated with a variety 
of cellular functions. Mono- and multi-ubiquitination have been shown to be sufficient as 
reports demonstrate that overexpression of ERBB4 promotes breast cancer cell proliferation 
and results in cellular transformation of fibroblasts (18, 19). In contrast, others have reported 
that ERBB4 activation correlates with decreased cell growth, coupled to differentiation 
and induction of cell cycle arrest as well as stimulation of apoptosis (20-22). 
 The central role of ERBB signaling in the generation of solid tumors has made the 
ERBB network one of the main targets for anti-tumor therapies in humans (12, 23). Several 
antibodies directed against the extracellular domain of individual ERBBs and small 
molecule tyrosine kinase inhibitors that compete with ATP for binding to the ATP binding 
cleft of their catalytic receptor domain are in clinical use or in advanced trials. The in vitro 
treatment of tumor cells with these agents affects many of the intracellular pathways that 
are involved in cancer development and progression and a few studies demonstrate that 
these pathways are downregulated in tumors from treated patients (23). Trastuzumab 
(Herceptin) is a humanized monoclonal antibody directed to the extracellular domain of 
ERBB2, which has been approved for the treatment of patients with ERBB2-overexpressing 
breast cancer (12, 24). Trastuzumab downregulates ERBB2 from the cell surface, but also 
reduces the number of cells in S phase (25) while in addition it recruits and activates 
immune effector cells to the ERBB2-overexpressing tumor (26). More recently, pertuzumab 
(Omnitarg), an antibody that prevents heterodimerization of ERBB2 with other ERBB 
receptors, has been approved for treatment of estrogen insensitive breast cancer (27). 
Cetuximab (Erbitux) is an antibody that targets EGFR and promotes EGFR internalization 
and downregulation. This antibody is used for treatment of colorectal cancer and, in 
combination with radiation therapy, for treatment of head and neck cancer (28). The 
tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) are ATP analogues that 
inhibit EGFR autophosphorylation and have been approved for treatment of NSCLC (non-
small-cell lung cancer). A third tyrosine kinase inhibitor is lapatinib, which displays 
specificity against both EGFR and ERBB2 and has been approved for treatment of breast 
cancer (28). 
 During normal physiology ERBB signaling is terminated by receptor-mediated 
endocytosis of the ligand-receptor complex and subsequent degradation by the lysosome 
(29). Uncontrolled ERBB signaling can result from increased receptor expression in 
combination with overexpression of ligands, or from activating mutations in the 
transmembrane, tyrosine kinase or cytoplasmic domains of the receptor resulting in 
enhanced signaling and/or decreased receptor downregulation. For example, the  EGFRvIII 
mutant which lacks the dimerization arm and part of the ligand-binding domain due to 
an in frame deletion, has been shown to be constitutively active and to be poorly 
downregulated (1, 12, 14). Stimulation of ERBB endocytosis and lysosomal degradation 
could therefore be an attractive strategy to inhibit tumor growth, as illustrated by the 
observation that the antibodies trastuzumab and cetuximab trigger ERBB endocytosis, 
although definitive proof is lacking that this causes the observed inhibition in tumor 
growth.
1CHAPTER 1 GENERAL INTRODUCTION
12 13
a signal for ligand-mediated endocytosis of plasma membrane receptors and to trigger 
sorting of internalized receptors into intralumenal vesicles (ILVs) of multi-vesicular bodies 
(MVBs) leading to subsequent degradation in lysosomes (39-42). K48-linked poly- 
ubiquitination serves as a signal for proteasomal degradation (43), whereas K63-linked 
 poly-ubiquitination has been shown to regulate non-proteosomal processes such as DNA 
repair, kinase activation, translational regulation and endosomal sorting (44). In addition, 
both mono-ubiquitination and K63-poly-ubiquitination has been implicated in endosomal 
sorting and lysosomal targeting (45). Furthermore K11-poly-ubiquitination is known to be 
mediated by the anaphase promoting complex (APC), a cell cycle-dependent multi-subunit 
E3 ligase complex. It has been implicated in ER-associated degradation of misfolded 
proteins (36) and ubiquitination of components of the TNFR-NFκB signaling pathway (46), 
and has been reported to result in proteasomal degradation of the substrate (47). Finally, 
K33-poly-ubiquitination has been documented for the tyrosine kinase-linked T cell 
receptor to regulate protein-protein interactions (48). 
3.1.1  E1 ubiquitin-activating enzymes
The two E1 ubiquitin-activating enzymes (reviewed in (50)) in the human genome, UBA1 
(UBE1) and UBA6 (UBE1L2), share a homology of approximately 40%. Differences in the 
ubiquitin fold domains of these two proteins allow E2s to discriminate between them, but 
these differences are still not completely understood. Free ubiquitin is activated in an 
ATP-dependent manner by the formation of a thiol-ester linkage between the E1 protein 
and the carboxyl terminal glycine of ubiquitin. Charging with ubiquitin triggers 
conformational changes in the E1, which induce exposure of cryptic E2-binding sites and 
the subsequent formation of a proper E1-E2 complex (51, 52). 
3.1.2  E2 ubiquitin-conjugating enzymes
E2 ubiquitin-activating enzymes were traditionally considered as enzymes that couple E1 
to E3 enzymes, but recent studies have revealed that E2s also have an active role in 
determining the length and topology of ubiquitin chains (53). E2s are characterized by the 
presence of a highly conserved 150-200 amino acids catalytic ubiquitin-conjugating (UBC) 
domain (54). This UBC domain provides a binding platform for interaction with E1s and 
E3s, as well as for the activated ubiquitin. It should be noted, however, that binding of E1 
and E3 enzymes to the E2 UBC domain is mutually exclusive as E1 and E3 enzymes use the 
same UBC domain interface for interaction. The catalytic cysteine residue of E2s is located 
in the UBC domain and accepts the activated C-terminus of ubiquitin via a thio-ester 
bond, prior to interaction with E3 ligases and subsequent substrate conjugation (54). To 
date, more than thirty E2s have been identified (for an overview see reference (55)). Most 
of the E2s mentioned in this thesis, such as UBE2L3 (UBCH7) and UBE2D (UBCH5), contain 
only a catalytic domain, making them so-called common E2s. Other E2s contain N- or 
C-terminal extensions to the UBC domain that contribute to the function of these E2s, Fi
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characterized by an N-terminal C2 domain, two to four WW domains and a C-terminal 
HECT domain (60). The C2 domain binds to phospholipids and mediates intracellular 
targeting to the plasma membrane, endosomes and/or MVBs (61, 62). The WW domains 
bind to phosphotyrosine motifs in substrate proteins (63, 64), while the C-terminal HECT 
domain contains the conserved cysteine residue which is involved in transfer of ubiquitin 
form the E2 to the substrate. Several NEDD4 family members have been suggested to 
affect key signaling pathways that regulate cellular growth and proliferation. For example, 
NEDD4L is involved in sorting of the epithelial Na channel (ENaC) by interaction with PY 
motifs, thereby promoting ubiquitination and endocytosis of the ENaC (63, 65). In yeast, 
the NEDD4 family HECT E3 ligase Rsp5 is the major ligase controlling endocytosis and 
sorting of cargo into MVBs (66). Interestingly, recent crystal structure analysis of a ubiqui-
tin-loaded NEDD4 HECT domain indicate that NEDD4 E3 ligase family members catalyse 
the formation of K63-linked poly-ubiquitin chains through addition of ubiquitin monomers 
to the distal end of the growing poly-ubiquitin chain (67). 
 RING E3s do not have an active-site cysteine residue and act as an adapter protein by 
bringing the E2-ubiquitin complex and substrate protein in close proximity in order to 
mediate the transfer of ubiquitin from the E2 directly to the substrate (68). The U-box 
domain is structurally related to the RING domain and can also recruit E2 enzymes (69). 
RING E3s contain an RING finger, which is a small domain of approximately 40-60 amino 
acids and contains two zinc ions that are coordinated by conserved cysteine and histidine 
residues. RING finger E3s can be monomeric, whereby the RING finger and substrate-inter-
acting motifs are present within a single protein, or they can be homo- or heteromeric 
multimers in which RING fingers and substrate interacting domains are present on distinct 
subunits of the multi-protein complex. The latter include multisubunit RING E3 ligase 
complexes such as the cullin, APC/C and the FANC RING E3 ligase complexes. In the cullin 
RING E3 ligase complex, a cullin protein serves as a scaffold to assemble multiple proteins, 
including a RING finger protein, adapter proteins and substrate interacting proteins (68). 
 In order to facilitate ubiquitination RING E3s recognize their substrates through 
various protein-protein interaction domains. Various RING fingers E3s are implicated in the 
regulation of ubiquitination and subsequent downregulation of receptor tyrosine kinases. 
For example, the CBL (casitas B-lineage Lymphoma) E3 ligase family, which includes CBL 
(C-CBL), CBLB (Cbl-b) and CBLC (CBL-3) mediates ubiquitination and downregulation of 
numerous receptor and non-receptor protein tyrosine kinases including the activated 
EGFR (70). Other RING E3 ligases have been implicated in ERBB receptor ubiquitination. 
NRDP1 is involved in ubiquitination and downregulation of ERBB3 (71) while the RING 
finger-related U-box protein CHIP mediates chaperone-dependent ubiquitination and 
downregulation of ERBB2 (72, 73). The regulation of ERBB receptors by E3 ligases will be 
discussed in more detail below. 
such as subcellular localization, stabilization of the interaction with E3 enzymes, or 
modulation of the activity of the interacting E3. 
 All active E2s have a UBC domain, while so-called ubiquitin E2 variant (UEV) proteins 
contain a UBC domain that lacks an active-site Cys residue (53). Those UEV proteins often 
form a heterodimer with an active UBC-containing E2. Of these, UEV1A (UBE2V1) and 
MMS2 (UBE2V2) are known to interact with UBC13 (UBE2N) and thereby catalyze K63-po-
ly-ubiquitination (56). The heterodimeric UBC13-UEV1A complex is involved in NF-kB 
activation, while the heterodimeric UBC13-MMS2 complex is involved in DNA-damage 
responses (57). 
 The decision whether a lysine residue in a substrate or in ubiquitin itself will receive 
the next ubiquitin molecule is frequently determined by the E2, since E2s play dedicated 
roles in ubiquitin chain initiation and elongation (53). The UBE2D family is involved in chain 
initiation but lacks specificity for a lysine residue in the substrate, thereby allowing them 
to initiate chain formation in a diverse set of substrates that are attached to multiple E3s. 
Members of other E2 families are more selective in promoting chain initiation and 
recognize specific substrates, for example UBE2T which is specific for FANCD2 (58). As E2 
enzymes use the same interface for interaction with either E1 or E3 enzymes, E2 enzymes 
must first dissociate from E3 enzymes after transfer of their ubiquitin to pick up another 
ubiquitin from an E1 enzyme. E2s involved in ubiquitin chain elongation generally lack the 
capacity to promote chain initiation. They interact only with substrate-attached ubiquitin, 
resulting in specificity of some E2s for certain types of poly-ubiquitin chains. For instance, 
UBE2S promotes K11-ubiquitination, while UBE2K, UBE2R1 and UBE2G2 promote K48-po-
ly-ubiquitination and the aforementioned UBE2N-UBE2V1 complex mediates  K63-po-
ly-ubiquitination of substrate proteins. As an example for chain initiation and elongation, 
UBE2D initiates and UBE2N-UBE2V1 elongates K63-poly-ubiquitination during NF-kB 
activation (59). 
3.1.3  E3 ubiquitin protein ligases
While the E2 determines the type of ubiquitin chain formed, the E3 ligase is responsible 
for the substrate specificity. E3 ligases contain a specific structural domain involved in E2 
binding, such as RING and HECT domains, in addition to a variety of substrate binding 
domains. Over 600 E3 ligases have been identified in the human genome (60). 
 HECT domain E3 ligases contain a cysteine residue that forms a thio-ester with the 
activated ubiquitin that is received from an E2 enzyme. Ubiquitin is then transferred from 
the HECT E3 ligase to a specific lysine residue in the substrate protein. The HECT domain 
is a module of approximately 350 amino acids that is usually found at the C-terminus. HECT 
E3 ligases can be classified into three groups based on their N-terminal domain structure, 
i.e. the NEDD4 family (9 members in humans), the HERC family (6 members) and other 
HECTs (13 members). The NEDD4 family includes NEDD4, NEDD4L, ITCH and WWP1, and 
this family is involved in intracellular signaling and trafficking. NEDD4 family members are 
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multiple ubiquitin molecules and thereby generate free ubiquitin. Furthermore, 
disassembly of ubiquitin chains generated by en bloc removal from substrates ensures 
that recycled ubiquitin re-enters the free ubiquitin pool. As an example, USP5 and USP13 
of the USP family are highly active against unattached chains regardless of the type of 
linkage and thereby efficiently refill the cellular free ubiquitin pool (83, 84). Second, DUBs 
can remove ubiquitin chains from ubiquitin-modified proteins, leading to reversal of 
ubiquitin downstream effector function. This action can rescue proteins from degradation, 
change the fate of the proteins or restore the free ubiquitin pool by preventing degradation 
of ubiquitin together with substrates of the proteasomal and lysosomal pathways. For 
3.1.4  Ubiquitin binding domains
The downstream functional effects of ubiquitin are mediated through binding of ubiquitin 
to proteins containing ubiquitin-binding domains (UBDs) which are able to bind ubiquitin 
in a non-covalent manner. At least 20 different types of UBDs have been identified so far, 
of which UIMs (ubiquitin interacting motifs) and UBA (ubiquitin associated)-domains form 
the major families. The UBA domain is found in a variety of ubiquitin-interacting proteins, 
including C-CBL and CBLB E3 ligases (74). The UIM domain, which consists of a single 20 
residue helix, is present in several endocytic proteins, including EPS15, HGS (HRS) and 
epsin1 (all discussed in later sections). The majority of identified UBDs bind in vitro to the 
hydrophobic region around Ile 44 of mono-ubiquitin (75), but structural and functional 
studies have identified UBDs that interact with linkage-specific polyubiquitin chains (75). 
Numerous UBA domain-containing proteins bind K48-linked poly-ubiquitin chains in 
strong preference to mono-ubiquitin (76), including shuttle proteins that are involved in 
targeting ubiquitinated substrate proteins for proteasomal degradation (74, 77). However, 
also K63-specific, linear ubiquitin chain-specific and non-specific UBA domains have been 
identified (78). Furthermore, two UIM motifs present in the proteasomal S5a subunit have 
also been demonstrated to bind to K48-polyubiquitin chains (79), while in addition UIM 
motifs have been identified that bind to K63-poly-ubiquitin (80). 
3.1.5  Deubiquitination enzymes
Ubiquitination is the covalent conjugation of a ubiquitin protein to one of the many 
cellular proteins. Even though ubiquitination can function as a degradation signal, 
ubiquitin itself is a long-lived protein in vivo due to the removal of ubiquitin from its 
conjugates by deubiquitination enzymes (DUBs) prior to substrate degradation. 
Approximately 90 DUBs have been identified in the human genome that can be 
subdivided into five families, i.e. (i) the ubiquitin C-terminal hydrolases (UCH) with Cys 
protease activity, (ii) the ubiquitin-specific proteases (USP), (iii) the ovarian tumor proteases 
(OTU), (iv) the josephin domain-containing proteins (JOSD), and  (v) the JAB1/MPN/MOV34 
zinc metalloenzymes (JAMM) (81). Cleavage of ubiquitin chains from a substrate protein 
(which includes ubiquitin itself) can occur from the ends (exo) or from within a chain 
(endo). Endo-DUBs must bind two ubiquitin molecules, whereas exo-DUBs bind the 
terminal ubiquitin only. Alternatively, DUBs may specifically recognize their substrates and 
remove the (poly)ubiquitin chain as a whole. For example the proteasomal subunit POH1, 
which belongs to the JAMM DUBs, shows specificity for K63-poly-ubiquitin chains, but can 
also cleave the first isopeptide bond that links the substrate and the proximal ubiquitin, 
thereby releasing poly-ubiquitin en bloc (82). Moreover, DUBs may shorten a poly-ubiquitin 
chain into a mono-ubiquitin adduct, after which  this mono-ubiquitin can be elongated 
again resulting in a poly-ubiquitin chain with a different type of linkage (chain editing) (81). 
 Based on their function DUBs can be divided into various categories (figure 2). First, 
DUB activity may be required to process ubiquitin precursors that contain linear chains of 
Figure 2  DUB activities
DUB activities can be divided in various functional categories. DUB activity may be required to 
process ubiquitin precursors that contain linear chains of multiple ubiquitin molecules and thereby 
generate free ubiquitin (a). DUBs can remove ubiquitin chains from ubiquitin-modified proteins, 
leading to reversal of ubiquitin signaling. This action can rescue proteins from degradation (b), 
change the fate of the proteins (c) or restore the free ubiquitin pool by preventing degradation of 
ubiquitin together with substrates of the proteasomal and lysosomal pathways (d). Disassembly of 
ubiquitin chains generated by en bloc removal from substrates ensures that recycled ubiquitin 
re-enters the free ubiquitin pool (e). A more general role for DUBs is the editing of the type of 
ubiquitin modification by trimming ubiquitin chains (f). From reference (81). Reprinted by permission 
from Macmillan Publishers Ltd: Nature reviews: Molecular cell biology 10, 550-563, copyright 2009. 
1CHAPTER 1 GENERAL INTRODUCTION
18 19
inner rings contain the active site of the protease that catalyzes protein degradation, while 
the outer rings create a narrow gated pore channel (102). Once the substrate is unfolded, 
deubiquitinated and translocated through the gate, the substrate is exposed to 
endoproteases which leads to ATP-dependent digestion by AAA-ATPases into small 
peptides. 
 The 19S RP has several roles, including (i) recognition of (poly)ubiquitinated substrate 
proteins, (ii) recognition of UBA and ubiquitin-like (UbL) domain-containing shuttle 
proteins that function as adapters between ubiquitinated substrate proteins and ubiqui-
tin-receptors in the 19S RP, (iii) deubiquitination of ubiquitinated substrate proteins by 
DUB enzymes, (iv) unfolding of the substrate proteins by AAA ATPases, and (v) opening of 
the α-annulus of the 20S core.
 Two subunits of the 19S RP are able to interact with ubiquitin: Rpn10/S5A (103-105) 
and Rpn13 (106), which both bind K48-linked polyubiquitin (79). Furthermore, Rpt5/S6’ and 
Rpn1/S2 have been suggested to function as additional ubiquitin interacting proteins (107, 
108). In addition, UBA-UbL shuttle proteins, such as Rad23, Dsk2 and Ddi, can bind 
ubiquitinated proteins by their UBA domain and can be recognized by UbL domain 
example, there are three DUBs associated with the proteasomes: POH1, UCH37 and USP14. 
POH1 can cleave the first isopeptide bond that links the substrate and the proximal 
ubiquitin. UCH37 inhibits the degradation of ubiquitinated proteins in the proteasome by 
removing ubiquitin from the distal end of the poly-ubiquitin chain (85). USP14 also 
disassembles poly-ubiquitin from the distal end and thereby regulates the chain length of 
proteasome substrates while releasing mono-ubiquitin (86). Several DUBs have been 
implicated in endosomal/lysosomal trafficking pathways. For instance, in addition to 
regulating the kinase activity of several NF-κB-related kinases, the DUB CYLD has also 
been shown to mediate endocytosis of the TrkA receptor (87) and to control signaling of 
the tyrosine kinase-linked T-cell receptor (88). Two DUB enzymes that are known to be 
involved in endocytic trafficking of EGFR are USP8 and AMSH, as will be discussed in later 
sections. Third, a more general role for DUBs is the editing of the type of ubiquitin 
modification by trimming ubiquitin chains. If the chain is not cleaved completely by DUBs 
and the proximal ubiquitin is left on the substrate, the chain type can be changed from 
one chain type to another (e.g. from K63-linked to K48-linked ubiquitin chains) by E3 
ligases, which may change the fate of the protein (89). 
 In addition to DUBs that do not discriminate between chain linkages, also many chain 
type-specific DUBs exist. This specificity is not restricted to particular DUB families, since 
the USPs, OTUs and JAMMs all include linkage-specific members. Most USPs do not show 
specificity towards a specific linkage (90), but the proteasome-associated USP14 shows 
specificity for K48-linked ubiquitin chains (86), whereas CYLD hydrolyses K63-linked and 
linear chains (90, 91). The OTU family has K48-specific members, including OTUB1 (92), but 
also K63-specific DUBs such as TRABID and OTUD5 (93, 94). Within the JAMM family, AMSH, 
AMSH-LP, CSN5, BRCC36, POH1 and MYSM1 are K63-specific, suggesting that the JAMM 
type of DUBs have a common mechanism for K63-specificity (81).  
3.2 The Ubiquitin Proteasome System (UPS)
Tetramers of K48-linked ubiquitin form the minimal recognition motif for degradation of 
proteins by the multi-subunit, ATP-dependent protease known as the proteasome (95, 96). 
However, several groups have also implicated K11 and K63 types of ubiquitin linkages in 
proteasomal targeting (36, 97, 98). The 26S proteasome contains two main subcomplexes: 
the 20S proteolytic core particle, consisting of 28 subunits, and the 19S regulatory particle 
(RP), which acts as an activator complex by capping the 20S particle on either side. The 19S 
RP is composed of a 10-subunit base complex and a 9-subunit lid complex (figure 3) (99).
 Poly-ubiquitinated proteasome substrates bind to the 19S RP via proteins that interact 
with ubiquitin and then translocate into the core particle, where they are hydrolyzed. Due 
to the narrow outer rings of the 20S core particle, the substrate needs to be unfolded 
before translocation. ATPases in the base complex of the 19S RP drive unfolding, 
translocation and opening of the core particle gate (100, 101). The 20S core is the catalytic 
component and forms a cylindrical chamber composed of four heptameric rings. The two 
Figure 3  Schematic of the proteasome
The 26S proteasome contains two main subcomplexes: the 20S proteolytic core particle, consisting 
of 28 subunits, which is capped on either side by an activator complex known as the 19S regulatory 
particle (RP), consisting of 19 subunits. The 20S core is the catalytic component and forms a 
cylindrical chamber composed of four heptameric rings. The 19S RP is composed of 10-subunit base 
complex and a 9-subunit lid complex. From reference (112). Reprinted by permission from Macmillan 
Publishers Ltd: Nature reviews. Molecular cell biology 12, 605-620, copyright 2011.
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EGF-induced tyrosine phosphorylation of the β2 subunit of AP-2 (125). However, mutation 
of these motifs did not affect EGFR internalization (123, 125) and the effect of AP-2 
depletion on EGFR internalization is controversial (126-128). This may be a result of varying 
efficiencies of RNAi-mediated inhibition of AP-2 expression or the possibility that other 
receptors that are present in the 19S RP (76, 104, 109). Furthermore, deubiquitination by 
the 19S RP is required for efficient substrate degradation and for recycling of the (poly)
ubiquitin tag. Various DUB proteins are known to associate with or to be part of the 19S RP. 
The DUBs POH1/Rpn11 and Uch37 (not present in yeast) are integral subunits of the 19S 
regulatory particle. The third DUB, Usp14, associates with Rpn1/S2 subunit of the 19S RP 
(82, 110). Also Doa4, the yeast counterpart of mammalian USP8, has been suggested to 
interact with the proteasome (111). 
3.3 Lysosomal degradation
Most studies regarding ligand-induced endocytic ERBB downregulation have been 
performed using EGFR as a model system (2, 113). Ligand-induced activation of the 
receptor tyrosine kinase results in phosphorylation of tyrosine residues in the carboxy-ter-
minal domain of the receptor, as well as of numerous cytoplasmic substrates. The activated 
receptor is subsequently relocated to invaginating clathrin-coated pits (CCPs) on the 
plasma membrane. These pits internalize and give rise to clathrin-coated endocytic 
vesicles. Upon internalization the clathrin coat is first removed by chaperones and 
subsequently the vesicles fuse with early endosomes, resulting in the delivery of activated 
receptor complexes to the limiting membrane of early (sorting) endosomes (114). The 
extracellular ligand-binding domain of the receptor is now located on the luminal side of 
the endosome, where it remains active as long as the ligand is bound. In early endosomes 
the activated ligand-receptor complex is either sorted to be recycled back to the cell 
surface or targeted for lysosomal degradation (115, 116). The latter is initiated by 
incorporation of the ligand-receptor complex into ILVs of MVBs, which results from 
invagination of the limiting membrane of sorting endosomes (117). Subsequently, these 
MVBs fuse with pre-existing primary lysosomes after which the activated receptor 
complex is degraded by the lysosome (figure 4). Thus, incorporation of ERBBs in 
intralumenal vesicles of MVBs abrogates their communication with cytoplasmic signaling 
molecules, leading to attenuation of signaling (2, 117). Following internalization EGF does 
not dissociate from its receptor, and therefore most of the intact EGF-receptor complex is 
degraded. It has been established that binding of TGFα to EGFR is strongly pH-dependent 
and consequently TGFα dissociates from the internalized EGFR in the acidic environment 
of endosomes. As a result, a substantial fraction of EGFR is recycled back to the cell surface 
upon TGFα-stimulation (118-120). 
3.3.1  Regulation of EGFR sorting into clathrin-coated pits
The heterotetrameric clathrin-adapter protein AP-2, consisting of four adaptin proteins, is 
thought to play a key role in the recruitment of cargo proteins into clathrin-coated pits 
(CCPs) at the plasmamembrane (121, 122). Indeed, EGFR was found to interact directly with 
the µ2 subunit of AP-2 through the Y974-RAL motif, which is de major AP-2 binding site in 
EGFR, (122-124) while the di-leucine motif (Leu1010/1011) was shown to be involved in the 
Figure 4  Endosomal trafficking receptors
The EGFR is internalized in clathrin-coated endocytic vesicles. These vesicles fuse with early 
endosomes, resulting in the delivery of the activated receptor complexes to the limiting membrane 
of early endosomes. In early endosomes the activated ligand-receptor complex is sorted to be 
recycled back to the cell surface or targeted for lysosomal degradation by incorporation into 
intralumenal vesicles of MVBs or late endosomes, which results from invagination of the limiting 
membrane of sorting endosomes. Subsequently, these MVBs fuse with pre-existing primary 
lysosomes upon which the activated receptor complex is degraded by the lysosome. The TfnR is 
recycled back to the plasma membrane, while the CI-MPR is recycled back to the trans-Golgi 
network. From reference (115). Reprinted by permission from Macmillan Publishers Ltd: Nature 
reviews. Molecular cell biology 9, 574-582, copyright 2008.
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membrane upon EGFR activation (144) and phosphorylation of EPS15 is necessary for 
EGFR internalization (145), but the exact role of this phosphorylation step is unknown. 
Binding of EPS15 to the ubiquitinated EGFR probably occurs via interactions of the UIM 
with ubiquitin bound to the EGFR. Moreover, knockdown of EPS15 and EPS15R resulted in 
decreased EGFR internalization (127).  Interestingly, both EPS15 and epsin 1 have a 
preference for poly-ubiquitin versus mono-ubiquitin chains in vitro, whereby the epsin 1 
UIM is capable of binding both K48- and K63-poly-ubiquitin chains (146, 147). Indeed, 
epsin-1 has been demonstrated to interact with ubiquitinated EGFR and knockdown of 
internalization motifs are present in EGFR. Thus, although the EGFR interacts with AP-2, the 
exact role of EGFR interaction with AP-2 remains elusive. 
 Autophosphorylation of Y1068 and Y1086 in the cytoplasmic tail of the EGFR leads to 
binding of GRB2. Mutation of these binding sites strongly inhibited EGFR internalization 
while knockdown of GRB2 reduced EGFR internalization (129). Moreover, GRB2-EGFR 
complexes were found in CCPs while in addition GRB2 was shown to be necessary for 
EGFR recruitment into clathrin-coated pits (128, 129). It has been reported that GRB2 
interacts with dynamin (130), a GTPase protein that mediates the fission of CCPs from the 
plasma membrane (131), but the exact role of this interaction on EGFR endocytosis has not 
been determined yet. GRB2 also interacts with the proline-rich region of CBL proteins (see 
below). In conclusion, the above data suggest that GRB2 and possibly AP2 clathrin adapter 
proteins are required for recruitment of the EGFR into clathrin-coated pits (figure 5). 
3.3.2  Involvement of ubiquitin during sorting into clathrin-coated pits
Ubiquitination is known to mediate endocytosis of membrane receptors for vacuolar 
degradation in yeast (132, 133) and has also been found to be involved in endosomal 
sorting of mammalian receptors such as EGFR (2). CBL proteins are complex multi-domain 
adapter proteins containing a RING finger E3 ubiquitin ligases domain that is required for 
ligand-induced ubiquitination of the EGFR (68, 70, 134). Upon ligand binding, CBL is 
recruited to the autophosphorylated EGFR, either directly through binding of its N-terminal 
tyrosine kinase binding (TKB) domain to phosphorylated tyrosine 1045 (pY1045) in the 
cytoplasmic tail of EGFR or indirectly via GRB2, wich in turn binds to EGFR pY1068 and 
pY1086 (figure 5) (135, 136). Although CBL is responsible for efficient ligand-induced EGFR 
ubiquitination, the involvement of CBL in EGFR internalization is still debated. In support 
of a role of CBL in internalization, it has been shown that CBL translocates to CCPs upon 
EGF stimulation (137) while the E2 enzyme Ubc4/5 colocalizes with CBL at the plasma 
membrane (138). Depletion of CBL by an siRNA approach, targeting both C-CBL and CBLB, 
resulted in partial inhibition of EGFR internalization (139). Furthermore, overexpression of 
several C-CBL RING finger dominant-negative mutants inhibited EGFR internalization (140, 
141). Still, a role of ubiquitination as an internalization signal for EGFR remains controversial. 
The EGFR mutant Y1045F, which lacks a CBL binding site, is only weakly ubiquitinated but 
shows wild-type internalization (140). Recently, six ubiquitin-modified lysine residues 
within the kinase domain of the EGFR have been identified using mass spectrometry (MS) 
(139). Mutation of these ubiquitination sites nor mutation of up to fifteen ubiquitination 
sites in EGFR did not affect EGFR internalization but markedly inhibited ubiquitination, 
suggesting that ubiquitination is not essential for EGFR internalization (139, 142). 
 Several proteins have been proposed to act as adapters for linking ubiquitinated 
proteins, such as the activated EGFR, to clathrin-coated pit proteins. EPS15 and epsin 1 
contain UIM-domains, and are found in CCPs (figure 5) (143). Furthermore, EPS15 binds 
adaptin, a component of the AP2 complex in CCPs. EPS15 is recruited to the plasma 
Figure 5  Regulation of receptor endocytosis
A; Ligand-induced activation of the receptor tyrosine kinase results in phosphorylation of tyrosine 
residues in the carboxy-terminal domain of the receptor. This leads to recruitment of GRB2 and CBL, 
which in turn ubiquitinates the receptor. Also EPS15 is recruited to the clathrin coated pits. B; Lysosomal 
targeting is mediated by the ESCRT complexes. ESCRT-0 (HRS and STAM) interacts with the 
ubiquitinated receptor. ESCRT-0 recruits ESCRT-I, -II and –III resulting in uptake in ILVs. From reference 
(70). Reprinted by permission from Macmillan Publishers Ltd: Nature reviews. Molecular cell biology 
6, 907-918, copyright 2005.
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upon EGF-induced activation of EGFR, HRS is phosphorylated on tyrosine residues Y329 
and Y334 by SRC family kinases, and it has been demonstrated that this phosphorylation 
step is enhanced by expression of C-CBL (155). Mutation of these phosphorylation sites 
results in suppressed EGFR degradation (155, 163, 164). 
3.3.3.2  ESCRT-I, -II and -III
After ESCRT-0 has retained the ubiquitinated EGFR within microdomains of the early 
endosomes, it interacts with and recruits ESCRT-I, -II and –III complexes to target the 
activated EGFR complex to ILVs of MVBs, which ultimately fuse with primary lysosomes to 
degrade the activated EGFR complex (152). However, the exact mechanism whereby the 
ESCRT-I, -II, and –III complexes function, is not clear. Some reports indicate that ESCRTs 
function sequentially, while others suggest that ESCRT-0, -I and –II function in a 
supercomplex (152). ESCRT-0, -I and –II contain proteins with ubiquitin-binding domains, 
but studies in yeast have shown only a modest effect of the UBDs in ESCRT-I and ESCRT-II 
in MVB sorting, in contrast to ESCRT-0 (165). It has been proposed that ESCRT-I and ESCRT-II 
play an important role in the deformation of limiting membranes, whereas ESCRT-III 
mediates limiting membrane fusion, resulting in the formation of an intraluminal vesicle 
(166).
 The ESCRT-I complex contains four subunits (TSG101, VPS28, VPS37 and MVB12). In 
humans multiple VPS37 isoforms (A-D) and MVB12 isoforms (A-B) exist which may affect 
the function of the ESCRT-I complex (figure 6). ESCRT-0 subunit HRS recruits ESCRT-I 
towards the endosomal membrane through a direct interaction with the UEV domain of 
the ESCRT-I subunit TSG101 (Vps23 in yeast), an interaction that is critical for cargo 
degradation in the lysosome. Depletion of TSG101 inhibits EGFR degradation and all 
ESCRT-mediated processes in the cell (167-169). Moreover, depletion of either HRS or 
TSG101 has been reported to result in enhanced recycling of EGFR (170). The ESCRT-I 
complex co-assembles with ESCRT-II on endosomal membranes (171) and this complex 
functions to bud the limiting endosomal membrane into its lumen (172). The ESCRT-II 
complex contains two copies of EAP20 and single copies of EAP30 and EAP45 (Vps25, 
Vps22 and Vps36 in yeast, respectively) (173). Evidence for the involvement of ESCRT-II in 
MVB formation in human cells is given by the observation that depletion of EAP20 (Vps25) 
and EAP30 (Vps22) blocks ligand-dependent EGFR degradation (174, 175). The ESCRT-III 
complex subunits are thought to assemble like filaments within the neck of the 
invaginating membrane and mediate membrane fission (176). In humans, ESCRT-III 
proteins are called CHMPs (charged MVB proteins). There are seven CHMP proteins 
(CHMP1-7), of which CHMP4 exists in three isoforms (CHMP4 A-C) and both CHMP1 and 
CHMP2 in two (A-B). Systematic analysis of the role of human CHMP proteins in vesicle 
fission has not been performed yet, but the different human ESCRT-III proteins are thought 
to function in MVB formation in a similar manner as their yeast counterparts  (174), for 
which a model of the action of ESCRT-III in membrane fission has been proposed. ESCRT-II 
the epsin 1 gene appears to inhibit clathrin-dependent endocytosis of EGFR. The resulting 
inefficient recruitment of EGFR to the CCPs (148) suggests a role for epsin-1 in translocation 
of ubiquitinated EGFR to CCPs. The modest effect of epsin-1 and EPS15 knockdown 
suggests that other proteins are involved and could act in parallel. Another candidate is 
CIN85, which is an adapter protein involved in regulation of EGFR endocytosis (figure 5). 
CBL binds to CIN85 through its SH3 domains, while CIN85 in turn interacts with endophilin. 
Inhibition of these interactions blocked EGFR endocytosis (149). Recently it has been 
demonstrated that CIN85 is able to bind ubiquitin through its SH3 domains, which would 
be a novel type of interaction. A competition between ubiquitin and CBL for binding to 
the SH3 domains of CIN85 has been suggested (150). Disruption of ubiquitin binding to 
CIN85 results in increased EGFR ubiquitination, suggesting that this competition regulates 
CBL function and EGFR endocytosis (150). 
3.3.3  Regulation of endosomal sorting
3.3.3.1 ESCRT-0
Lysosomal targeting is mediated by the ESCRT (endosomal sorting complex for transport) 
complexes ESCRT-0, -I, -II and –III (figure 5) (151, 152). The components of ESCRT-0 are HRS 
(hepatocyte growth factor receptor tyrosine kinase; also known as HGS) and STAM1/2 
(signal transducing adapter molecule), Both STAM and HRS interact with clathrin, which 
results in recruitment of ESCRT-0 complex-associated proteins to clathrin-coated 
microdomains of sorting endosomes (153, 154). HRS and STAM both contain UIM and VHS 
domains, each of which is important for the functioning of ESCRT-0. Ubiquitinated cargo 
is recognized by the UIM of HRS and STAM (155, 156). Loss of the UIM domain of Hse1 
(yeast homologue of STAM)  and Vps27 (yeast homologue of HRS) within yeast ESCRT-0 
causes defects in ubiquitin mediated cargo sorting (157) and loss of the Hse1 VHS domain 
and the Vps27 UIM domain blocks sorting of the ubiquitinated cargo (158). In mammalian 
cells, loss of the UIM domain of HRS results in a disability of HRS to associate with 
ubiquitinated proteins and to transport cargo to endosomes (155, 156, 159). Deletion of 
either VHS or UIM of STAM gives rise to a partial loss of functioning of ESCRT-0 (158, 160). 
Interestingly, ESCRT-0 binds K63-linked tetra-ubiquitin with a 50-fold higher affinity than 
mono-ubiquitin, though only 2-fold more tightly than K48-linked tetra-ubiquitin (158). 
Indeed, STAM shows selectivity for K63- over K48-polyubiquitination (158). Furthermore, it 
has been shown that HRS efficiently interacts with poly-ubiquitinated EGFR and that HRS 
preferentially binds to K63-poly-ubiquitin chains in vitro (138, 161). 
 Further evidence for a role of ESCRT-0 in the binding and recruitment of EGFR within 
sorting endosomes is presented by the observation that HRS associates with EPS15, which 
binds EGFR and localizes to HRS-positive microdomains of endosomes (162). Furthermore, 
HRS contains a FYVE zinc-finger domain which can bind to the endosomal lipid phospha-
tidylinositol 3-phosphate, thereby recruiting the ESCRT-0 complex towards the endosomal 
membrane (152). Depletion of HRS leads to inhibition of EGFR degradation (163). Moreover, 
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recruits two Vps20/CHMP6 subunits of the ESCRT-III machinery and appears to help the 
assembly of two spiraling Snf7/CHMP4 filaments within the necks. These filaments are 
capped by Vps24/CHMP3 while Vps2/CHMP2 completes the filament (176). Functional 
studies confirm the requirement of Vps24/CHMP3 for EGFR degradation (177). Finally, 
Vps2/CHMP2 recruits Vps4 (VPS4A-B in humans), an AAA-ATPase that functions to 
disassemble the ESCRT-III protein complexes from the endosomal membranes and 
thereby recycles ESCRT-III proteins (178). 
4  E3 ligases involved in ERBB ubiquitination  
and degradation
4.1 CBL-mediated EGFR degradation 
Most studies on receptor downregulation have been performed on EGFR and, as 
described above, the E3-ubiquitin ligase CBL is one of the key players in this process. The 
structure of all three members, C-CBL, CBLB and CBLC, includes an N-terminal tyrosine 
kinase-binding (TKB) domain, a linker region which is crucial for the regulation of CBL’s E3 
function, a RING finger domain, proline-rich domains which mediate interaction with 
SH3-containing proteins, and tyrosine residues that are phosphorylated upon RTK 
activation. These phosphorylated tyrosines recruit SH2 domain containing proteins 
including  Crk(L) and p85 PI3K (68). The CBL proteins differ in the length of their C termini 
and therefore in their ability to function as an adapter protein (70). C-CBL and CBLB contain 
a C-terminal UBA domain, which is important for ubiquitin binding, but it also plays a role 
in dimerization and tyrosine phosphorylation of CBL (180, 181). Whereas C-CBL and CBLB 
are ubiquitously expressed, CBLC is mainly expressed in epithelial cells, but the function of 
CBLC is poorly understood (182). The three CBL members all contain a functional RING E3 
ligase, but in addition they function as adapter proteins which mediate the dynamics of 
the actin and microtubule cytoskeleton (70). Thus, the adapter function of CBL proteins 
does not only lead to targeting of specific substrates for ubiquitination and degradation, 
but also to the recruitment of proteins that are involved in endosomal trafficking of the 
target receptor tyrosine kinase, dynamics of the actin and microtubule cytoskeletons and 
the activation of signaling pathways (70). 
 Upon stimulation of EGFR, CBL is recruited to the autophosphorylated EGFR, directly 
or indirectly via GRB2 (135, 136). C-CBL has been demonstrated to interact with the E2 
enzymes UbcH7 (UBE2L3) (183-185), UBC4/5 and UBCH5 (UBE2D) (185-187), which transfer 
the activated ubiquitin to lysine side chains of the EGFR substrate protein (138). The EGFR 
is known to undergo both mono- and K63-poly-ubiquitination, and it has been 
demonstrated that mono-ubiquitination is sufficient to drive EGFR internalization and 
lysosomal targeting (117, 139). Using Mass Spectrometromics (MS) six ubiquitin-modified 
lysine residues have been identified within the kinase domain of the EGFR (139). Mutation Fi
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CBL degradation are not fully understood, but the tyrosine phosphorylation by SRC may 
be required (193, 194). 
 A fourth mechanism for CBL regulation is interference with ubiquitin-dependent 
sorting of activated receptors in sorting endosomes by STS-1 (UBASH3B) and STS-2 
(UBASH3A). These proteins contain a UBA domain that interacts with ubiquitin and an SH3 
domain that interacts with the proline-rich region of CBL. Upon activation of the EGFR, 
STS-1 and STS-2 are recruited to the EGFR and inhibit CBL-mediated ubiquitination and 
downregulation (195). 
 Fifth, another factor that can influence CBL’s function is ALIX (PDCD6IP), a protein that 
interacts with both CIN85 and endophilins, which in turn are binding partners of CBL. ALIX 
inhibits CBL-mediated ubiquitination and downregulation of the EGFR, although the 
underlying mechanism remains unclear (196).  
 Sixth, apart from its role as an E3 ligase for various receptor and non-receptor tyrosine 
kinases, CBL is also involved in regulation of the actin and microtubule cytoskeletons. 
Removal of the active receptor tyrosine kinases from the plasma membrane requires the 
actin and microtubule networks to drag receptor-containing vesicles away from the cell 
surface into the cytoplasm and towards the perinuclear region where MVBs and lysosomes 
are located (197, 198). SRC-family kinases, which are constitutively associated with CBL, 
phosphorylate essential tyrosines in the C-terminal region of CBL and thereby attract 
SH2-domain-containing adapters, such as Crk and PI3K, that link CBL to the actin 
cytoskeleton (70, 199). Furthermore, CBL can be linked to the cytoskeleton by binding of 
its proline-rich domain to various SH3-domain-containing proteins, including CIN85 and 
ALIX (70). CBL is not only associated with actin-binding proteins, but also affects the 
activation status of GTPases which regulate actin polymerization (70). Thus, apart from its 
role as an E3 ligase, CBL seems to be a master regulator of endosomal trafficking through 
the regulation of the actin and microtubule cytoskeletons. 
4.2 CHIP-dependent ERBB2 degradation
Previous studies have shown that ERBB2, ERBB3 and ERBB4 are impaired in ligand-induced 
downregulation in comparison with EGFR (200, 201). The molecular basis for the difference 
in internalization and downregulation efficiency of ERBB2, ERBB3 and ERBB4 remains, 
however, poorly understood. Previous studies have suggested that the difference may be 
due to the absence of positive or the presence of negative sequences in the cytoplasmic 
domains of these various receptors (200, 201). 
 The impaired downregulation of ERBB2 has been correlated with poor recruitment of 
ERBB2 into CCPs, resulting in a reduced rate of internalization (200-203), impaired lysosomal 
targeting of the internalized receptor and enhanced recycling from sorting endosomes 
back to the plasma membrane (204-206). Moreover, the ERBB2 is able to impair the 
downregulation of EGFR by formation of heterodimers (204-207). When comparing the 
molecular structure of EGFR with that of ERBB2, impaired downregulation of ERBB2 has 
of a single lysine does not appear to detectably alter the ubiquitination status of EGFR, 
probably because of the redundancy of the ubiquitination sites. Moreover, mutation of up 
to 15 lysine residues resulted in a substantial decrease, but still not complete abolishment, 
of EGFR ubiquitination, demonstrating that many EGFR cytoplasmic tail lysine residues are 
ubiquitin-modified after activation (139, 142). Although MS revealed that more than 40% 
of the ubiquitin that is attached to the EGFR is in the form of K63-poly-ubiquitin, the exact 
sites of K63-poly-ubiquitination on the EGFR have not been determined yet (139). 
 CBL has been shown to translocate to CCPs upon EGF stimulation and to play an 
important role in EGFR internalization (137, 139). Direct CBL binding appears to play a 
minor role in internalization, whereas GRB2-mediated interaction with EGFR is critical (140). 
However, overexpression of CBL mutants inhibited EGFR downregulation (141) and 
overexpression of CBL stimulates ligand-induced EGFR degradation (136). Furthermore, 
CBL-mediated EGFR ubiquitination may not be necessary for EGFR internalization, since 
the EGFR Y1045F mutant with altered CBL binding is weakly ubiquitinated, but normally 
internalized (140). Furthermore, mutation of the known ubiquitination sites in EGFR did 
not affect EGFR internalization, suggesting that ubiquitination is not essential for internal-
ization (139, 142). However, studies using EGFR Y1045F and lysine mutants, demonstrated 
that EGFR ubiquitination is essential for the lysosomal targeting and degradation of the 
EGFR (136, 139, 140, 187, 188). These results suggest that ubiquitination of EGFR is not 
absolutely required for internalization, but is required for efficient lysosomal degradation. 
4.1.1  Regulation of CBL during endocytosis and sorting of EGFR
Over 150 proteins have been identified that interact with or are affected or regulated by 
CBL (70). Such interactions may regulate CBL’s function and thereby the efficiency of EGFR 
downregulation. Several mechanisms have been described by which regulation of CBL 
can affect EGFR degradation. First, upon EGFR activation, Sprouty2 expression is induced 
which is subsequently transported to the plasma membrane, where it is phosphorylated 
on a conserved tyrosine residue (Y55) which mimics the CBL-binding motif within EGFR. 
CBL binding to Sprouty2 therefore removes CBL from the activated EGFR, leading to 
impaired EGFR ubiquitination and degradation, and thus sustained receptor signaling 
(189, 190). 
 Second, a similar mechanism has been described for Cdc42, which is able to  bind 
β-Pix (also known as Cool-1) upon EGF treatment. Subsequently, β-Pix interacts with CBL 
and prevents it from binding to the activated receptor, thus resulting in decreased EGFR 
ubiquitination (191). 
 Third, negative regulation of CBL can also be mediated by its proteasomal degradation 
whereby CBL is ubiquitinated by HECT-type E3-ligases ITCH or NEDD4 (192). Alternatively, 
SRC binds to and tyrosine phosphorylates C-CBL, but by binding to C-CBL SRC is negatively 
regulated by CBL-mediated ubiquitination. On the other hand, SRC increases self-ubiquiti-
nation of C-CBL, leading to proteasomal degradation of C-CBL. The mechanisms underlying 
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ERBB3, suggesting that the majority of ERBB3 is degraded by NRDP1 (221). Furthermore, 
knockdown of NRDP1 enhanced the cellular response to NRG1, again indicating that 
NRDP1 mediates the degradation of signaling-competent receptors. However, NRDP1 is 
an unstable protein which is stabilized by interaction with the rhodanese-like domain of 
the DUB USP8. Stimulation of cells with the ERBB3 ligand NRG1 stabilizes USP8, which in 
turn stabilizes NRDP1. Knockdown of either NRDP1 or USP8 suppressed neuregulin-in-
duced ERBB3 ubiquitination and degradation (222-224). The ubiquitination of ERBB3 by 
NRDP1 leads to proteasomal degradation (71). Thus, in contrast to early studies, endosomal 
trafficking of ERBB3 is likely to be regulated by NRDP1 regulated ubiquitination.
4.4 NEDD4 family-mediated ERBB4 degradation 
Research on ERBB4 is complicated by the existence of four structurally and functionally 
distinct ERBB4 isoforms, which are the result of tissue-specific alternative mRNA splicing 
from a single ERBB4 gene (225). The two ERBB4 juxtamembrane (JM) isoforms (JM-a and 
JM-b) differ in a stretch of amino acids at the extracellular domain of the receptor. JM-a 
contains a unique stretch of 23 amino acids which makes the receptor susceptible to 
ectodomain shedding, while JM-b with 13 alternative amino acids is  non-cleavable  (226). 
Following activation of ERBB4 by neuregulin, JM-a is cleaved  by TACE (tumor necrose 
factor-α converting enzyme), a member of the transmembrane ADAM metalloprotease 
family, also known as ADAM17 (227). The remaining truncated receptor undergoes 
subsequent intracellular proteolysis by γ-secretase, resulting in a soluble intracellular S80 
domain (228, 229). The catalytically active tyrosine kinase S80 domain translocates to the 
nucleus where it acts as a transcriptional cofactor (228, 230, 231). 
 In addition, two cytoplasmic ERBB4 isoforms exist, which differ by either including 
(CYT-1) or excluding (CYT-2) a stretch of 16 amino acids in the cytoplasmic tail (232). This 16 
amino acid region contains two important domains: a YXXM and a PPXY motif, which 
share a common Y1056. The YXXM motif in CYT-1 is a known consensus binding motif for 
p85 phospho-inositide 3-kinase (PI3-K) SH2 domain and as a result CYT-1, in contrast to 
CYT-2, can activate the (PI3-K)-Akt pathway, which is associated with cell survival and 
chemotaxis (232, 233). However, both isoforms can activate the Shc/Ras/MAPK pathway 
and mediate cell proliferation (233). The CYT-2 isoform contains two PPXY motifs, whereas 
CYT-1 contains three PPXY motifs due to the 16 amino acid insertion. The PPXY motif, 
which among the ERBB receptors is unique for ERBB4, forms a binding site for WW do-
main-containing proteins (234-236), including the NEDD4 subfamily of E3 ubiquitin ligases. 
Indeed, it has been shown in a variety of studies that in addition to NRDP1 (220), members 
of the NEDD4 subfamily are also involved in regulation and ubiquitination of ERBB4. The 
NEDD4 family member Aip4/ITCH, which contains four WW domains, has been shown to 
bind and ubiquitinate both CYT isoforms of ERBB4, albeit to a different extent (235, 237). 
Wild-type ITCH, but not its ligase-inactive point mutant S830A, mediates ligand-indepen-
dent ubiquitination and degradation of ERBB4, while knockdown of ITCH inhibited 
been correlated with (i) reduced recruitment of the clathrin adapter protein AP2µ to drive 
internalization (123, 201, 208), (ii) the absence of a dileucine signal in the cytoplasmic tail of 
ERBB2 equivalent to LL1010/1011 in EGFR (125), (iii) the presence of an additional 45 amino 
acids insert in the cytoplasmic tail of ERBB2 (209) and (iv) impaired recruitment of CBL E3 
ligases to activated ERBB2 receptors (210). However, a CBL docking site has been shown to 
be present in ERBB2 (31, 187) and CBL is able to ubiquitinate ERBB2 (31, 211, 212). These 
results indicate that poor downregulation of ERBB2 is not due to the absence of a 
functional CBL binding site in ERBB2.
 It has been shown that apart from CBL, the E3 ligase CHIP is also involved in ERBB2 
ubiquitination and degradation (213). The chaperone Hsp90 helps to maintain many 
signaling proteins in their fully folded state by using its ATPase activity to fuel the 
renaturation of partially unfolded proteins. Hsp90 acts in conjunction with a second 
chaperone, the Hsp70 complex, which includes the E3 ubiquitin ligase CHIP. Misfolded 
proteins exchange their association with Hsp90 for association with the Hsp70 complex, 
after which CHIP mediates the ubiquitination and degradation of misfolded proteins. 
Hsp90 can be inhibited by geldanamycin (GA) which results in activation of CHIP and 
subsequent ubiquitination of ERBB2. One study found that Hsp90-inhibition led to 
degradation of ERBB2 in a proteasome-dependent manner (214), but later studies 
demonstrated that ERBB2 is endocytosed and degraded in lysosomes after GA stimulation 
(215, 216). Proteasome inhibitors retarded degradation of ERBB2 and proteasomal activity 
is required to sort internalized ERBB2 to lysosomes (216, 217). These results suggest that 
lysosomal degradation is the major degradation pathway for ERBB2. 
4.3 NRDP1-mediated ERBB3 degradation
Studies on ERBB3 have been complicated by the fact that ERBB3 has no intrinsic tyrosine 
kinase activity. ERBB3 has been reported to be similarly impaired in internalization as 
ERBB2 and ERBB4 (201). Moreover, NRG bound to ERBB3 and ERBB4 was found to internalize 
less efficiently than EGF bound to EGFR (218). Replacement of the C-terminus of EGFR after 
the kinase domain by the C-terminus of ERBB3 has been reported to result in efficient 
endocytosis and recycling of the chimeric receptor upon EGF binding (219). These studies 
indicate that sequences C-terminal to the kinase domain play an important role in the 
regulation of endosomal sorting of EGFR and ERBB3 receptors. It should be noted that 
ERBB3 receptors do not contain a CBL E3 ligase binding site. However, using a yeast 
two-hybrid system the RING finger domain-containing E3 ubiquitin ligase NRDP1 
(neuregulin receptor degradation protein-1; RNF41) has been shown to interact with the 
intracellular domain of ERBB3 (220). Subsequent studies showed that NRDP1 co-immuno-
precipitates with both ERBB3 and ERBB4, but not with EGFR and ERBB2. NRDP1 mediates 
ubiquitination of both ERBB3 and ERBB4, and suppresses the steady state expression of 
ERBB3 and ERBB4, even in the absence of growth factor (71, 220, 221). However, NRG 
enhances NRDP1-mediated ubiquitination of ERBB3. Knockdown of NRDP1 stabilizes 
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MVB pathway (243-245). AMSH contains an MIT domain, a nuclear localization sequence, a 
clathrin-binding domain (CBD), an RXXK motif and a catalytic JAMM domain. The CBD 
binds to the clathrin heavy chain and this interaction promotes its recruitment to early 
endosomes (154, 246). The RXXK motif is capable of associating with the SH3 domain of 
the ESCRT-0 protein STAM. STAM and HRS are most likely targets for AMSH activity, since 
enhanced ubiquitination of STAM and HRS is observed in cells overexpressing dominant 
negative AMSH (244, 247). Through its MIT-domain AMSH interacts with the ESCRT-III 
subunits CHMP1A, CHMP1B, CHMP2A and CHMP3 (243, 245, 248). A dominant-negative 
CHMP3 mutant, which is still capable of binding to AMSH, prevents targeting of AMSH to 
endosomes leading to strong inhibition of EGFR degradation, suggesting a role for 
AMSH-CHMP3 interaction in EGFR degradation (249). AMSH has a close homolog, 
AMSH-like protein (AMSH-LP), which lacks the binding site for STAM, but retains its deu-
biquitination activity in vitro (246).
 AMSH has been shown to deubiquitinate the EGFR (243, 244), but the effect of AMSH 
on EGFR downregulation is controversial. While one group proposes on the basis of 
overexpression studies with a catalytically inactive mutant that AMSH plays a role in 
limiting the sorting of the EGFR into ILVs of MVBs (154, 244), others have shown that EGFR 
downregulation is inhibited upon AMSH depletion (243, 249). This controversy may be 
explained by the various techniques used and consequently further studies are necessary 
to draw a conclusion on the role of AMSH in EGFR downregulation. The crystal structure 
of AMSH-like protein bound to K63-linked di-ubiquitin has been solved (80), while 
functional studies have indicated that AMSH an AMSH-LP specifically cleave K63-po-
ly-ubiquitin chains (244, 246). It has therefore been suggested that AMSH facilitates 
recycling of receptors by removing K63-poly-ubiquitin chains (241). 
5.1.2  USP8
USP8 is a member of the USP (ubiquitin specific protease) family that removes K48- and 
K63-linked poly-ubiquitin in vitro and has been proposed to recycle ubiquitin from 
substrate proteins prior to incorporation into ILVs of MVBs to refill the cellular ubiquitin 
pool (250-255). USP8 contains an N-terminal MIT-domain, a rhodanese-like domain (Rhod), 
two RXXK motifs which bind to SH3 domains and a USP DUB domain. Similar to AMSH, 
USP8 binds with its MIT domain to several components of the ESCRT-III machinery, 
including CHMP1A, CHMP1B, CHMP4 and CHMP7, but the exact role of these interactions 
is not clear (255). USP8 binds with its SH3 binding domains to STAM and as a result USP8 
protects HRS and STAM from proteasomal degradation (256). Furthermore, the Rhod 
domain of USP8 is catalytically inactive due to the absence of an active-site Cys residue, 
but this Rhod domain is able to interact with NRDP1, which will be discussed in a later 
section. 
 Using catalytically inactive dominant negative DUB enzymes, RNA interference 
techniques and gene knock-out models, it has been firmly established that USP8 deubiq-
ubiquitination and degradation of ERBB4 (237). ITCH-mediated ERBB4 ubiquitination, 
ERBB4 localization into intracellular vesicles, and ERBB4 degradation was higher for the 
CYT-1 than for the CYT-2 isoform, which may result from the additional PPXY motif in the 
CYT-1 isoform (235, 237). These studies suggest a model whereby ITCH mediates the 
ubiquitination of membrane-bound ERBB4, facilitating its trafficking to the lysosome for 
degradation. Another member of the NEDD4 subfamily of E3 ligases, WWP1, has also been 
implicated in ERBB4 ubiquitination and degradation, whereby CYT-1 was more efficiently 
ubiquitinated and degraded than CYT-2 (238). The WW domains of WWP1 associate with 
pY motifs of CYT-1 but not with that of other ERBB receptors, and this association 
contributes to ERBB4 ubiquitination and degradation (236). 
 Previous studies have demonstrated that ERBB4 CYT-1 can be targeted for both 
lysosomal and proteasomal degradation (234, 236, 237), while ERBB4 CYT-2 is only targeted 
for proteasomal degradation (237). Moreover, CYT-1 isoforms appear more efficiently 
endocytosed and more rapidly degraded than CYT-2 isoforms (235, 239). In agreement 
with these observations, ERBB4 CYT-1, but not CYT--2 isoforms colocalize in endocytic 
vesicles with Rab5 and Rab7, markers of early and late endosomal vesicles, indicating that 
trafficking of CYT-1 takes place from early endosomes to late endosomes/lysosomal 
structures (235). Furthermore, a previous study has demonstrated that ERBB4 is 
constitutively subjected to proteasomal degradation, while in the presence of ITCH, ERBB4 
is degraded by the lysosome (237). Overall, it seems that both the proteasomal and 
lysosomal degradation pathways are involved in ERBB4 degradation, although the exact 
mechanism of degradation of the various ERBB4 isoforms remains unclear. 
5  DUBs involved in ERBB receptor deubiquitination  
and degradation
5.1 Deubiquitination of EGFR
Previous research from our group has demonstrated that following internalization the 
activated EGFR is deubiquitinated prior to lysosomal degradation (240). Indeed, two deu-
biquitinating (DUB) enzymes, USP8 and AMSH, have been demonstrated to deubiquitinate 
EGFR prior to incorporation into the intraluminal vesicles of MVBs (241). Both AMSH and 
USP8 bind to the ESCRT-0 protein STAM through a non-canonical SH3-binding motif. 
Moreover they bind with their MIT (Microtubule Interacting and Transport) domain to 
several CHMP proteins of the ESCRT-III complex (154, 241-243), but the exact role of these 
interactions remains to be elucidated. 
5.1.1  AMSH
AMSH, also known as STAMBP, is a metazoan-specific JAMM-type DUB that is specific for 
K63-linked poly-ubiquitin and has been proposed to inhibit sorting of the EGFR into the 
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maturation and stability (85). POH1 has been demonstrated to cleave the first isopeptide 
bond that links the substrate with the proximal ubiquitin (82), and displays specificity for 
K63-linked poly-ubiquitin chains (268). Knockdown of the POH1 gene or addition of 
proteasomal inhibitors resulted in increased levels of ERBB2 ubiquitination, but ERBB2 did 
not show detectable accumulation, suggesting that the proteasomal pathway is not the 
major degradation pathway of ERBB2 (269). These results are in line with the previously 
described results that proteasomal activity is not required for GA-induced endocytosis of 
ERBB2 (216, 217), again suggesting that lysosomal degradation is the major degradation 
pathway for ERBB2. 
5.3 Deubiquitination of ERBB3 and ERBB4
Direct evidence for deubiquitination of ERBB3 and ERBB4 has not been reported yet. 
However, the Rhod domain of USP8 is known to interact with the E3 ligase NRDP1, which 
mediates ERBB3 and ERBB4 ubiquitination. Stimulation of cells with the ERBB3 ligand NRG1 
stabilizes USP8, which in turn stabilizes NRDP1. Knockdown of the NRDP1 or USP8 gene 
showed suppressed neuregulin NRG-induced ERBB3 ubiquitination and degradation 
(222-224). Since USP8 plays an important role in stabilization of NRDP1, it is possible that 
USP8 plays a role in deubiquitination of ERBB3 and ERBB4. However, experimental evidence 
is lacking so far. 
6 Thesis outline
The ERBB receptors are critical regulators of normal development, but are also frequently 
involved in the formation of solid tumors. Attenuation of ERBB receptor signaling is 
mediated by the clathrin-dependent pathway of receptor-mediated endocytosis and 
subsequent sorting of the activated ligand-receptor complex via the MVB pathway to 
lysosomes for degradation. Most studies have been performed on the EGFR, for which 
ubiquitination by the E3 ligase CBL plays an important role in EGFR internalization and 
lysosomal targeting. The work described in this thesis aims to unravel the ubiquitination 
and deubiquitination of the other ERBB receptors, in particular ERBB2 and ERBB4. 
 Chapter 2 describes studies to investigate the functional significance of a CBL 
binding site in ERBB2 and ERBB4. Replacement of the EGFR CBL binding site by that of 
ERBB2 or ERBB4 did not affect EGF-mediated CBL recruitment, receptor-ubiquitination, 
-degradation, -downregulation or ligand degradation, indicating that poor downregulation 
of ERBB2 and ERBB4 is not due to sequence variations in the CBL binding site of these 
receptors.
 In chapter 3 we describe studies investigating the role of CBL-mediated ubiquitination 
and USP8-mediated deubiquitination of ERBB2. We demonstrate that the CBL binding site 
in ERBB2 is functionally active in the context of a chimeric EGFR-ERBB2 receptor and that 
uitinates EGFR (243-245, 251-255). While some reports suggest that USP8 inhibits EGFR 
degradation (252), we and others have demonstrated that USP8 stimulates EGFR 
degradation (253, 254). Furthermore, it has been suggested that USP8 targets more 
substrates than AMSH, since inhibition of USP8 causes the accumulation of ubiquitinated 
proteins of various molecular sizes (254, 256, 257). Furthermore, inhibition of USP8 appears 
to cause a morphological aberration of early endosomes (254, 257), suggesting that this 
protein is required for regulation of certain endosomal proteins to maintain the endosomal 
morphology. 
 It is not known how the activity of USP8 is regulated, but it appears to undergo a 
variety of posttranslational modifications. First, USP8 undergoes ubiquitination upon 
EGF stimulation (252), while we have previously demonstrated that USP8 is tyrosine 
phosphorylated in an EGFR- and SRC-kinase dependent manner following EGF stimulation 
(253). However, the site of tyrosine phosphorylation and the functional significance of 
USP8 tyrosine phosphorylation remains unknown. Second, USP8 can be phosphorylated 
on T907 (threonine 907) in an Akt-dependent manner in response to NRG stimulation of 
ERBB3. This phosphorylation contributes to the stabilization of the USP8 protein, 
suggesting a role for Akt in the regulation of USP8 (224). Third, phosphorylation of S680 
(serine 680) within the RSYS680SP sequence of USP8, which corresponds to the 14-3-3 
binding motif, leads to association with 14-3-3 proteins (258-262). Binding of these proteins 
to phosphorylated target proteins can alter their enzymatic activity, subcellular localization, 
their interaction with other proteins, and state of phosphorylation (263). Moreover, 14-3-3 
proteins may regulate the cell cycle since it has been shown that during M-phase of the 
cell cycle USP8 is dephosphorylated at S680, resulting in dissociation from 14-3-3 and 
enhanced USP8 functioning (259). Furthermore, mutation of Ser680 resulted in enhanced 
USP8 activity towards EGFR, although the EGFR-USP8 interaction itself was not affected by 
the mutation. Stimulation of cells with EGF did not change the level of S680 phosphoryla-
tion or 14-3-3 binding of USP8 (259). Moreover, USP8 has been shown to colocalize with 
ubiquitinated proteins at the mid-body during cytokinesis (264), consistent with the 
finding that various ESCRT proteins function at the mid-body (265, 266). The activity of the 
endocytic pathway is downregulated during cell division and endosomes need to be 
divided to two daughter cells. Therefore, a role of USP8-mediated deubiquitination of 
endosomal proteins during cell division has been suggested (259, 264).
5.2 Deubiquitination of ERBB2
Recently the proteasomal DUB POH1 has been implicated in deubiquitination of ERBB2. 
POH1 (Rpn11 in yeast) is an integral part of the 19S regulatory particle of the 26S proteasome 
(267) and belongs to the JAMM domain family of metallo-proteases. Association of POH1 
with the 19S regulatory particle is critical for proteasome function in yeast and humans. 
Knockdown of the POH1 gene leads to inhibited growth, an increase in poly-ubiquitinat-
ed proteins, defective degradation of cellular proteins, and a defect in 26S proteasome 
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stimulation of this receptor by EGF leads to efficient CBL recruitment, CBL tyrosine phos-
phorylation and CBL binding site-dependent K63-poly-ubiquitination. Furthermore, we 
show that ERBB2 is a target for USP8-mediated deubiquitinating activity. 
 In chapter 4 we describe studies to investigate how endosomal trafficking of EGFR 
and ERBB2 is related to the level of tyrosine phosphorylation of the ESCRT-0 subunit HRS 
and deubiquitination by the HRS-associated DUB AMSH. We demonstrate that recycling 
of EGFR and ERBB2 is associated with impaired HRS tyrosine phosphorylation and 
decreased deubiquitination by AMSH. Enhanced recycling, decreased HRS tyrosine phos-
phorylation and decreased AMSH-mediated deubiquitination of EGFR-ERBB2 chimeras is 
primarily due to the presence of ERBB2 sequences or the absence of EGFR sequences 
C-terminal to the CBL binding site. 
 Chapter 5 describes studies to investigate the regulation of ubiquitination and deu-
biquitination of ERBB4. We demonstrate that the Y1103 CBL binding site of ERBB4 is 
functionally active and leads to CBL recruitment and K48-poly-ubiquitination of CYT-1 and 
CYT-2, while the PPXY1056 ITCH binding site is responsible for K63-poly-ubiquitination of 
CYT-1. CYT-1 is not a target for AMSH deubiquitination activity, but is deubiquitinated to 
some extent by USP8.  
 In chapter 6 we describe studies to investigate posttranslational modifications of 
USP8. We demonstrate that USP8 is efficiently phosphorylated on tyrosine and serine 
residues and made an attempt to unravel the tyrosine phosphorylation sites in USP8. 
 In chapter 7, we integrate and discuss our results about ubiquitinaton and deubiq-
uitination of ERBB receptors.
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Abstract
Poor downregulation of ERBB receptors is associated with enhanced downstream 
signaling and tumorigenesis. It has been suggested that poor downregulation of ERBB-2, 
-3 and -4 receptors when compared to ERBB1 is due to decreased recruitment of CBL E3 
ligase proteins. However, a highly conserved CBL binding site is not only present in ERBB1/
EGFR (FLQRpY1045SSDP), but also in ERBB2 (PLQRpY1091SEDP) and ERBB4 (STQRpY1103SADP). 
We therefore replaced the ERBB1 CBL binding site by that of ERBB2 and ERBB4. Whereas 
retrovirally infected NIH3T3 cells containing the EGFR Y1045F mutation showed 
dramatically impaired CBL recruitment, EGFR ubiquitination and delayed EGFR 
degradation, replacement of the EGFR CBL binding site by that of ERBB2 or ERBB4 did not 
affect CBL recruitment, receptor-ubiquitination, -degradation, -downregulation or ligand 
degradation. We conclude that poor downregulation of ERBB2 and ERBB4 receptors is not 
due to sequence variations in the CBL binding site of these receptors. 
Introduction
The ERBB receptor tyrosine kinase family is involved in various cell biological processes such 
as mitosis, rescue from apoptosis, cell differentiation, cell migration, epithelial mesenchymal 
transition, and stimulation of angiogenesis [1, 2]. ERBB receptor tyrosine kinases are one of 
the main targets for anti-cancer therapy as the ERBB receptor system is involved in many 
solid tumors in humans, including colon cancer, lung cancer, breast cancer, prostate cancer, 
brain tumors etc [1, 2]. The involvement of the ERBB receptor system in tumorigenesis varies 
from (i) overexpression of ligands leading to enhanced autocrine or paracrine growth, (ii) 
overexpression of receptors leading to enhanced constitutive ligand-independent 
activation, (iii) mutation, deletion or shedding of the extracellular domain of the ERBB 
receptors leading to a constitutively active truncated receptor, (iv) mutational activation of 
the tyrosine kinase domain, and (v) inhibition of receptor downregulation [1, 2]. 
 ERBB receptor downregulation (the removal of ERBB receptors from the cell surface) 
is mediated by both constitutive and ligand-induced endosomal sorting signals. Ligand 
binding greatly enhances EGFR internalization and lysosomal targeting through the 
activation of the EGFR tyrosine kinase activity and specific downstream signaling 
pathways. In contrast to ERBB1 (also known as the EGFR) which is efficiently downregulated 
following EGF-stimulation, other ERBB receptors (ERBB-2, -3 and -4) show poor 
ligand-induced downregulation [3-5]. Also, heterodimerization of the EGFR with ERBB2 
has been reported to inhibit ligand-induced EGFR downregulation [6-9]. The EGFR has 
been intensively studied as a model system for ligand-induced receptor mediated 
endocytosis. However, the molecular basis for differences in downregulation of various 
ERBB receptors remains poorly understood. Nevertheless, it has been proposed that poor 
recruitment of the CBL E3 ligase adapter protein to ERBB2-4 receptors may be responsible 
for poor ligand-induced downregulation of these receptors [10-12]. 
 Constitutive endosomal sorting signals that have been identified in the EGFR 
cytoplasmic tail include binding sites for clathrin AP2 adapter proteins (Tyr974xxΦ and 
Leu1010/Leu1011) [13, 14] and the Q996QGFF b-turn motif [15, 16]. However, the role of AP2 
adapter proteins in EGFR downregulation is not entirely clear. Although the AP2µ subunit 
associates with the EGFR via the Tyr974xxΦ motif, the EGFR Y974A mutation does not affect 
EGFR internalization [13]. Moreover, overexpression of a dominant negative AP2µ subunit 
inhibits transferrin receptor but not EGFR internalization [17]. Depletion of clathrin heavy 
chain through RNA interference techniques has been reported to inhibit EGFR internaliza-
tion [18, 19] or to have no effect [20], perhaps depending on the level of clathrin heavy 
chain knock down achieved. The AP2β subunit may associate with the EGFR dileucine 
sequence Leu1010/Leu1011 and has been hypothesized to be involved in lysosomal targeting 
[14]. 
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ternalization, but is required for lysosomal targeting and degradation of the EGFR [41], 
although redundancy with CBLB may still occur in this setting. On the other hand, RNA 
interferences studies against both C-CBL and CBLB have suggested that CBL proteins are 
required for internalization [39]. 
 In this study, we (i) demonstrate that the CBL binding sites ERBB-1, -2 and -4 receptors 
are highly conserved during vertebrate evolution, and (ii) tested the hypothesis that ERBB2 
and ERBB4 CBL binding sites are functionally impaired. Our results demonstrate that the 
CBL binding sites of ERBB2 and ERBB4 are fully functional, and that the EGFR CBL binding 
site is not essential for endosomal trafficking.
Material and methods
Cell culture and reagents
Parental NIH3T3 cells and HER14 cells (NIH3T3 cells stably transfected with the human 
EGFR) were kindly provided by Dr. J. Schlessinger (Yale University, New Haven, CT) [45]. 
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% newborn calf serum (NCS; Hyclone) in flasks coated with 0.1% gelatin. Cells were 
trypsinized when confluent and seeded in flasks for regular maintenance. Lipofectamine™ 
2000 was purchased from Invitrogen. EGF was obtained from BD Bioscience.  The following 
antibodies were used in these studies: a-EGFR monoclonal antibody (mAb) 528, a-EGFR 
polyclonal antibodies (pAb) 1005, a-CBL mAb C15 (all Santa Cruz), a-EGFR mAb 13G8 
(Alexis Biochemicals), a-EGFR mAb cocktail Ab12 (Neomarkers), a-EGFR mAb LA22 and 
a-phosphotyrosine mAb 4G10 (Upstate Biotechnology), a-GAPDH ab9485 (Abcam), 
a-ubiquitin pAb U5379 (Sigma). Goat anti-rabbit (GARPO) and goat anti-mouse (GAMPO) 
mAbs linked to horseradish peroxidase were purchased from Signal Transduction 
Laboratories. Sepharose beads coupled to protein A were obtained from Amersham 
Biosciences. All PCR primers were obtained from Sigma.
Recombinant DNA technology and constructs
pcDNA3 EGFR CBL binding site mutants
pcDNA3 EGFR and pcDNA3 EGFR Y1045F were kindly provided by Dr. Y.Yarden (Weizmann 
Institute of Science, Rehovot, Israel). Mutations of the EGFR CBL binding site were made 
using a modified pcDNA3 EGFR expression construct containing an AgeI site directly 3’ of 
the codon for Pro1049, which was introduced by two-step PCR. The AgeI site was then used 
for the design of 3’ primers carrying various mutations in the CBL binding site (Table 1) 
followed by PCR amplification of the unique BstEII-AgeI fragment. Silent diagnostic 
restriction sites were introduced whenever feasible to facilitate screening of transformed 
bacteria. Primer sequences are available upon request. All mutations were verified by DNA 
sequencing.
Ligand-induced downregulation of the EGFR has been reported to be regulated through 
ligand-induced post-translational modifications such as EGFR tyrosine-, threonine-, and 
serine-phosphorylation as well as EGFR ubiquitination. Simultaneous mutation of multiple 
major tyrosine autophosphorylation sites has been reported to affect ligand-induced 
EGFR downregulation [16, 21], an effect that may be due to loss of GRB2 adapter protein 
recruitment, which is known to associate with dynamin and the CBL family of E3 ligase 
adapter proteins. Indeed, GRB2 associates with the EGFR either directly or indirectly (via 
Shc) through multiple major EGFR autophosphorylation sites [16, 21]. In addition, CBL 
proteins (C-CBL, CBLB and CBLC) can bind the EGFR directly via their N-terminal tyrosine 
kinase binding (TKB) domain to EGFR phosphoTyr1045 and indirectly via GRB2 (vide supra) 
[16, 22-24]. Phosphorylation of Thr654 has also been reported to affect endosomal trafficking 
by inhibiting the kinase activity of the EGFR [25] through an as yet unknown mechanism. 
Various serines are known to undergo phosphorylation including Ser1046 and Ser1047 within 
the CBL binding site of the EGFR and these have been reported to affect endosomal 
trafficking [26-32]. Finally, recruitment of CBL proteins leads to ligand-induced 
ubiquitination of the EGFR. In turn, ubiquitin moieties serve as binding sites for ubiqui-
tin-binding domains of various proteins involved in endosomal trafficking, such as EPS15, 
HRS, and various ESCRT proteins [33]. Moreover, CBL proteins function as adapters for 
recruitment of additional proteins to the activated receptor such as the CIN85-endophilin 
complex [34-36]. Thus, the role of EGFR post-transcriptional modifications on endosomal 
trafficking appears to be very complex.
 The role of CBL proteins in internalization, recycling and lysosomal targeting of ERBB 
receptors is under debate. The EGFR Y1045F mutation profoundly reduces but does not 
completely eliminate CBL recruitment and ligand-induced receptor ubiquitination, as CBL 
may still bind EGFR indirectly through GRB2 [16, 22-24]. Evidence supporting a role for 
EGFR ubiquitination in EGFR downregulation has therefore remained indirect. Although it 
was initially assumed that EGFR stimulation leads to CBL-mediated poly-ubiquitination, 
subsequent experiments using antibodies that distinguish between mono- and 
poly-ubiquitin adducts suggested that the EGFR is mainly modified by monoubiquitin on 
multiple lysines (multi-ubiquitination) [37, 38]. More recently however, mass spectrometry 
analysis has suggested that the EGFR contains predominantly Lys63-linked poly-ubiquitin 
chains [39]. Strikingly, even mutation of up to nine different lysine residues in the kinase 
domain of the EGFR does not completely abolish ligand-induced EGFR ubiquitination [39]. 
The EGFR Y1045F mutation has been reported to decrease receptor internalization and 
degradation and to enhance receptor recycling in Chinese Hamster Ovary (CHO) cells [23, 
40], although differences with the wild-type receptor are (relatively) small and such 
differences have not been universally reported in all cell types [23, 32, 40, 41]. Overexpression 
of a dominant negative CBL has also been reported to inhibit internalization, enhance 
recycling, and inhibit lysosomal targeting of the EGFR [16, 22, 42-44]. Studies using c-CBL 
deficient mouse embryonic fibroblasts suggested that C-CBL is not required for EGFR in-
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and 2.5 mM KCl, pH 2.5) to remove all non-internalized receptor-bound ligand. The cell 
medium was then neutralized by rinsing twice with DMEM, after which incubation was 
continued for an additional 1 h at 37°C in 1 ml DMEM/10% NCS to allow any internalized 
intact receptors to return to the cell surface. Subsequently, cells were put on ice and after 
the medium was aspired, they were incubated for 2 h on ice with 100 ml 1 ng/ml of 
[125I]-mEGF in binding buffer. Cells were then rinsed with ice-cold PBS, followed by a 1 h 
incubation with 250 ml/well 1% (v/v) Triton X-100. Extracted radio-ligand was measured in 
a g-counter (Packard Cobra II).
EGFR recycling
EGFR recycling assays were performed as previously described [47]. Cells were seeded in 
gelatin-coated 24 well plates, 1x105 cells per well. The following day, the cells were chilled 
on ice, the medium was aspired and cells were incubated in the presence of TGFa (60 ng/
ml) for 2 h on ice (indicated as time point –60 min). Subsequently, cells were transferred to 
room temperature for 1 h to allow receptor internalization. Cells were quickly rinsed with 
PBS to remove unbound ligand and after addition of 200 µl of prewarmed DMEM plus 
10% NCS, transferred to 37°C for various lengths of time (0-120 min). Ligand binding was 
measured by incubating the cells with 1 ng/ml of [125I]-mEGF in binding buffer for 2 h on 
ice as described in the previous paragraph.
EGFR internalization
EGFR internalization was performed as previously described [47]. Briefly, cells were seeded 
in gelatin-coated 24 well plates, 1x105 cells per well. The following day, the cells were 
chilled on ice and incubated with EGF (60 ng/ml) in 50 mM BES containing DMEM (pH 6.8) 
for 2 h on ice. Receptor internalization was subsequently induced by transferring the cells 
to room temperature for various lengths of time (0-120 min). Receptor internalization was 
quantified by measuring the decrease in cellular [125I]-mEGF binding after removal of all 
non-internalized receptor-bound ligand by a mild acid wash, as described above.
EGF degradation
EGF degradation assays were performed as described previously [47]. Briefly, cells were 
seeded in gelatin-coated 24 well plates, 1x105 cells per well. The following day, the cells 
were chilled on ice and incubated with 1 ng/ml [125I]-mEGF in binding buffer for 2 h on ice 
to allow ligand binding in the absence of endocytosis. Cells were then transferred to room 
temperature for 60 min to induce ligand internalization. The medium was aspired and 
cells were rinsed twice with ice-cold PBS. After removal of all receptor-bound ligand from 
the cell surface by a short incubation with 250 µl of acid buffer at 4°C, cells were rinsed 
with ice-cold binding buffer, and incubated at 37°C in 250 ml DMEM plus 10% NCS. After 
various incubation times (0-240 min), medium was collected and cells were lysed in 1 M 
NaOH. Acetone precipitations were performed on both cell lysates and medium, as 
Constructs for retroviral infection
pLXSN Neo was obtained from Dr. G.P. Nolan (Stanford University School of Medicine, CA, 
USA) [46]. The VspI site present in the ampicillin resistance gene of pLXSN Neo was 
removed by PCR-mediated site directed mutagenesis using the NdeI and PvuI sites. A 
linker containing a VspI site (5’aattccattaatccgcatc3’ and 5’tcgagatgcggattaatgg3’) was 
introduced into the multiple cloning site of pLXSN Neo using EcoRI and XhoI. The EGFR 
constructs containing CBL binding site variations (vide supra) were cloned into the 
modified pLXSN Neo vector using VspI and XhoI restriction sites. Primer sequences are 
available upon request. All mutations were verified by DNA sequencing.
Recombinant protein expression in NIH3T3 cells
NIH3T3 cells were either transiently transfected using Lipofectamine™ 2000 according to 
the manufacturer’s protocol or retrovirally infected with (mutant) EGFR constructs. 
Phoenix ecotrophic cells were kindly provided by Drs. G.P. Nolan (Stanford University 
School of Medicine, CA, USA) and Y.E. Noordman (Dept. Cell Biology, Nijmegen Center for 
Molecular Life Sciences, Faculty of Medicine, Radboud University Nijmegen). To produce 
ecotrophic retroviral particles for subsequent infection of mouse NIH3T3 cells, 2x106 
Phoenix cells were seeded in 10 cm diameter dishes (day 0). Next day (day 1) Phoenix cells 
were transfected with 20 µg DNA of the appropriate constructs by standard calcium 
phosphate transfection procedures. NIH3T3 cells were seeded in 6-well plates at 2x105 
cells/well. On day 2, 6 ml of Phoenix media containing viral particles were collected and 
filtered through 0.45 µm filters to which 6 µl of polybrene (Sigma) (5 mg/ml) were added. 
After 10 min incubation on ice, NIH3T3 cells were infected with 2 ml virus containing 
media. On day 3, infected NIH3T3 cells were washed twice with media and subsequently 
kept on culture medium containing 800 mg/ml G418 for 7 to 10 days to ensure death of 
uninfected cells. Infected G418 resistant cells were subsequently cultured on medium 
without G418 and used in experiments.
125I-EGF ligand binding assays
EGFR downregulation
EGFR downregulation was performed exactly as previously described [47]. On day 1, cells 
were seeded at 1x105 cells per well and grown to confluence in gelatinized 24-well plates. 
The next day, cells were chilled on ice, medium was aspired and growth factors were 
added in 1 ml of serum-free 50 mM BES containing DMEM (pH 6.8) containing 0.5% BSA 
for 2 h on ice to prevent receptor internalization during EGF loading. Cells were then 
transferred to 37°C for various lengths of time (0-120 min) in the presence of 0.3 mM 
monensin (Sigma) to prevent recycling of internalized EGFRs. At the end of the incubation 
period, the extent of ligand-induced downregulation of the EGFR was quantified by 
measuring the decrease in the ability of [125I]-murine (m)EGF to bind to the cells. This was 
carried out by washing the cells twice with ice cold acid buffer (135 mM NaCl, 5 mM HAc 
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 So far it is not clear whether variations in positions -4, -3 and +2 between human ERBB 
paralogs are functionally significant. However, functional sites in proteins are usually 
highly conserved during evolution [51]. We therefore searched public ongoing draft and 
completed genome sequences deposited at the NCBI genbank database for the CBL 
binding sites of ERBB receptors. As seen in Table 1 and the supplementary Table 1, the 
ERBB receptor CBL binding sites appear to be absolutely conserved among 21 species of 
placental mammals (only 3 amino acid substitutions are observed, which are likely due to 
low (2x) sequence coverage of the specific genome projects). Moreover, ERBB CBL binding 
sites are highly conserved among other tetrapods. Bony fish contain 2 paralogs for each of 
the ERBB1, ERBB3 and ERBB4 genes[52]. The ERBB4 CBL binding site (STQRYSADPT) is also 
highly conserved among bony fish, with variations seen mainly at positions -4 and -3. In 
contrast, the EGFR (F[L/I/V]QRYS[S/T]DPT) and ERBB2 (PLQRYSEDPT) CBL binding sites are 
less conserved among bony fish. These findings indicate that sequence variations among 
human ERBB CBL binding sites are highly conserved during tetrapod- and to a lesser 
extent vertebrate-evolution, suggesting that sequence variations among ERBB receptor 
paralogs in the CBL binding site are functionally important. The motif RpYXXDPT appears 
to be nearly absolutely conserved among all vertebrate ERBB-1, -2 and -4 receptor CBL 
binding sites.
described previously [47]. Ligand degradation was calculated from the percentage of non- 
precipitable radioactivity present in both cell lysate and medium at a given time point.
Cell lysis, immunoprecipitation, immunoblotting and densitometry
Cell lysis, immunoprecipitation and immunoblotting were performed exactly as described 
previously [48]. Signals on X-ray films of immunoblots were quantified using Adobe 
Photoshop 5.5 software. Briefly, 8-bit grayscale images were inverted and a small 
predefined rectangle was used to measure the mean pixel value of relevant signals and 
background using the histogram command. Background signals were subtracted from 
relevant signals leading to a corrected mean pixel value. Values obtained from post-trans-
lational modifications were then divided by the corrected mean pixel values of the immu-
noprecipitated material and subsequently normalized relative to a given sample (either 
EGFR wild-type or T=0). These normalized background-corrected relative mean pixel 
values (crMPVs) are indicated at the bottom of relevant figure panels. It should be noted 
that quantification of EGFR ubiquitin signals relative to EGFR levels is inherently difficult 
because the variable increase in EGFR molecular weight is associated with a concommitant 
decrease in the 180 kDa EGFR band. 
Results
Evolutionary conservation of ERBB receptor CBL binding sites
It has previously been reported that the CBL variant SH2 domain selects a D(N/D)XpY 
motif from a degenerate phosphopeptide library containing variable amino acids at 
position -3, -2, -1, +1, +2, and +3 relative to the phosphotyrosine [49]. However, subsequent 
structural analysis of the interaction between the CBL TKB domain and a tyrosine 
phosphorylated substrate peptide derived from the cytoplasmic tyrosine kinase ZAP-70 
revealed that the primary specificity determinants are likely to be C-terminal to the phos-
photyrosine [50]. Specifically, a proline in the +4 position of the phosphopeptide packs in 
a shallow hydrophobic pocket of the CBL TKB domain. It was concluded that additional 
contributions are provided by a negatively charged glutamic acid at position +3 and 
possibly an asparagine at position -2 of the substrate peptide. Comparison of the human 
ERBB receptor CBL binding sites (Table 1) reveals that the CBL binding site of ERBB-1, -2 and 
-4 proteins all contain a CBL binding site with sequence XXQRpYSXDPT, with conservation 
of the central tyrosine, the proline at position +4, a negatively charged aspartate at 
position +3, and an arginine and glutamine at positions -1 and -2, respectively. Multiple 
sequence alignment (Jansen S.M., Sleumer L.S., unpublished data) indicates that the 
corresponding sequence of ERBB3 is HSQRHSLLTP, lacking the central tyrosine and 
replacement of the proline at +4 by a threonine, consistent with lack of CBL binding to the 
tyrosine kinase deficient ERBB3 receptor [4, 42]. 
Table 1   ERBB receptor CBL binding sites and EGFR CBL binding site mutants used in  
this study.
#Sequence identical to hERBB2 CBL binding site. * Sequence identical to hERBB4 CBL binding site.
hErbB1 FLQRpY1045SSDPT 
hErbB2 PLQRpY1091SEDPT 
hErbB3 HSQR H1118SLLTP 
hErbB4 STQRpY1103SADPT 
Wild type FLQRpY1045SSDPT 
Y1045F FLQR F1045SSDPT 
S1046A FLQRpY1045ASDPT 
S1047A FLQRpY1045SADPT 
S1046/1047A FLQRpY1045AADPT 
S1046E FLQRpY1045ESDPT 
S1047E FLQRpY1045SEDPT 
S1046/1047E FLQRpY1045EEDPT 
F1041P PLQRpY1045SSDPT 
F1041P/S1047E PLQRpY1045SEDPT# 
F1041S/L1042T STQRpY1045SSDPT 
FL→ST/S1047A STQRpY1045SADPT* 
Receptor Cbl binding site
ErbB1 Mutants used in this study
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Figure 1   Role of EGFR Ser1046 and Ser1047 in EGFR tyrosine phosphorylation, 
ubiquitination and CBL recruitment
(A), (B) and (C) NIH3T3 cells were transiently transfected with EGFR wt, Y1045F, S1046A/S1047A or 
S1046E/S1047E EGFR constructs. Cells were starved overnight and stimulated with EGF (100 ng/ml) 
for 20 minutes. Anti-EGFR (528) immunoprecipitates (IPs) and whole cell lysates were analyzed by 
Western blotting using anti-phosphotyrosine (4G10), anti-EGFR (1005), anti-ubiquitin (Ubq) or 
anti-CBL (C15) antibodies. Densitometric corrected relative mean pixel values (crMPVs) for EGFR 
tyrosine phosphorylation, EGFR ubiquitination and EGFR-CBL recruitment are normalized relative to 
the wild-type and indicated below each lane.
Figure 1   Continued
(D) Densitometric corrected relative mean pixel values of EGFR tyrosine phosphorylation (n=3), 
EGFR ubiquitination (n=3) and EGFR-CBL recruitment (n=2) are plotted as mean ± standard error of 
the mean (SEM). Note that the SEM of the EGFR WT + EGF group is equal to zero as this category was 
used for normalization (crMPV = 1).
D
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Serine 1046 and 1047 phosphorylation sites
Given that (i) phosphorylation of EGFR Ser1046 and Ser1047 has previously been reported to 
play a role in endosomal trafficking of the EGFR [27-29, 32, 53, 54], (ii) it has been 
hypothesized that poor CBL binding to ERBB2 and ERBB4 correlates with poor 
downregulation of these ERBB receptors [3, 10], and that (iii) amino-acid substitutions 
among ERBB receptor CBL binding sites are highly conserved among tetrapods, we 
investigated the functional significance of CBL binding site variations seen among human 
ERBB receptors with respect to ERBB receptor ubiquitination and endosomal trafficking. 
Initially, we simultaneously replaced the two serine residues for (i) alanine, or (ii) glutamate 
(to mimic a constitutively phosphorylated serine residue) (see also Table 1) and investigated 
the effect of these mutations on ligand-induced CBL recruitment and EGFR ubiquitination. 
We also used EGFR Y1045F mutant as a negative control for ligand-induced CBL recruitment 
and EGFR ubiquitination. Recombinant proteins were transiently transfected into NIH3T3 
cells. As shown in Figure 1A, the EGFR Y1045F and the S1046/1047A and S1046/1047E 
double mutants displayed EGF-induced tyrosine phosphorylation, similar to the wild type 
EGFR. Anti-EGFR immunoblotting also showed that both wild-type and mutant EGFRs 
display a characteristic upward mobility shift upon stimulation with ligand (Figure 1A). As 
shown in Figure 1B, the Y1045F mutant displayed severely reduced ubiquitination, as 
expected. In contrast to a previous publication [32], EGF-induced ubiquitination of the 
S1046/1047A and S1046/1047E double mutants was readily observed and similar compared 
to wild type (Figure 1B). It should be noted that ubiquitination of the EGFR results in a 
variable upward shift in the molecular weight of the protein and a concomitant decrease 
in the amount of the 180 kDa protein band. Consistent with normal EGF-induced 
ubiquitination, co-precipitation analysis demonstrated that the S1046/1047A and 
S1046/1047E double mutants also showed normal binding of c-CBL to the EGFR, while CBL 
interaction with the Y1045F mutant was strongly reduced (Figure 1C). Quantification of 
bands from multiple experiments further confirmed these conclusions (Figure 1D). Similar 
results were also obtained when either Ser1046 or Ser1047 alone were substituted for alanine 
or glutamate (Jansen S.M., Sleumer L.S., unpublished data).
 To better investigate ligand-induced EGFR degradation and endosomal trafficking of 
the mutant EGFR proteins, we established retrovirus infected NIH3T3 cell lines of the EGFR 
wild-type and mutant constructs. EGFR expression was analyzed by Western blotting and 
flow cytometry and compared to HER-14 cells that express approximately 3x105 EGF 
receptors at the cell surface [45]. As seen in supplemental Figure 1 (top panel), EGFR cell 
surface expression of the retrovirus infected wild-type and mutant EGFR cell lines was very 
similar compared to HER-14 cells. EGFR expression of the retroviral cell lines was also 
evaluated by flow cytometry (Supplemental Figures 2A-C). All EGFR mutant cell lines 
showed expression comparable to HER-14 (Supplemental Figure 2A, 2C) or EGFR wt 
(Supplemental Figure 2B, 2C). As seen in Supplemental Figure 2C, HER-14 and NIH3T3/
EGFR wt cell lines also show similar expression levels. We therefore conclude that all these 
Figure 2   Role of EGFR Ser1046 and Ser1047 residues in EGF-induced EGFR degradation
(A) and (B) Retroviral infected NIH3T3 cell lines expressing the indicated constructs were starved 
overnight and stimulated for various periods of time with 60 ng/ml EGF or they were left 
unstimulated. Whole cell lysates were analyzed by electrophoresis and Western blotting with 
a-EGFR (1005) or anti-GAPDH antibodies. Densitometric corrected relative mean pixel values are 
normalized for each constructs at timepoint 0 and indicated below each lane. (C) Densitometric 
corrected relative mean pixel values of EGFR degradation in HER14 (n=2), EGFR WT (N=3), EGFR 
Y1045F (n=3), EGFR S1046/1047A (n=2) and EGFR S1046/1047E (n=2) are plotted as mean ± standard 
error of the mean (SEM). Note that the SEM at T=0 hours is equal to zero as this category was used 
for normalization (crMPV = 1).
A
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cell lines show similar EGFR expression levels, which are comparable to the expression 
seen in HER-14 cells, thereby allowing a fair comparison between different cell lines.
 To determine whether CBL-mediated EGFR ubiquitination correlates with EGFR 
degradation, we analyzed whole cell lysates for EGFR expression following EGF stimulation. 
As seen in Figure 2A and 2C, EGF-induced EGFR degradation is delayed (but not blocked) 
in the Y1045F mutant relative to the wild-type EGFR. However, EGF-induced EGFR 
degradation of the S1046/1047A and S1046/1047E double mutants was similar as wild-type 
EGFR and HER-14 cells (Figure 2B and 2C). Similar results were also obtained when either 
Ser1046 or Ser1047 alone were substituted for alanine or glutamate or when using lower EGF 
concentrations (Jansen S.M., Sleumer L.S., unpublished data). These findings demonstrate 
that phosphorylation of Ser1046 or Ser1047 does not profoundly affect EGF-induced tyrosine 
phosphorylation, ubiquitination or degradation of the EGFR in NIH3T3 cells. 
 Retroviral cell lines were then used to evaluate endosomal trafficking of the EGFR 
mutant constructs by standard 125I-EGF labeled ligand binding assays, as detailed in the 
Materials and Methods section. As a negative control, we used the truncated EGFR C’957 
construct, which contains a stop codon after the last residue (Ile957) of the EGFR kinase 
domain (Suppl. Figure 2C). It has been demonstrated that this truncated EGFR fails to 
undergo significant EGF-induced internalization [55]. As seen in Figure 3 (top panel), the 
truncated EGFR C’957 construct failed to undergo significant EGFR downregulation, while 
the S1046/1047A and S1046/1047E double mutants showed EGFR downregulation similar 
to wild type, EGFR Y1045F mutant and HER-14 cells. Consistent with our previously 
published data [56], we could not detect EGF-induced recycling of the wild-type EGFR in 
HER-14 cells, nor could we detect EGF-induced EGFR recycling for the Y1045F, S1046/1047A 
and S1046/1047E double mutant constructs (Jansen S.M., Sleumer L.S., unpublished data). 
In contrast to EGF, TGFα displays pH-dependent binding to the EGFR leading to premature 
dissociation of TGFα from the EGFR in acidifying endosomes [56]. As a result, a significant 
fraction of internalized EGFRs is recycled to the plasma membrane after TGFα stimulation 
[6, 56] and we previously demonstrated that this correlates with decreased ubiquitination 
and decreased degradation of the receptor [48]. The EGFR S1046/1047A and S1046/1047E 
double mutant constructs were also indistinguishable from wild-type EGFR and the 
Y1045F mutant following TGFα-induced EGFR recycling (Figure 3, middle panel). Analysis 
of 125I-EGF ligand degradation (Figure 3, bottom panel) also revealed no significant 
differences between EGFR wt, Y1045F, S1046/1047A and S1046/1047E double mutant constructs. 
Thus, our findings demonstrate that phosphorylation of the EGFR Ser1046 and Ser1047 
residues within the CBL binding site does not affect EGFR-internalization, -downregulation, 
-recycling or ligand degradation in NIH3T3 cells. These findings also demonstrate that the 
EGFR Y1045F mutation, despite severely hampering CBL recruitment and EGFR 
ubiquitination, does not affect ligand-induced EGFR downregulation, internalization, 
recycling or ligand degradation in NIH3T3 cells. Nevertheless, the EGFR Y1045F mutation 
does slow down EGFR degradation as assessed by Western blotting. We speculate that 
Figure 3   Role of EGFR serine1046/1047 residues in ligand-induced receptor- 
downregulation, -recycling and ligand degradation
NIH3T3 cells were infected with retrovirus containing EGFR wt (closed squares), Y1045F 
(open triangles), S1046A/S1047A (open circles), S1046E/S1047E (open squares) or truncated 
EGFR C’957 (closed circles). HER14 cells (closed diamonds) were used as a control. Data 
points represent the mean of triplicate measurements. Top panel, EGF-induced EGFR 
downregulation; Middle panel, TGFα-induced EGFR recycling; Bottom panel, 125I-EGF 
degradation. Results are representative of 3 independent experiments.
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this may be due to prolonged retention times of the EGFR Y1045F protein on the limiting 
membrane of acidifying endosomes [57], leading to premature dissociation of (part of) 
the bound EGF which, in turn, may be transported to the lysosome for degradation.
ERBB2 and ERBB4 CBL binding sites
It has previously been reported that ERBB2 and ERBB4 receptors poorly bind CBL proteins 
[10, 11]. However, the molecular basis for this observation has not been established. As 
phylogenetic analysis has demonstrated that variations in the CBL binding site of ERBB-1, -2 
and –4 receptors are highly conserved among tetrapods, it is possible that such variations 
cause decreased CBL binding and ERBB receptor ubiquitination. Furthermore, it has previously 
been suggested that amino acids N-terminal of the phosphorylated Tyr1045 residue of the EGFR 
may contribute to the specificity and affinity of CBL binding [49, 50]. Moreover, secondary 
structure prediction of the EGFR cytoplasmic tail using the SOPM secondary structure 
prediction server [58] suggests the possibility that the CBL binding site in ERBB1 -but not in 
ERBB2 or ERBB4- is preceded by a short α-helix, i.e. EDSFLQR. It is therefore interesting to note 
that, nearly all vertebrate ERBB2 receptors contain a proline residue at -3 or -4 positions 
which likely distorts such a putative α-helix. On the other hand, ERBB4 receptors contain a 
branched threonine residue which has a low propensity to form α-helices. 
 To further investigate the functional significance of CBL binding site variations, we 
introduced single, double and triple mutations into the EGFR CBL binding site to resemble 
amino acid substitutions seen in ERBB2 and ERBB4 (Table 1). We then established retroviral 
cell lines of these constructs, verified similar EGFR expression levels of the mutant cell lines 
by western blotting (Supplemental Figure 1, 2nd panel) and flow cytometry (Supplemental 
Figures 2A-2C), and subsequently used them for analysis. The EGFR F1041P/S1047E double 
mutation, which mimics the ERBB2 CBL binding site (Table 1) did not abolish EGF-induced 
EGFR ubiquitination (Figure 4A), EGFR tyrosine phosphorylation (Jansen S.M., Sleumer L.S., 
Meijer I., unpublished data) or CBL binding (Figure 4A). Similarly, the EGFR F1041S/L1042T/
S1047A triple mutation, which mimics the ERBB4 CBL binding site (Table 1), also did not 
abolish EGFR ubiquitination, EGFR tyrosine phosphorylation or CBL binding (Table 1, 
Figure 4A). Similar results were also obtained for the EGFR F1041P single and F1041S/L1042T 
double mutations (Jansen S.M., Sleumer L.S., Meijer I., unpublished data). Indeed, we did 
not observe severely decreased ubiquitination or CBL binding for any of the mutants 
except for the EGFR Y1045F mutation (Figure 4A and 4C). Please note that coprecipitation 
of CBL with the EGFR F1041P mutant was established by anti-phosphotyrosine blotting 
(Figure 4A, 3rd panel, lane 6) although it was not seen by anti-CBL blotting in the experiment 
shown in Figure 4A, (Figure 4A, 2nd panel, lane 6). Duplicate experiments confirmed co-
precipitation of the EGFR F1041P mutant with CBL (data not shown). Introduction of the 
ERBB2 CBL binding site (F1041P/S1047E) or the ERBB4 CBL binding site (F1041S/L1042T/
S1047A) into the EGFR also did not significantly affect EGF induced EGFR degradation as 
assessed by Western blotting (Figure 4B and 4D). 125I-ligand binding assays using these cell 
Figure 4   ERBB2 and ERBB4 CBL binding sites support efficient EGFR ubiquitination and 
degradation
NIH 3T3 cells were retrovirally infected with EGFR wt, Y1045F, F1041P/S1047E (=ERBB2 CBL binding 
site) or F1041S/L1042T/S1047A (=ERBB4 CBL binding site). (A) Cells were starved overnight, and 
stimulated with EGF (100 ng/ml) for 20 min. Anti-EGFR immunoprecipitates were analyzed by elec-
trophoresis and Western blotting with the indicated antibodies. (B) Cells were starved overnight 
and stimulated with EGF (60 ng/ml) EGF for 2, 4 and 6 h, or left unstimulated. Cell lysates were 
analyzed by electrophoresis and Western blotting with anti-EGFR. Densitometric corrected relative 
mean pixel values are normalized relative to the wild-type (A) or timepoint 0 (B) and indicated below 
each lane.
A
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Figure 5   Introduction of ERBB2 or ERBB4 CBL binding sites in EGFR does not affect 
EGFR downregulation, EGFR recycling or ligand degradation
NIH 3T3 cells were retrovirally infected with EGFR wt (closed squares), F1041P/S1047E (=ERBB2 CBL 
binding site, open circles) or F1041S/L1042T/S1047A (=ERBB4 CBL binding site, open squares). Data 
points represent the mean of triplicate measurements. Top panel, EGF-induced EGFR downregulation; 
Middle panel, TGFα-induced EGFR recycling; Bottom panel, 125I-EGF degradation. Results are 
representative of 2 independent experiments.
Figure 4  Continued
(C) Densitometric relative corrected mean pixel values of EGFR ubiquitination (N=3) and EGFR-CBL 
recruitment (n=3) are plotted as mean ± standard error of the mean (SEM). Note that the SEM of the 
EGFR WT + EGF group is equal to zero as this category was used for normalization (crMPV = 1). 
Abbreviations: FS-PE (F1041P/S1047E), FL-ST (F1041S/L1042T), FLS-STA (F1041S/L1042T/S1047A). (D) 
Densitometric corrected relative mean pixel values of EGFR degradation in EGFR WT (N=3), EGFR 
FS-PE (F1041P/S1047E) (n=2), and EGFR FLS-STA (F1041P/L1042T/S1047A) (n=2) are plotted as mean ± 
standard error of the mean (SEM). Note that the SEM at T=0 hours is equal to zero as this category 
was used for normalization (crMPV = 1).
C
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reported that EGFR S1046/1047A double mutants showed defective EGFR internalization 
and downregulation at low EGF concentrations [28], while subsequent studies from the 
same group suggested that moderately expressed EGFR S1046/1047A double mutants 
showed no defects a low EGF concentrations but displayed impaired internalization and 
downregulation at high EGF concentrations [30]. More recently, Oksvold et al. [32] reported 
that the S1046/1047A double mutant (i) does not display the characteristic EGF induced 
mobility shift, (ii) fails to undergo efficient ubiquitination despite normal CBL recruitment, 
and (iii) shows reduced EGFR degradation based on short term semi-quantitative Western 
blotting and confocal microscopy studies in NIH3T3 cells. In contrast, our results obtained 
in NIH3T3 cells clearly show EGF-induced mobility shift, CBL recruitment and efficient 
EGF-induced ubiquitination of the EGFR S1046/1047A double mutant (Figure 1). Moreover, 
quantitative analysis of receptor downregulation using 125I-EGF ligand binding assays 
demonstrated no significant differences between wild-type and S1046/1047A in terms of 
(i) EGFR downregulation, (ii) EGFR internalization, (iii) EGFR recycling, and (iv) EGF ligand 
degradation (Figure 3). This was further supported by EGFR degradation assays as assessed 
by Western blotting (Figure 2). The reason for these discrepant results is not clear but may 
be related to the use of different host cell types, read-out assays and/or differences in 
EGFR expression levels. 
 Thus, our findings indicate that poor downregulation of ERBB2 and ERBB4 relative to 
the EGFR is not due to functional differences in the CBL binding site of these receptors, but 
is likely due to other differences between these receptors. As previously discussed, the 
EGFR contains additional endosomal sorting signals, including Tyr974 and a dileucine 
signal at Leu1010/Leu1011 that associate with AP2µ and AP2β respectively. Evaluation of the 
presence of similar motifs in vertebrate ERBB receptors reveals that ERBB2 and ERBB4 (but 
not ERBB3) contain evolutionary conserved motifs that resemble the EGFR YxxΦ AP2µ 
binding motif (Suppl. Table 2). Whether mutation of these sites in ERBB2 and ERBB4 affects 
their endosomal sorting is not clear yet. Interestingly, the EGFR dileucine motif that has 
been hypothesized to affect lysosomal targeting of the EGFR [14] is present only in EGFR 
orthologs but not in ERBB2, ERBB3 or ERBB4 (data not shown). Thus, the absence of this 
motif in ERBB-2, and -4 may be a reason for reduced lysosomal targeting and enhanced 
recycling of these receptors. EGFR orthologs also contain the QQGFF motif (Suppl. Table 
3), a predicted β-turn that follows an acidic α-helical region, that was previously shown to 
be functional as an endocytic sorting signal [15, 16]. Analysis of vertebrate ERBB orthologs 
reveals that this motif is evolutionary conserved also in ERBB2, but this motif is absent in 
ERBB3 and ERBB4 orthologs. The absence of this motif in ERBB4 may therefore also reduce 
the downregulation capacity of ERBB4. Finally, there may be yet unidentified endosomal 
sorting signals that differ between the EGFR, ERBB2 and ERBB4. It is clear that multiple 
endosomal sorting signals cooperate to regulate downregulation of ERBB receptors [16], 
but further studies are required to obtain a complete understanding of the molecular 
basis for the endosomal trafficking of ERBB receptors.
lines further demonstrated that introduction of the ERBB2 CBL binding site (F1041P/
S1047E) or the ERBB4 CBL binding site (F1041S/L1042T/S1047A) did not affect EGF-induced 
EGFR downregulation (Figure 5, top panel), TGFα-induced EGFR recycling (Figure 5, middle 
panel), or 125I-EGF ligand degradation (Figure 5, bottom panel). These findings demonstrate 
that ERBB2 and ERBB4 CBL binding sites (as defined from positions -4 to +4) cannot be 
distinguished from the wild-type EGFR CBL binding site in terms of ligand-induced EGFR 
tyrosine phosphorylation, EGFR ubiquitination, EGFR degradation, CBL recruitment, EGFR 
downregulation and EGF ligand degradation. We therefore conclude that the molecular 
basis for the reported poor downregulation of ERBB2 and ERBB4 receptors is unlikely to be 
due to evolutionary conserved variations in the CBL binding site of these receptors relative 
to the EGFR.
Discussion
It has previously been reported that ERBB receptors other than the EGFR are poorly 
downregulated. It has been postulated that poor downregulation of these receptors 
correlates with decreased binding to CBL E3 ligase adapter proteins [10, 11]. However, this 
hypothesis has not been experimentally verified. Here we demonstrate that the EGFR CBL 
binding site (residues 1041-1049; residues -4 to +4 relative to pTyr1045) can be readily 
replaced by the evolutionary highly conserved CBL binding sites of ERBB2 and ERBB4, 
without any profound effect on EGFR-tyrosine phosphorylation, -ubiquitination, 
-degradation, -internalization, -downregulation and -recycling or on ligand degradation 
in NIH3T3 cells. We conclude that phosphorylated serine residues located within the EGFR 
CBL binding site do not affect EGFR downregulation and that the CBL binding sites of 
ERBB2 and ERBB4 receptors can functionally replace the EGFR CBL binding site. 
EGFR serine 1046/1047 phosphorylation
Various EGFR serine residues have been reported to undergo phosphorylation. Specifically, 
the serine residues within the EGFR CBL binding sites (Ser1046 and Ser1047) have been 
reported to undergo PMA-, PDGF- and EGF-induced phosphorylation in vivo based on 
phosphopeptide mapping data [26, 27]. They were also reported to be efficiently 
phosphorylated by CaM Kinase II in vitro [28, 31]. In contrast to the EGFR Ser1047, the 
corresponding ERBB2 Ser1093 residue is not efficiently phosphorylated by CaM Kinase II in 
vitro [59]. Ouyang et al. [60] reported the generation of ERBB2 phosphoSer1093 specific 
antibodies and reported ERBB2 Ser1093 phosphorylation in response to EGF-induced 
EGFR-ERBB2 heterodimerization. 
 The functional significance of EGFR Ser1046 and Ser1047 phosphorylation is a matter of 
debate. Countaway et al. initially reported that single S1046A and S1047A mutations did 
not affect EGFR downregulation in CHO cells [27]. In a subsequent study, Countaway et al. 
2CHAPTER 2 ERBB2 AND ERBB4 CBL BINDING SITES CAN REPLACE THE ERBB1 CBL BINDING SITE
72 73
References
[1]  Olayioye MA, Neve RM, Lane HA, Hynes NE, Embo J. 2000;19:3159-3167.
[2]  Yarden Y, Sliwkowski MX, Nat Rev Mol Cell Biol. 2001;2:127-137.
[3]  Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G, The Journal of biological chemistry. 1996;271:
5251-5257.
[4]  Waterman H, Alroy I, Strano S, Seger R, Yarden Y, Embo J. 1999;18:3348-3358.
[5]  Sorkin A, Di Fiore PP, Carpenter G, Oncogene. 1993;8:3021-3028.
[6]  Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van 
Zoelen EJ, Yarden Y, Embo J. 1998;17:3385-3397.
[7]  Wang Z, Zhang L, Yeung TK, Chen X, Mol Biol Cell. 1999;10:1621-1636.
[8]  Hommelgaard AM, Lerdrup M, van Deurs B, Mol Biol Cell. 2004;15:1557-1567.
[9]  Haslekas C, Breen K, Pedersen KW, Johannessen LE, Stang E, Madshus IH, Mol Biol Cell. 2005;16:5832-5842.
[10]  Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y, Oncogene. 1996;12:1117-1125.
[11]  Muthuswamy SK, Gilman M, Brugge JS, Mol Cell Biol. 1999;19:6845-6857.
[12]  Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y, J Biol Chem. 2000;275:35532-35539.
[13]  Sorkin A, Mazzotti M, Sorkina T, Scotto L, Beguinot L, J Biol Chem. 1996;271:13377-13384.
[14]  Huang F, Jiang X, Sorkin A, The Journal of biological chemistry. 2003;278:43411-43417.
[15]  Chang C, Lazar C, Walsh B, Komuro M, Collawn J, Kuhn L, Tainer J, Trowbridge I, Farquhar M, Rosenfeld M, Wiley 
HS, Gill GN, J Biol Chem. 1993;268:19312-19320.
[16]  Jiang X, Huang F, Marusyk A, Sorkin A, Molecular biology of the cell. 2003;14:858-870.
[17]  Nesterov A, Carter RE, Sorkina T, Gill GN, Sorkin A, Embo J. 1999;18:2489-2499.
[18]  Motley A, Bright NA, Seaman MN, Robinson MS, J Cell Biol. 2003;162:909-918.
[19]  Huang F, Khvorova A, Marshall W, Sorkin A, J Biol Chem. 2004;279:16657-16661. Epub 12004 Feb 16625.
[20]  Hinrichsen L, Harborth J, Andrees L, Weber K, Ungewickell EJ, J Biol Chem. 2003;278:45160-45170.
[21]  Sorkin A, Frontiers in Bioscience. 1998;3:d729-d738.
[22]  Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y, Genes & 
development. 1998;12:3663-3674.
[23]  Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y, The EMBO journal. 2002;21:303-313.
[24]  Huang F, Sorkin A, Mol Biol Cell. 2005;16:1268-1281. Epub 2005 Jan 1265.
[25]  Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, Gruenberg J, Yarden Y, J Biol Chem. 2000;275:26178-26186.
[26]  Heisermann GJ, Gill GN, J Biol Chem. 1988;263:13152-13158.
[27]  Countaway JL, McQuilkin P, Girones N, Davis RJ, J Biol Chem. 1990;265:3407-3416.
[28]  Countaway JL, Nairn AC, Davis RJ, J Biol Chem. 1992;267:1129-1140.
[29]  Theroux SJ, Taglienti-Sian C, Nair N, Countaway JL, Robinson HL, Davis RJ, J Biol Chem. 1992;267:7967-7970.
[30]  Theroux SJ, Latour DA, Stanley K, Raden DL, Davis RJ, J Biol Chem. 1992;267:16620-16626.
[31]  Feinmesser RL, Wicks SJ, Taverner CJ, Chantry A, J Biol Chem. 1999;274:16168-16173.
[32]  Oksvold MP, Thien CB, Widerberg J, Chantry A, Huitfeldt HS, Langdon WY, Oncogene. 2003;22:8509-8518.
[33]  Dikic I, Biochem Soc Trans. 2003;31:1178-1181.
[34]  Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I, Nature. 2002;416:183-187.
[35]  Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S, Nature. 2002;416:187-190.
[36]  Kowanetz K, Husnjak K, Holler D, Kowanetz M, Soubeyran P, Hirsch D, Schmidt MH, Pavelic K, De Camilli P, 
Randazzo PA, Dikic I, Mol Biol Cell. 2004;15:3155-3166.
[37]  Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I, Nature cell biology. 2003;5:461-466.
[38]  Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, Yarden Y, The Journal of biological chemistry. 
2003;278:21323-21326.
[39]  Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A, Molecular cell. 2006;21:737-748.
[40]  Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, 
Lipkowitz S, Yarden Y, Mol Cell. 1999;4:1029-1040.
[41]  Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson 
K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V, Band H, The Journal of biological 
chemistry. 2003;278:28950-28960.
Acknowledgement
This study was supported by a grant from the Dutch Cancer Society (KUN 2001-2453). 
2CHAPTER 2 ERBB2 AND ERBB4 CBL BINDING SITES CAN REPLACE THE ERBB1 CBL BINDING SITE
74 75
[42]  Waterman H, Sabanai I, Geiger B, Yarden Y, J Biol Chem. 1998;273:13819-13827.
[43]  Lill NL, Douillard P, Awwad RA, Ota S, Lupher ML, Miyake S, Meissner-Lula N, Hsu VW, Band H, J Biol Chem. 
2000;275:367-377.
[44]  Thien CB, Walker F, Langdon WY, Mol Cell. 2001;7:355-365.
[45]  Honegger A, Dull TJ, Bellot F, Van Obberghen E, Szapary D, Schmidt A, Ullrich A, Schlessinger J, Embo J. 
1988;7:3045-3052.
[46]  Kinsella TM, Nolan GP, Hum Gene Ther. 1996;7:1405-1413.
[47]  van de Poll ML, van Rotterdam W, Gadellaa MM, Jacobs-Oomen S, van Zoelen EJ, Exp Cell Res. 2005;304:630-
641.
[48]  Alwan HA, van Zoelen EJ, van Leeuwen JE, J Biol Chem. 2003;278:35781-35790. Epub 32003 Jun 35726.
[49]  Lupher ML, Songyang Z, Shoelson SE, Cantley LC, Band H, J Biol Chem. 1997;272:33140-33144.
[50]  Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ, Nature. 1999;398:84-90.
[51]  Lichtarge O, Sowa ME, Curr Opin Struct Biol. 2002;12:21-27.
[52]  Stein RA, Staros JV, BMC evolutionary biology. 2006;6:79.
[53]  Countaway JL, Girones N, Davis RJ, J Biol Chem. 1989;264:13642-13647.
[54]  Countaway JL, Northwood IC, Davis RJ, J Biol Chem. 1989;264:10828-10835.
[55]  Chen WS, Lazar CS, Lund KA, Welsh JB, Chang CP, Walton GM, Der CJ, Wiley HS, Gill GN, Rosenfeld MG, Cell. 
1989;59:33-43.
[56]  Lenferink AE, Kramer RH, van Vugt MJ, Konigswieser M, Di Fiore PP, van Zoelen EJ, van de Poll ML, Biochem J. 
1997;327:859-865.
[57]  Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH, J Cell Biol. 2002;156:843-854. Epub 
2002 Feb 2025.
[58]  Combet C, Blanchet C, Geourjon C, Deleage G, Trends Biochem Sci. 2000;25:147-150.
[59]  Feinmesser RL, Gray K, Means AR, Chantry A, Oncogene. 1996;12:2725-2730.
[60]  Ouyang X, Gulliford T, Zhang H, Smith G, Huang G, Epstein RJ, Mol Cell Biochem. 2001;218:47-54.
3
ERBB2 is a target for USP8-mediated 
deubiquitination
Inez M.J. Meijer, Jeroen E.M. van Leeuwen
Cellular Signalling. 2011 Feb; 23(2):458-467
3CHAPTER 3 ERBB2 IS A TARGET FOR USP8-MEDIATED DEUBIQUITINATION
78 79
Abstract
Overexpression and poor downregulation of ERBB receptor tyrosine kinases are associated 
with enhanced signaling and tumorigenesis. Attenuation of EGF-receptor (EGFR) signaling 
is mediated by endocytosis and ubiquitination by the E3-ligase CBL. En route to lysosomes, 
but before incorporation of the EGFR into internal vesicles of MVBs, the EGFR undergoes 
USP8-mediated deubiquitination. ERBB2 displays enhanced recycling back to the cell 
surface, and therefore we hypothesized that USP8 is not part of the ERBB2 trafficking 
pathway. Here, we demonstrate, in the context of a chimeric EGFR-ERBB2 receptor, that (i) 
EGF induces pY1091 CBL binding site-dependent K63-polyubiquitination of EGFR-ERBB2, 
(ii) CBL is tyrosine phosphorylated upon stimulation of EGFR-ERBB2 wt and Y1091F mutant 
receptor, (iii) EGF-induced activation of EGFR-ERBB2 induces USP8 tyrosine phosphoryla-
tion, and (iv) ubiquitination of the EGFR-ERBB2 wt and Y1091F mutant is enhanced upon 
coexpression of catalytically inactive USP8-C748A in the presence and absence of EGF. We 
further show that USP8 tyrosine phosphorylation upon stimulation of EGFR-ERBB2 is (a) 
independent of Y1091, (b) dependent on SRC- and EGFR-ERBB2-kinase activity, (c) 
enhanced upon co-expression of USP8-C748A, and (d) partly dependent on the 
Microtubule Interacting and Transport (MIT) domain of USP8. Our findings demonstrate 
that USP8 is part of the ERBB2 endosomal trafficking pathway.
Introduction
The ERBB family of receptor tyrosine kinases consists of four members denoted ERBB1 
(also known as EGFR), ERBB2, ERBB3 and ERBB4, that form homo- and hetero-dimeric 
complexes upon ligand binding. ERBB2 is an orphan receptor, which functions by forming 
heterodimeric complexes with ligand-bound ERBB receptors, including the tyrosine 
kinase inactive ERBB3 [1]. The ERBB receptors are critical regulators of normal cellular 
growth, differentiation and tissue development in many different organs. While EGFR 
plays an essential role during epithelial-cell development [2, 3], ERBB2 has been 
demonstrated to be important in the developing heart [4], central [5] and peripheral [6] 
nervous system and mammary gland morphogenesis [7]. Besides their role in normal 
physiology, EGFR, ERBB2 and ERBB3 are also frequently involved in the formation of solid 
tumors and as a consequence the ERBB signaling network is one of the main targets for 
anti-tumor therapy in humans [8]. ERBB2 overexpression triggers ligand-independent 
activation of the kinase domain and is observed in a large proportion of breast and ovarian 
cancers, where it is associated with tumour size, spread of the tumour, resistance to 
anti-oestrogen therapy and poor prognosis [9]. A humanized monoclonal antibody to the 
extracellular domain of ERBB2, Herceptin (trastuzumab), has been approved for clinical use 
[10].
 Attenuation of ERBB receptor signaling is mediated by the clathrin-dependent 
pathway of receptor-mediated endocytosis and subsequent sorting of the activated 
ligand- receptor complex via the multivesicular body (MVB) pathway to lysosomes for 
degradation [11]. Thus, incorporation of ERBB receptors in internal vesicles of MVBs abrogates 
the communication with cytoplasmic signaling molecules, leading to attenuation of 
signaling. Moreover, uncontrolled ERBB receptor signaling that results from increased 
receptor expression, over-expression of ligands, or activating mutations in the trans-
membrane, tyrosine kinase or cytoplasmic domains is often correlated with decreased 
ERBB receptor downregulation (removal from the cell surface) [1]. 
 Most studies on receptor downregulation have been performed on EGFR. Upon EGF 
binding, the CBL family of RING finger E3-ubiquitin ligases catalyses the ligand-induced 
ubiquitination of the EGFR, which plays an important role in EGFR internalization and 
lysosomal targeting [11]. CBL is recruited to the EGFR, either directly through its tyrosine 
kinase binding (TKB) domain to phosphorylated tyrosine residue pY1045 in the cytoplasmic 
tail of EGFR or indirectly via GRB2, which binds to phosphorylated tyrosine residues Y1068 
and Y1086 [12]. The RING finger of CBL simultaneously interacts with UBC4/5 E2-ubiquitin 
activating enzymes that transfer the activated ubiquitin to lysine side chains of the EGFR 
substrate protein [13]. Ubiquitination can either exist as mono-, multi- (mono-ubiquitination on 
multiple lysines) or poly-ubiquitination. Whereas K48-linked poly-ubiquitination serves as 
a signal for proteasomal degradation, K63-linked poly-ubiquitination has been shown to 
regulate non-proteosomal processes such as DNA repair, kinase activation, translational 
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 Given the impaired downregulation of ERBB2, we have investigated in the present 
study whether ERBB2 and USP8 functionally interact. Using a chimeric EGFR-ERBB2 model 
system, which can be activated by EGF and therefore allows a fair comparison between 
the EGFR and the orphan ERBB2 receptor, we demonstrate that ERBB2 is regulated by 
CBL-mediated K63-linked polyubiquitination and USP8-mediated deubiquitination, 
similarly to EGFR. Moreover, we show that USP8 interacts with ERBB2 and is tyrosine 
phosphorylated in a ERBB2- and SRC kinase dependent manner, although its tyrosine 
phosphorylation is to a lesser extent than in the case of  EGFR stimulation. 
Material and methods
Reagents
The following antibodies were used in these studies: a-EGFR monoclonal antibody (mAb) 
528, a-EGFR polyclonal antibodies (pAb) 1005, a-CBL mAb C15, a-ERBB2 pAb C18, a-GFP 
pAb FL (Santa Cruz), a-EGFR mAb LA22, a-phosphotyrosine mAb 4G10, a-K63 ubiquitin 
mAb Apu3 (Upstate Biotechnology), a-FLAG mAb M2, a-ubiquitin pAb U5379 and 
a-tubulin (Sigma). Immunoprecipitation of EGFR was carried out using mAb528, while 
pAb1005 was used for EGFR detection on Western blots, unless specified otherwise. Goat 
anti-rabbit (GARPO) and goat anti-mouse (GAMPO) mAbs, both linked to horseradish 
peroxidase, were purchased from Signal Transduction Laboratories. Other reagents used 
in this study included Sepharose beads coupled to proteins A and G (Amersham 
Biosciences), Turbofect™ (Fermentas), EGF (BD Bioscience), SRC Inhibitor I (Sigma) PP2 SRC 
kinase inhibitor and PD153035 EGFR/ERBB2-tyrosine kinase inhibitor (Calbiochem). All PCR 
primers were obtained from Sigma.
Recombinant DNA technology and constructs
pcDNA3 EGFR and pcDNA3 EGFR Y1045F were kindly provided by Dr. Y.Yarden (Weizmann 
Institute, Israel). Mutations of the EGFR CBL binding site were introduced as previously 
described by us [22]. The K721A mutation was introduced in pcDNA3 EGFR by 
PCR-mediated primer overlap extension using the Eco81I sites. pLTR2 EGFR-ERBB2IC 
(denoted here as the EGFR-ERBB2 chimera) [18] was kindly provided by Dr. P.P. di Fiore 
(Fondazione Instituto FIRC di Oncologia Moleculare, Italy). The EGFR-ERBB2 was removed 
from the LTR2 vector by SauI and XhoI digestion, and subsequently inserted into SauI-XhoI 
digested pcDNA3 EGFR. The Y1091F mutation was introduced in pcDNA3 EGFR-ERBB2 
chimera by PCR-mediated primer overlap extension using the BstEII and XhoI sites. The 
K733A mutation was introduced in pcDNA3 EGFR-ERBB2 by PCR-mediated primer overlap 
extension using the Eco81I and BstEII sites. pLXSN Neo was obtained from Dr. G.P. Nolan 
(Stanford University Medical Center) . The retroviral pLXSN EGFR construct has been 
described previously [22]. The EGFR and pcDNA3 EGFR-ERBB2 constructs containing 
regulation and vesicular trafficking [14]. Mono- and multi-ubiquitination has been 
implicated in ligand-mediated endocytosis [15, 16]. Previous reports demonstrate that the 
EGFR is undergoing predominantly mono-, multi- and K63-linked poly-ubiquitination [17]. 
 Much less is known about the role of ubiquitination in the intracellular routing of the 
other ERBB receptors. Previous studies have shown that ERBB2, ERBB3 and ERBB4 show 
impaired ligand-induced downregulation compared to EGFR [18, 19]. On the other hand, 
ERBB2 and ERBB4 contain similar CBL binding sites as EGFR [20-22]. The impaired 
downregulation of ERBB2 has been correlated with poor recruitment into clathrin-coated 
pits resulting in reduced internalization [18, 19, 23, 24], impaired lysosomal targeting of the 
internalized receptor and enhanced recycling from sorting endosomes back to the plasma 
membrane [25-27]. Moreover, heterodimerization with ERBB2 impairs the downregulation 
of EGFR [25-28]. When comparing the molecular structure of EGFR and ERBB2, impaired 
downregulation of ERBB2 may result from (i) reduced recruitment of the clathrin adapter 
protein AP2µ to drive internalization [19, 29, 30], (ii) the absence of a dileucine signal in the 
cytoplasmic tail of ERBB2 that corresponds to EGFR LL1010/1011 which associates with 
AP2β to promote lysosomal targeting of the EGFR [22, 31], (iii) the presence of a unique 45 
amino-acid insert in the cytoplasmic tail of ERBB2 [32] and/or (iv) impaired recruitment of 
CBL E3 ligases [33]. Notably, we previously demonstrated that the replacement of the 
EGFR CBL-binding site by that of ERBB2 did not affect CBL recruitment, receptor 
-ubiquitination, -degradation, -downregulation or ligand degradation of EGFR, suggesting 
that poor downregulation of ERBB2 is not due to sequence variations in the CBL binding 
site of these receptors [22].
 We have previously demonstrated that, following ligand-induced CBL-mediated 
ubiquitination, the EGFR is deubiquitinated before lysosomal degradation [34]. Indeed, 
two deubiquitinating (DUB) enzymes have now been demonstrated to deubiquitinate 
EGFR prior to incorporation into internal vesicles of MVBs [14]. AMSH is a metazoan-specific 
JAMM-type DUB that is specific for K63-linked poly-ubiquitin and has been proposed to 
limit sorting of the EGFR into the MVB pathway [35-37]. USP8 is a member of the Ubiquitin 
Specific Protease (USP) family that removes K48- and K63-linked poly-ubiquitin and has 
been proposed to recycle ubiquitin from substrate proteins to refill the cellular ubiquitin 
pool [38-43]. Both enzymes bind with their PxxP motif to the SH3 domain of the ESCRT-0 
subunit STAM and with their N-terminal MIT domain to ESCRT-III subunits [14]. Using 
catalytically inactive dominant negative DUB enzymes, RNA interference techniques and 
gene knock-out models, it has been firmly established that AMSH and USP8 deubiquitinate 
the EGFR [35-37, 39-43]. While some reports suggest that USP8 inhibits EGFR degradation 
[40], we and others demonstrated that USP8 stimulates EGFR degradation [41, 42]. 
Moreover, we also demonstrated that USP8 is tyrosine phosphorylated in an EGFR- and 
SRC kinase dependent manner following EGF stimulation [41]. However, the functional 
significance of USP8 tyrosine phosphorylation is as yet unknown.
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EGFR-ERBB2 receptors were generated and expression of chimeric receptors in retroviral 
cell lines was verified by Western blot (Fig. 1A, 4th panel). 
 To test whether CBL induces ubiquitination of the EGFR-ERBB2 chimera, serum-starved 
cells were treated with EGF. As shown in Fig. 1A (upper panel), CBL is tyrosine phosphorylated 
15 min after EGF stimulation and coprecipitates with the tyrosine phosphorylated 
EGFR-ERBB2 chimera. These data indicate that CBL is recruited to the EGFR-ERBB2 chimera 
upon stimulation, although less efficient than to EGFR itself (Fig. 1A, upper panel). Mutation 
of the CBL binding site in the EGFR (Y1045F) and the chimeric EGFR-ERBB2 (Y1091F) 
reduced but did not completely abrogate EGF-induced CBL tyrosine phosphorylation and 
co-precipitation of the ERBB receptor (Fig. 1A, upper panel). Moreover, as shown in Fig. 1B, 
the EGFR-ERBB2 chimera displayed prominent EGF-induced ubiquitination, while 
mutation of the ERBB2 CBL binding site (Y1091F) in the context of the EGFR-ERBB2 chimera 
almost completely abolished EGF-induced ubiquitination of the ERBB2 cytoplasmic 
domain. In addition, using K63-linked polyubiquitin specific antibodies, we show that 
both EGFR and EGFR-ERBB2  undergo ligand-induced K63-linked polyubiquitination 
which is abolished in EGFR Y1045F and ERBB2 Y1091F mutant constructs (Fig. 1C). In 
contrast, we could not detect any ligand-induced increase in K48-linked polyubiquitina-
tion of either EGFR or EGFR-ERBB2 using K48-linked polyubiquitin specific antibodies 
(results not shown). These findings directly show the efficacy of the ERBB2 CBL binding 
site in supporting ligand-induced ERBB2 K63-linked polyubiquitination, which agrees with 
our previous findings that the ERBB2 CBL binding site is fully functional when introduced 
into EGFR [22]. 
USP8 tyrosine phosphorylation upon stimulation of the chimeric 
EGFR-ERBB2 is enhanced in catalytically inactive USP8 C748A mutant
The activity of E3 ligases is counterbalanced by the activity of deubiquitination enzymes. 
We previously reported that the deubiquitination enzyme USP8 is tyrosine phosphorylated 
upon stimulation of EGFR [41]. However, USP8 is present on endosomal membranes and 
since ERBB2 shows efficient recycling from early endosomes back to the cell surface [25], 
it is possible that internalized ERBB2 and Ups8 do not interact within the cell. To address 
whether USP8 is tyrosine phosphorylated upon stimulation of EGFR-ERBB2, we 
co-transfected HEK293 cells with EGFR-ERBB2 and EGFP-Flag-USP8. As shown in Fig. 2, 
USP8 becomes tyrosine phosphorylated upon treatment of EGFR-ERBB2 with EGF, 
although to a lesser extent than in EGFR stimulated cells. Moreover, activated EGFR-ERBB2 
coprecipitates with tyrosine-phosphorylated Flag-tagged USP8, demonstrating that USP8 
binds to this chimeric receptor. This finding demonstrates that USP8 is not only a substrate 
of ERBB2-induced tyrosine kinase activity, but also that USP8 and ERBB2 colocalize inside 
the cell.
 It has previously been shown that a catalytically inactive mutant of USP8 (C748A) 
displays enhanced binding to activated EGFR, which has been attributed to substrate-trap-
mutations in the CBL binding site were cloned into the modified pLXSN Neo vector using 
VspI and XhoI restriction sites. The pME18S Flag mUSP8 construct containing the Flag 
epitope-tagged murine USP8 cDNA was kindly provided by Dr. N. Kitamura (Tokyo 
Institute of Technology, Japan) [44]. Construction of the catalytically inactive Flag mUSP8 
C748A mutant has been described previously [41]. Both wild-type and C748A Flag mUSP8 
cDNAs were subsequently cloned in frame to the C-terminus of EGFP using the pEGFP C1 
vector (Clontech), using XhoI and MfeI restriction sites. Construction of USP8 Δ140 was 
performed by overlap extension PCR of pEGFP C1 USP8 wt with a temporarily removed 
NotI site, and subsequent cloning using the NotI and Acc65I sites. Primer sequences are 
available upon request. All mutations were verified by DNA sequencing.
Cell lines and recombinant protein expression 
Parental NIH3T3 cells, kindly provided by Dr. J. Schlessinger (Yale University, New Haven, 
CT) , and human embryonic kidney cells (HEK293 cells) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% newborn calf serum (NCS; 
Hyclone). Cells were trypsinized when confluent and seeded in flasks for regular 
maintenance. HEK293 cells were transiently transfected using Turbofect™ according to the 
manufacturer’s protocol, while NIH3T3 cells were retrovirally infected with (mutant) EGFR 
or EGFR-ERBB2 constructs, as previously described for EGFR [22].
Cell lysis, immunoprecipitation, immunoblotting and densitometry 
Cell lysis, immunoprecipitation, immunoblotting and densitometry were performed as 
described previously by us [22, 34, 41].
Results
CBL-mediated ubiquitination of the ERBB2 cytoplasmic tail depends  
on Y1091
We previously demonstrated that the replacement of the EGFR CBL binding site by that of 
ERBB2 did neither affect CBL recruitment, receptor ubiquitination, degradation and 
downregulation, nor ligand degradation, suggesting that the poor downregulation of 
ERBB2 is not due to sequence variations in the CBL binding site of these receptors [22]. 
Indeed, it has previously been demonstrated that CBL is tyrosine phosphorylated and 
recruited to ERBB2 pY1091 [45]. Moreover, the ERBB2 Y1091F mutant showed decreased 
CBL binding and ERBB2 ubiquitination [20]. However, little is known about ligand-induced 
ERBB2 ubiquitination. To test whether the CBL binding site in ERBB2 is essential for CBL 
recruitment, CBL tyrosine phoshorylation and receptor ubiquitination, we made use of 
chimeric constructs containing the extracellular and transmembrane domains of the 
EGFR and the ERBB2 cytoplasmic tail. Retroviral cell lines containing such chimeric 
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ping on the endosomal membrane [40, 46]. Consistent with this model, our data in Fig. 2 
show that USP8-C748A displays enhanced tyrosine phosphorylation and increased copre-
cipitation with the receptor upon EGF stimulation of both EGFR or EGFR-ERBB2 containing 
cells. These findings strongly suggest that the USP8-C748A mutant shows enhanced 
steady state binding to both EGFR and EGFR-ERBB2 relative to USP8 wild-type, which is 
consistent with the model that the C748A mutation interferes with dissociation of Ups8 
from the ubiquitinated ERBB receptor.
USP8 tyrosine phosphorylation is independent of an intact CBL  
binding site 
To determine whether USP8 tyrosine phosphorylation is critically dependent on ERBB 
receptor ubiquitination by CBL, we analyzed USP8 tyrosine phosphorylation after EGF 
stimulation of cells containing the CBL binding mutants EGFR-Y1045F and EGFR-ERBB2-
Y1091F (Fig. 3A-D). Quantification of the USP8 tyrosine phosphorylation signal of three 
independent experiments indicate that USP8 wt and its C748A mutant  were similarly 
tyrosine phosphorylated in cells with ERBB wild-type or the CBL binding mutant receptors 
(Fig. 3C-D), although the level of USP8-C748A tyrosine phosphorylation appeared 
somewhat decreased in the EGFR-Y1045F and EGFR-ERBB2-Y1091 mutants cells in the 
experiments shown in Fig. 3A-B. Also the extent of coprecipitation of in particular 
USP8-C748A with the EGFR-Y1045F and EGFR-ERBB2-Y1091F mutant receptors was slightly 
decreased in this experiment compared to their wild-type counterparts, but again this 
was not confirmed by quantitative densitometric analysis of multiple experiments (data 
not shown). Collectively, these data demonstrate that the CBL binding site of the wild-type 
EGFR and the EGFR-ERBB2 chimera is not required for efficient EGF-induced USP8 tyrosine 
phosphorylation or coprecipitation of the ERBB receptors with USP8.
Figure 2   Ligand stimulation of EGFR-ERBB2 induces USP8 tyrosine phosphorylation
HEK293 cells were transiently transfected with EGFP-Flag-USP8 wt or C748A mutant, as well as with 
EGFR or EGFR-ERBB2. Serum-starved cells were EGF-stimulated for 1 hour and WCL were used for 
anti-flag IP and IB with anti-pTyr and anti-flag antibodies as indicated. Data are representative of 2 
experiments.
Figure 1   Ligand stimulation couples EGFR-ERBB2 to CBL-induced K63-linked  
polyubiquitination
NIH3T3 cells were retrovirally infected with EGFR wt, EGFR Y1045F, EGFR-ERBB2 or EGFR-ERBB2 
Y1091F. A, Infected cells were serum starved overnight and stimulated for 15 min with 100 ng/ml EGF. 
Whole cell lysates (WCL) were used for anti-CBL immunoprecipitation (IP) and immunoblot (IB) with 
the indicated antibodies. B, Infected cells were serum starved overnight and stimulated for 30 min 
with 100 ng/ml EGF. WCL were used for anti-EGFR IP and IB with the indicated antibodies. C, HEK293 
cells were transiently transfected with EGFR wt, EGFR, Y1045F, EGFR-ERBB2 wt or EGFR-ERBB2 Y1091F. 
Serum-starved cells were EGF-stimulated for 15 min. WCL were used for anti-EGFR IP and IB with the 
indicated antibodies. Data are representative of 2-4 experiments.
A
B
C
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USP8 tyrosine phosphorylation upon stimulation of EGFR-ERBB2 is  
SRC- and ERBB2- kinase dependent 
The data presented in Fig. 2 and 3 suggest that the mechanism responsible for EGF-induced 
USP8 tyrosine phosphorylation might be the same for EGFR and ERBB2. Our previous 
results have shown that USP8 tyrosine phosphorylation upon EGF-induced stimulation is 
EGFR-  and SRC- tyrosine kinase dependent [41]. To test whether the kinase activity of 
ERBB2 is required for USP8 tyrosine phosphorylation in EGFR-ERBB2 containing cells, we 
used the EGFR/ERBB2-kinase inhibitor PD153035. As shown in Fig.4A-B (3rd panel), this 
inhibitor effectively blocked EGF-induced tyrosine phosphorylation of both EGFR and 
Figure 3   USP8 tyrosine phosphorylation is independent of an intact CBL binding site
A and B, HEK293 cells were transfected with EGFP-flag-USP8 wt or C748A mutant and with either 
EGFR wt, EGFR-Y1045F, EGFR-ERBB2 wt or EGFR-ERBB2 Y1091F constructs. Serum-starved cells were 
stimulated for 1 h with 100 ng/ml EGF after which WCLs were used for anti-flag IP and IB with the 
indicated antibodies. C and D, densitometric relative corrected mean pixel values of USP8 tyrosine 
phosphorylation plotted as mean ± standard error of the mean (SEM). Phospho-signal of the IPs in A 
and B were related to the amount of precipitated USP8 in the second panels and normalised to the 
EGFR/EGF or EGFR-ERBB2/EGF group. Data are representative of 3 experiments.
Figure 3   Continued
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ERBB2. In agreement with our previous observation, USP8 tyrosine phosphorylation 
following stimulation of EGFR was completely blocked in the presence of PD153035 
(Fig. 4A, top panel, and 4C). In EGFR-ERBB2 expressing cells, EGF-induced USP8 tyrosine 
phosphorylation was even lower in the presence of PD153035 than the USP8 tyrosine 
phosphorylation level observed in unstimulated and mock-treated cells (Fig. 4B, top panel, 
and 4D), which is likely due to the fact that 18h of serum-deprivation does not result in 
complete downregulation of ERBB2 kinase activity. As expected, coprecipitation of auto-
phosphorylated EGFR and EGFR-ERBB2 with USP8 was no longer observed in the presence 
of the kinase inhibitor (Fig. 4A and 4B, top panel). To provide further evidence for ERBB 
 kinase-dependent USP8 tyrosine phosphorylation, we generated kinase-dead mutants of 
EGFR and EGFR-ERBB2. Stimulation of EGFR K721A and EGFR-ERBB2 K733A resulted in 
complete inhibition of USP8 tyrosine phosphorylation and abrogated the co-precipitation 
of the autophosphorylated EGFR and EGFR-ERBB2 with USP8 (Fig. 4E-F). 
 EGFR- and ERBB2-tyrosine kinases activate various downstream signaling molecules 
including members of the SRC-family of tyrosine kinases [47]. To test whether SRC-family 
tyrosine kinases may be responsible for USP8 tyrosine phosphorylation upon stimulation 
of EGFR-ERBB2, we used the specific SRC-family kinase inhibitors PP2 and SRC Inhibitor I. 
Complete inhibition of USP8 tyrosine phosphorylation in the presence of PP2 was 
achieved in both EGFR and EGFR-ERBB2 transfected cells (Fig. 5A-B, top panel, and 
Fig. 5C-D). To further support these results, we also used another inhibitor, SRC Inhibitor I. 
As expected, SRC Inhibitor I resulted in complete inhibition of USP8 tyrosine phoshorylation 
upon EGFR stimulation, even though EGFR phosphorylation remained largely intact (Fig. 
5E). These data extend our previous findings that USP8 is tyrosine phosphorylated in an 
EGFR- and SRC kinase-dependent manner [41] and demonstrate that USP8 is a substrate 
for ERBB2-activated SRC-family tyrosine kinases. 
Optimal USP8 tyrosine phosphorylation is MIT domain dependent 
The MIT (Microtubule Interacting and Transport) domain, which is located at the 
N-terminus of USP8, interacts with ESCRT-III CHMP proteins and is important for endosomal 
recruitment [43]. Furthermore, the MIT domain of USP8 is required for EGFR degradation 
[43], suggesting that this domain is essential for proper USP8 function. Given that ERBB 
receptors are present on endosomal membranes, we hypothesized that MIT-dependent 
endosomal recruitment of USP8 is required for USP8 tyrosine phosporylation. In cells 
expressing either EGFR (Fig. 6A and C) or EGFR-ERBB2 (Fig. 6B and D), removal of the 
MIT domain (USP8 Δ140) resulted in a decrease of the EGF-induced USP8 tyrosine 
phosphor ylation, when compared to USP8 wt. However, removal of the MIT domain did 
not completely abolish USP8 tyrosine phosphorylation. Nevertheless, our findings clearly 
demonstrate that optimal USP8 tyrosine phosphorylation requires an intact USP8 MIT 
domain. 
Figure 4   USP8 is tyrosine phosphorylated in an EGFR/ERBB2-kinase-dependent manner
A and B, HEK293 cells were transfected with EGFP-flag-USP8 and either EGFR or EGFR-ERBB2. 
Serum-starved cells were pre-treated for 1 hour with 10 µM PD153035 or DMSO and subsequently 
stimulated for 1 h with 100 ng/ml EGF. WCL were used for anti-flag IP and IB with the indicated 
antibodies. C and D, densitometric relative corrected mean pixel values of USP8 tyrosine phospho-
rylation plotted as mean ± SEM. Phospho-signal of the IPs in A and B were related to the amount of 
precipitated USP8 in the second panels and normalised to the EGFR/EGF or EGFR-ERBB2/EGF group. 
E and F, HEK293 cells were transfected with EGFP-flag-USP8 and with either EGFR wt, EGFR K721A, 
EGFR-ERBB2 wt or EGFR-ERBB2 K733A. Serum-starved cells were stimulated for 1 h with 100 ng/ml 
EGF. WCL were used for anti-flag IP and IB with the indicated antibodies. Data are representative of 
3 experiments.
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ERBB2 is undergoing deubiquitination by USP8 in an EGF-dependent 
and -independent system
The findings described above demonstrate that USP8 is part of the ERBB2 signaling 
cascade. We previously showed that overexpression of the USP8-C748A mutant strongly 
enhances accumulation of the steady state level of ubiquitinated EGFR in the absence 
of EGF [41]. To provide evidence that EGFR and EGFR-ERBB2 are substrates for USP8 
 deubiquitination activity, we performed an in vivo deubiquitination assay for which the 
EGFR wt, EGFR-Y1045F, EGFR-ERBB2 wt or EGFR-ERBB2-Y1091F receptors were co-transfected 
with either USP8 wt or USP8-C748A mutant into HEK293 cells. As expected, EGF stimulation 
of serum-starved cells resulted in an increased molecular size of EGFR as a result of 
ubiquitination, which was largely abolished in the EGFR Y1045F CBL binding site mutant 
(Fig. 7, upper panel, 1st four lanes, arrow a). Interestingly, coexpression of USP8-C748A with 
EGFR in unstimulated cells led to accumulation of ubiquitinated EGFR isoforms that 
migrated at a size above the 170 kDa EGFR band (Fig. 7, upper panel, 5th lane, arrow b), but 
clearly below the EGF-induced ubiquitinated forms of EGFR (arrow a). Moreover, in 
EGF-stimulated cells expressing both EGFR and USP8 C748A, we observed not only a 
modest increase in the amount of high MW ubiquitinated EGFR species (Fig. 7, 6th lane, 
arrow a), but also a strong increase in the low MW ubiquitinated EGFR forms (arrow b). The 
low size ubiquitinated EGFR isoforms were also detected when USP8-C748A was 
coexpressed with the EGFR-Y1045F CBL binding site mutant (Fig. 7, 7th and 8th lanes, arrow b). 
It is possible that the former signal (arrow a) represents highly multi- or poly-ubiquitinated 
EGFR forms, whereas the latter signal (arrow b) represents mono- or oligo-ubiquitinated 
EGFR species. 
Figure 4   Continued
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Figure 5   SRC kinase activity is essential for EGFR-ERBB2-mediated USP8 tyrosine 
 phosphorylation
A and B, HEK293 cells were transfected with EGFP-flag-USP8 and either EGFR or EGFR-ERBB2. 
Serum-starved cells were pre-treated for 1 h with 5 µM PP2 or DMSO and subsequently stimulated 
for 1 h with 100 ng/ml EGF. WCL were used for anti-flag IP and IB with the indicated antibodies. C and 
D, densitometric relative corrected mean pixel values of USP8 tyrosine phosphorylation plotted as 
mean + SEM. Phospho-signal of the IPs in A and B were related to the amount of precipitated USP8 
in the second panels and normalised to the EGFR/EGF or EGF-ERBB2/EGF group. E, HEK293 cells were 
transfected with EGFP-flag-USP8 and EGFR wt. Serum-starved cells were pre-treated for 1 h with SRC 
inhibitor I or DMSO and subsequently stimulated for 1 h with 100 ng/ml EGF. WCL were used for 
anti-flag IP and IB with the indicated antibodies. Data are representative of 3 experiments.
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To determine whether these findings can be extended to the chimeric EGFR-ERBB2 model 
system, we performed similar experiments for EGFR-ERBB2 wt and EGFR-ERBB2-Y1091F. 
EGFR-ERBB2 displayed EGF-induced ubiquitination resulting in a high molecular size band, 
while the EGFR-ERBB2- Y1091F CBL binding site mutant showed almost no EGF-induced 
ubiquitination (Fig. 8, 1st four lanes,  arrow a). Coexpression of USP8-C748A with EGFR-ERBB2 
wt only modestly decreased accumulation of the high molecular size ubiquitination 
signal induced by EGF stimulation (Fig. 8, 5th and 6th lanes, arrow a). This contrasts with the 
EGFR model system shown in Fig. 7, where expression of inactive USP8 resulted in only a 
modest increase of high molecular size ubiquitination signal, which suggests that another 
enzyme may be involved in deubiquitinating ERBB2 (Fig. 8, arrow a). However, in cells 
coexpressing USP8-C748A with EGFR-ERBB2 wt or EGFR-ERBB2-Y1091F a marked increase 
in the intensity of the low MW ubiquitination band was observed in both EGF-stimulated 
and -unstimulated cells (Fig. 8, 2nd four lanes, arrow b). Overall, these data demonstrate 
that ERBB2 is a substrate for the USP8 deubiquitinating enzyme.
 In conclusion, our findings demonstrate that USP8 removes ubiquitin not only from 
the EGFR wt and Y1045F mutant receptor, but also from both the EGFR-ERBB2 wt and 
Y1091F mutant receptor in both ligand-independent and ligand-dependent model 
systems.
Figure 6   The USP8 MIT domain is required for optimal EGFR-ERBB2-induced USP8 
tyrosine phosphorylation
A and B, HEK293 cells were transfected with EGFP-flag-USP8 wt or Δ140 and either EGFR or 
EGFR-ERBB2. Serum-starved cells were stimulated for 1 h with 100 ng/ml EGF. WCL were used for 
anti-flag IP and IB with the indicated antibodies. C and D, densitometric relative corrected mean pixel 
values of USP8 tyrosine phosphorylation plotted as mean ± SEM. Phospho-signal of the IPs in A and 
B were related to the amount of precipitated USP8 in the second panels and normalised to the 
EGFR/EGF or EGFR-ERBB2/EGF group. Data are representative of 3 experiments.
Figure 5   Continued
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Discussion
The results presented in this study demonstrate that the deubiquitinating enzyme USP8 is 
part of the ERBB2 endosomal trafficking pathway. In the context of a chimeric EGFR-ERBB2 
receptor, we have shown that (i) EGF-induced K63-linked polyubiquitination of the ERBB2 
cytoplasmic tail occurs efficiently in a pY1091-dependent manner, (ii) c-CBL is efficiently 
tyrosine phosphorylated upon stimulation of the EGFR-ERBB2 wt and Y1091F mutant, (iii) 
EGF-induced activation of the EGFR-ERBB2 chimera induces USP8 tyrosine phosphoryla-
tion, and (iv) ubiquitination of the EGFR-ERBB2 chimera (wt and Y1091F) is enhanced upon 
coexpression of catalytically inactive USP8-C748A mutant in both an EGF-dependent and 
-independent system. We further show that USP8 tyrosine phosphorylation upon 
stimulation of EGFR-ERBB2 is (a) independent of Y1091, (b) dependent on SRC- and ERBB2- 
kinase activity, (c) enhanced upon co-expression of catalytically inactive USP8 C748A, and 
(d) partly dependent on the MIT domain of USP8. Our results are consistent with the 
model that ERBB2 is less efficiently sorted into the MVB pathway compared to the EGFR.
 Here, we demonstrate that C-CBL is tyrosine phosphorylated and recruited to the 
ligand stimulated chimeric EGFR-ERBB2 receptor, albeit to a lesser extent than the EGFR 
(Fig. 1). These results contrast with those of Levkowitz and coworkers, who initially reported 
that, using the same model system, CBL is not tyrosine phosphorylated and recruited to 
ERBB2 [33], Subsequently, these authors demonstrated that CBL is recruited to ERBB2 
pY1091 of the oncogenic Neu ERBB2 receptor and in wt ERBB2 upon Herceptin-induced 
crosslinking [20, 21, 45]. We have previously reported that the Y1091 CBL binding site of 
ERBB2 can functionally replace the EGFR Y1045 CBL binding site without any obvious 
decrease in CBL tyrosine phosphorylation, CBL recruitment or receptor ubiquitination [22]. 
Overall, these findings suggest that the decreased efficiency of steady state CBL tyrosine 
phosphorylation level and steady state CBL recruitment to ERBB2 is not primarily due to 
the inefficiency of the ERBB2 Y1091 CBL binding site, but rather a consequence of an as yet 
undefined mechanism that limits steady state recruitment of CBL to the ERBB2 receptor. It 
is possible that decreased sorting of ERBB2 into the MVB pathway and/or enhanced 
recycling of ERBB2 back to the cell surface limits steady state CBL-ERBB2 interaction, which 
may be caused by the presence or absence of a unique regulatory region in the ERBB2 
cytoplasmic tail. As previously indicated, this may relate to (i) the absence of a dileucine 
signal in the cytoplasmic tail of ERBB2 at a position corresponding to EGFR LL1010/1011, 
which associates with AP2β to promote lysosomal targeting [22, 31], and (ii) the presence 
of a unique 45 amino-acid insert in the cytoplasmic tail of ERBB2 that may be responsible 
for enhanced recycling [32]. Regardless of the exact mechanism, our results demonstrate 
that ligand stimulation couples ERBB2 to CBL RING E3 ligase, resulting in receptor-induced 
ERBB2 ubiquitination (Fig. 1B). Furthermore, using K63-linked polyubiquitin specific 
antibodies, we show that EGFR and EGFR-ERBB2 undergo ligand-induced K63 poly-ubiq-
uitination which is dependent on an intact CBL binding site. This result is reminiscent of 
Figure 7   USP8 deubiquitinates EGFR by an EGF-dependent and -independent 
mechanism
HEK293 cells were co-transfected with EGFR wt or Y1045F mutant and either EGFP-flag-USP8 wt or 
C748A mutant. Serum-starved cells were stimulated for 15 min with or without EGF. WCL were used 
for anti-EGFR IP and IB with the indicated antibodies. Data are representative of 3 experiments.
Figure 8   USP8 deubiquitinates EGFR-ERBB2 by an EGF-dependent and -independent 
mechanism
HEK293 cells were co-transfected with EGFR-ERBB2 wt or Y1091F mutant and either EGFP-flag-USP8 
wt or C748A mutant. Serum-starved cells were stimulated for 15 min with or without EGF. WCL were 
used for anti-EGFR IP and IB with the indicated antibodies. Data are representative of 3 experiments.
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interacts with ESCRT-III CHMP proteins and is necessary for the recruitment of USP8 to 
endosomal membranes [43]. Although we cannot exclude the possibility that reduced 
USP8 tyrosine phosphorylation upon removal of the MIT domain is due to conformational 
effects, we believe this explanation is less likely as this mutant has been extensively 
studied before [43]. Interestingly, removal of the MIT domain does not completely abolish 
USP8 tyrosine phosphorylation, suggesting that USP8 might be recruited to endosomal 
membranes also via alternative mechanisms (e.g. via Hbp/STAM [44] or ubiquitin [41]). 
Alternatively, the remaining tyrosine phosphorylation of the USP8-Δ140 mutant may also 
indicate that USP8 is partly phosphorylated by activated SRC-family kinases in the cytoplasm. 
Finally, it should also be noted that at present we cannot rule out the possibility that USP8 
is tyrosine phosphorylated within its MIT domain. Nevertheless, our findings demonstrate 
that optimal USP8 tyrosine phosphorylation requires an intact USP8 MIT domain, which is 
consistent with the proposed role of the MIT domain in recruitment of USP8 to endosomal 
membranes where activated ERBB receptor-SRC complexes are located. 
 Most importantly, our current findings not only demonstrate that USP8 is a substrate 
for ERBB2-induced tyrosine kinase activity but also that ERBB2 is a substrate for 
USP8-mediated deubiquitination (Fig. 8). Moreover, overexpression of dominant negative 
USP8-C748A led to enhanced ubiquitination of EGFR and EGFR-ERBB2 under both li-
gand-dependent and -independent conditions (Fig. 7-8). These findings indicate that 
EGFR and EGFR-ERBB2 are constitutively ubiquitinated and deubiquitinated. The CBL 
binding site mutants of EGFR (Y1045F) and EGFR-ERBB2 (Y1091F) are also deubiquitinated 
by USP8 both with and without EGF stimulation (Fig. 7-8). We therefore propose that USP8 
is not solely counteracting CBL-mediated ubiquitination but also counteracts ligand- and 
CBL-independent ERBB receptor ubiquitination. Our findings suggest that USP8 mainly 
removes the low molecular size ubiquitination signal from ERBB receptors and we suggest 
the possibility that these signals represent mono- or oligo- ubiquitinated ERBB receptor 
isoforms (Fig. 7-8, upper panel, arrow b). This hypothesis is supported by our finding that 
EGFR wt and EGFR-ERBB2 wt but not their Y1045F and Y1091F CBL binding site mutants 
undergo ligand-induced K63-linked polyubiquitination (Fig. 1). Indeed, the Y1045F and 
Y1091F CBL binding site mutants are deubiquitinated by USP8, suggesting that this 
ubiquitination signal may represent mono- or oligo-ubiquitin (Fig. 7-8, upper panel, arrow 
b). However, additional studies are required to verify this hypothesis. Indeed, it has 
previously been suggested that USP8 may disassemble mono- and oligo-ubiquitin chains, 
in addition to K63- and K48-linked chains [40, 42]. Thus, the role of USP8 in the removal of 
monoubiquitin adducts has not yet been confirmed, neither in vitro nor in vivo. Our results 
further suggest that E3 ligases other than CBL may be involved in ligand-independent low 
molecular size ubiquitination of both EGFR and EGFR-ERBB2. In addition, when 
overexpressing inactive USP8 together with EGFR-ERBB2, a slight decrease in high 
molecular size ubiquitin was detected. It is possible that other DUBs may also be involved 
in deubiquitination of ERBB2. 
previous findings demonstrating that the EGFR is undergoing predominantly mono-, 
multi- and K63-linked poly-ubiquitination [17] and extends ligand-induced K63-linked 
polyubiquitination to ERBB2.
 We also showed that USP8 is coprecipitated and tyrosine phosphorylated upon EGF 
stimulation of the EGFR-ERBB2 chimera (Fig. 2). Interestingly, the CBL binding site of 
EGFR-ERBB2 is not required for USP8 tyrosine phosphorylation and coprecipitation (Fig. 3), 
suggesting that USP8 might be recruited to the EGFR-ERBB2 also via  mechanisms other 
than interaction between the USP8 DUB domain and ubiquitinated cargo (e.g. via Hbp/
STAM [44] or the MIT domain [43]). This finding extends our previous observations that 
USP8 is tyrosine phosphorylated upon stimulation of the EGFR and that USP8 is recruited 
to the EGFR via multiple interactions including (direct) binding of the USP8 DUB domain 
to ubiquitinated EGFR and (most likely indirect) recruitment of USP8 to the EGFR on 
endosomal membranes via the USP8 N-terminal MIT domain [41]. 
Ligand-induced EGFR-ERBB2-mediated USP8 tyrosine phosphorylation was lower than 
observed for EGFR. This may be explained by the fact that ERBB2 displays reduced inter-
nalization and enhanced recycling from early endosomes back to the cell surface when 
compared to the EGFR [18, 19]. Furthermore, it has been shown that USP8 localizes at early 
endosomes and removes ubiquitin from proteins after their sorting into the MVB pathway, 
but before incorporation of cargo proteins into internal vesicles of MVBs [14]. Thus, our 
results are consistent with the model that only a relatively small fraction of USP8 is 
subjected to ERBB2-induced tyrosine phosphorylation because less ERBB2 receptors are 
sorted into the MVB pathway. Alternatively, the stoichiometry of ERBB2-induced USP8 
tyrosine phosphorylation may be lower than in the case of EGFR. It has been shown that 
the enzymatically inactive USP8-C748A mutant displays substrate-trapping on the 
endosomal membrane [40, 42] and consistent with this model, we demonstrated that 
USP8 C748A displays enhanced tyrosine phosphorylation (Fig. 2-3). Overall, we showed 
that USP8 is a substrate of ERBB2-induced tyrosine kinase activity. 
 Our current findings further demonstrate that USP8 binds to ERBB2 and that USP8 
tyrosine phosphorylation is dependent on ERBB2- (Fig. 4) and SRC- kinase (Fig. 5) activities, 
thereby extending our initial findings in the EGFR model system to ERBB2 [41]. SRC is 
an SH2- and SH3-domain containing cytoplasmic tyrosine kinase acting downstream of 
ERBB receptors, where it regulates a wide variety of cellular functions . It has been reported 
that interaction of tyrosine-phosphorylated ERBB2 in mammary tumors enhances SRC 
kinase activity [48, 49]. Moreover, using chimeric EGFR-ERBB2 receptors, it has also been 
shown that SRC associates with ERBB2 [47, 50]. We therefore hypothesize that tyrosine 
phosphorylation of USP8 occurs in an ERBB receptor-SRC-USP8 trimolecular complex. 
 Our finding that the MIT domain of USP8 is essential for optimal USP8 tyrosine 
 phosphorylation (Fig. 6) is consistent with the model that USP8 is tyrosine phosphorylated 
upon MIT-dependent recruitment of USP8 to endosomal membranes. The MIT domain in 
USP8 was first identified by Row and coworkers, who showed that the MIT domain 
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Conclusions
The results presented in this study demonstrate that (i) USP8 is a substrate for ERBB2- and 
SRC-induced tyrosine kinase activity, (ii) EGF stimulation of the EGFR-ERBB2 chimera results 
in pY1091 CBL binding site-dependent K63-linked poly-ubiquitination of the ERBB2 
cytoplasmic tail, and that (iii) ERBB2 is a substrate for USP8-mediated deubiquitination. 
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Abstract
ERBB receptors play an important role in normal cellular growth, differentiation and 
development, but overexpression or poor downregulation can result in enhanced 
signaling and cancerous growth. ERBB signaling is terminated by clathrin-dependent re-
ceptor-mediated endocytosis, followed by incorporation in multi-vesicular bodies and 
subsequent degradation in lysosomes. In contrast to EGFR, ERBB2 displays poor 
ligand-induced downregulation and enhanced recycling, but the molecular mechanisms 
underlying this difference are poorly understood. Given our previous observation that 
both EGFR and an EGFR-ERBB2 chimera undergo CBL-mediated K63-polyubiquitination, 
we investigated in the present study whether activation of the EGFR and the EGFR-ERBB2 
chimera is associated with tyrosine phosphorylation of the ESCRT-0 complex subunit HRS 
and AMSH-mediated deubiquitination. EGF stimulation of the EGFR resulted in efficient 
HRS tyrosine phosphorylation and deubiquitination by the K63-polyubiquitin 
chain-specific deubiquitinating enzyme AMSH. In contrast, EGF activation of EGFR-ERBB2 
showed significantly decreased HRS tyrosine phosphorylation and deubiquitination by 
AMSH. To test whether this phenotype is the result of endosomal recycling, we induced 
recycling of the EGFR by stimulation with TGFα. Indeed, even though TGFα-stimulation of 
EGFR is associated with efficient ligand-stimulated K63-polyubiquitination, we observed 
that HRS tyrosine phosphorylation as well as AMSH-mediated deubiquitination is 
significantly reduced under these conditions. Using various EGFR-ERBB2 chimeras, we 
demonstrate that enhanced recycling, decreased HRS tyrosine phosphorylation and 
decreased AMSH mediated deubiquitination of EGFR-ERBB2 chimeras is primarily due to 
the presence of ERBB2 sequences or the absence of EGFR sequences C-terminal to the CBL 
binding site. We conclude that endosomal recycling of the EGFR and ERBB2 receptors is 
associated with significantly impaired tyrosine phosphorylation of the ESCRT-0 subunit 
HRS as well as decreased deubiquitination by AMSH, which is consistent with the finding 
that recycling receptors are not efficiently incorporated in the MVB pathway.
Introduction
The receptors ERBB1-4 belong to the family of receptor tyrosine kinases and play an 
important role in the regulation of normal cellular growth, differentiation and development. 
However, overexpression or poor downregulation of these receptors can result in 
enhanced signaling and development of a broad range of human cancers. ERBB1, also 
known as the EGF receptor (EGFR) has various ligands, including EGF and TGFα, while 
ERBB2 is an orphan receptor that needs to heterodimerize with ligand-activated receptors, 
including EGFR, to be functionally active [1, 2]. 
 Following activation, ERBB signaling is terminated by the clathrin-dependent pathway 
of receptor-mediated endocytosis, followed by incorporation into intraluminal vesicles 
(ILVs) of multi-vesicular bodies (MVBs) and subsequent degradation in lysosomes [3]. 
Ubiquitination serves as a signal to facilitate both internalization and endosomal sorting 
of plasma membrane receptors. Mono-ubiquitination is sufficient as a signal for li-
gand-mediated endocytosis [4, 5]. In addition, both mono-ubiquitination and K63-poly-
ubiquitination have been implicated in endosomal sorting and lysosomal targeting [6]. In 
contrast, K48-polyubiquitination serves as a signal for proteasomal degradation [7]. Upon 
stimulation of the EGFR, the E3-ubiquitin ligase CBL is recruited to the autophosphorylat-
ed EGFR, either directly to tyrosine 1045 (pY1045) or indirectly via GRB2 to pY1068 and 
pY1086, and is subsequently responsible for ubiquitination of the EGFR [8, 9]. The EGFR is 
known to undergo both mono- and K63-polyubiquitination [10, 11]. Using an EGFR-ERBB2 
chimera, which contains the extracellular and transmembrane domain of the EGFR fused 
to cytoplasmic ERBB2 sequences, we have previously shown that EGF induces CBL binding 
site (pY1091)-dependent K63-polyubiquitination of this chimeric receptor [10].
 ERBB2, ERBB3 and ERBB4 display poor ligand-induced downregulation compared to 
the EGFR [12, 13]. Moreover, heterodimerisation of the EGFR with ERBB2 reduces 
ligand-induced EGFR downregulation [14, 15]. The poor downregulation of ERBB2 has 
been attributed to reduced recruitment into clathrin-coated pits [13, 16, 17] or impaired 
lysosomal targeting and increased recycling back to the cell surface [14, 18]. However, the 
molecular basis for the difference in downregulation efficiency of the EGFR and ERBB2 
receptors remains poorly understood. Previous studies using EGFR-ERBB2 chimeras have 
shown that poor ERBB2 downregulation is due to the absence of positive or the presence 
of negative sorting signals in the C-terminal cytoplasmic tail of the ERBB2 receptor [13]. The 
impaired downregulation has been explained by reduced recruitment of ERBB2 to the 
clathrin adapter protein AP2 [12, 19], the absence of a dileucine signal in the cytoplasmic 
tail of ERBB2 that corresponds to EGFR LL1010/1011 [19, 20], the presence of an additional 
45 amino acids in the ERBB2 cytoplasmic tail [21], or the reduced recruitment of CBL E3 
ligases to activated ERBB2 receptors [22]. However, we have previously demonstrated that 
the ERBB2 CBL binding site is functionally active and responsible for K63-polyubiquitina-
tion of this receptor [10, 20]. 
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activation of the EGFR-ERBB2 chimera is associated with HRS tyrosine phosphorylation 
and AMSH-mediated deubiquitination. We show that endosomal recycling of the EGFR 
and ERBB2 receptors correlates with significantly impaired tyrosine phosphorylation of the 
ESCRT-0 subunit HRS, as well as decreased deubiquitination by AMSH. Using various EGFR- 
ERBB2 chimeras we demonstrate that this phenotype is due to the absence of EGFR 
sequences or the presence of ERBB2 sequences, C-terminal to their respective CBL-binding sites.
Material and methods
Reagents
The following antibodies were used in this study: a-EGFR monoclonal antibody (mAb) 
528, a-EGFR polyclonal antibody (pAb) 1005, a-ERBB2 pAb C18, a-GFP pAb FL, a-HRS pAb 
M79, a-ubiquitin mAb P4D1 (Santa Cruz), a-phosphotyrosine mAb 4G10, a-K63 ubiquitin 
mAb Apu3 (Upstate Biotechnology), a-ubiquitin pAb U5379 and a-tubulin mAb (Sigma). 
Immunoprecipitation of EGFR was performed using mAb528, while pAb1005 was used for 
EGFR detection on Western blots. Secondary antibodies goat anti-rabbit (GARPO) and 
goat anti-mouse (GAMPO) mAbs, both linked to horseradish peroxidase, were purchased 
from Signal Transduction Laboratories. Other reagents used in this study included 
Sepharose beads coupled to protein A (Amersham Biosciences), Turbofect™ (Fermentas), 
mouse receptor grade EGF (BD Bioscience), recombinant human TGFa (R&D systems), 
K48-linked poly-ubiquitin WT chains and K63-linked poly-ubiquitin WT chains (Boston 
Biochem). All PCR primers were obtained from Sigma.
Recombinant DNA technology and constructs
pcDNA3 EGFR was kindly provided by Dr. Y Yarden (Weizmann Institute, Israel). The 
pcDNA3 EGFR-ERBB2 construct and the retroviral construct pLXSN EGFR-ERBB2 have been 
described previously [10, 20]. pcDNA3 EGFR-ERBB2 CTC chimera (C-terminal to CBL-site), in 
which the EGFR-ERBB2 boundary is located C-terminal of the EGFR CBL binding site, was 
generated by PCR-mediated primer overlap extension using Eco91I and XhoI sites. The 
pcDNA3 EGFR chimera was subsequently cloned into a modified pLXSN Neo vector using 
VspI and XhoI restriction sites. pEGFP-C1-AMSH wt and catalytically inactive AMSH D348A 
were kindly provided by Dr. S. Urbé (University of Liverpool, UK). Primer sequences are 
available upon request. All mutations were verified by DNA sequencing.
Cell lines and recombinant expression
Parental NIH3T3 cells and HER14 cells (NIH3T3 cells stably expressing human EGFR), both 
kindly provided by Dr. J. Schlessinger (Yale University, New Haven, CT), and human 
embryonic kidney cells (HEK293 cells) were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% newborn calf serum (NCS; Hyclone). HEK293 
 In early endosomes the activated ligand-receptor complex is sorted to be recycled 
back to the cell surface or targeted for lysosomal degradation by incorporation into ILVs of 
MVBs [3]. Lysosomal targeting is mediated by the endosomal sorting complex for transport 
(ESCRT) complexes. Ubiquitinated receptors are recognized by the UIM (Ubiquitin Interacting 
Motif) of HRS (hepatocyte growth factor receptor tyrosine kinase; or HGS) and STAM (signal 
transducing adaptor molecule), which are both parts of the ESCRT-0 complex [23, 24]. It has 
been shown that HRS preferentially binds to K63-ubiquitinated EGFR [25, 26]. Further 
evidence for the binding and recruitment of EGFR towards the endosome by ESCRT-0 is 
given by the observation that HRS associates with Eps15b, an UIM-containing protein which 
binds EGFR and localizes to HRS-positive microdomains of endosomes [27]. The FYVE 
zinc-finger domain of HRS binds the endosomal lipid phosphatidylinositol 3-phosphate, 
thereby recruiting the ESCRT-0 complex towards the endosomal membrane [28]. 
Furthermore, both STAM and HRS interact with clathrin, which results in recruitment of ESCRT-0 
complex-associated cargo to clathrin-coated micro-domains of sorting endosomes [29, 30]. 
Depletion of HRS results in inhibition of EGFR degradation [31]. Moreover, upon activation of 
EGFR by EGF, HRS is phosphorylated on tyrosine residues 329 and 334 by SRC family kinases, 
and this phosphorylation is enhanced by expression of CBL [23]. Mutation of these phos-
phorylation sites results in suppressed HRS and EGFR degradation [23, 31, 32]. ESCRT-0 
interacts with and recruits ESCRT-I, -II and –III complexes to target the activated EGFR 
complex to ILVs of MVBs, which ultimately fuse with primary lysosomes for degradation [28].
 Before incorporation of the activated EGFR complex in ILVs of MVBs, the attached 
ubiquitin is removed by deubiquitination (DUB) enzymes [33]. USP8 is an ESCRT-0 and 
ESCRT-III associated Ubiquitin Specific Protease, which removes both K48- and K63-poly-
ubiquitin chains, and is known to be involved in EGFR deubiquitination [34-37]. We 
recently showed that USP8 also deubiquitinates ERBB2, albeit to a much lesser extent than 
EGFR [10]. AMSH, also known as STAMBP, is another ESCRT-0 and ESCRT-III associated deu-
biquitinating enzyme that belongs to the DUB-family of JAMM domain metalloproteases, 
and which is specific for K63-linked polyubiquitin chains [38]. Both AMSH and USP8 bind 
to ESCRT-0 protein STAM through a non-canonical SH3-binding motif, and with their 
MIT-domain to several CHMP proteins of the ESCRT-III machinery [30, 37, 39, 40]. Further 
evidence that AMSH is involved in MVB sorting is given by the observation that AMSH 
binds clathrin directly and that this interaction promotes AMSH recruitment to early 
endosomes [30, 41]. Furthermore, AMSH has been shown to deubiquitinate the EGFR [38, 
40], but the effect of AMSH on EGFR downregulation is controversial. While one report 
proposes a role of AMSH in limiting the sorting of the EGFR into ILVs of MVBs [38], others 
show that EGFR downregulation is inhibited upon AMSH depletion [42]. The role of AMSH 
in deubiquitination and downregulation on ERBB receptors other than the EGFR has not 
been investigated so far. 
 Given the observation that both EGFR and an EGFR-ERBB2 chimera undergo 
CBL-mediated K63-polyubiquitination, we investigated in the present study whether 
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[125I]-EGF was corrected for non-specific binding after which total recycled [125I]-EGF was 
calculated by summing the surface-bound [125I]-EGF and intact recycled [125I]-EGF as 
previously described [43, 44]. 
Cell stimulation and cell lysis
Cell stimulation and cell lysis were performed as described previously [33]. Near confluent 
HER14, stably infected NIH3T3 or transfected HEK293 cells were incubated with serum-free 
medium for 18 hr. Growth factors were then resuspended in DMEM to a final concentration 
of 100 ng/ml. Following the incubation period, cells were washed twice with ice-cold PBS 
and adherent cells were lysed during a 20-min incubation at 4°C in lysis buffer (150 mM 
NaCl, 25 mM Tris pH 7.5, 1% Brij97, 5 mM EDTA pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml pepstatin). 
Cell lysates were subsequently transferred to Eppendorf tubes and centrifuged for 10 min 
at 4°C at 1.104xg in an Eppendorf centrifuge to remove nuclei and cell debris. Samples 
were prepared for SDS-PAGE analysis by adding Laemmli sample buffer to clear whole cell 
lysates and then heated for 5 min at 95 °C prior to loading SDS-PAGE gels under reducing 
conditions. 
Immunoprecipitation, immunoblotting and densitometry
Immunoprecipitation, immunoblotting and densitometry were performed as described 
previously [20, 33]. Anti-HRS M79 and anti-EGFR clone 528 antiserum were used to immu-
noprecipitate HRS and EGFR respectively. Antibodies were first coupled to protein 
A-Sepharose beads for 30–60 min at 4 °C. Cleared cell lysates were then added to the an-
tibody-absorbed beads and incubated for at least 3 h at 4 °C. Unbound cellular proteins 
were then removed by washing 2 times with ice-cold lysis buffer and once with ice-cold 
phosphate-buffered saline. Immunocomplexes were then resuspended in 2x Laemmli 
sample buffer. Samples were heated for 5 min at 95 °C and kept at –20 °C or loaded directly 
onto 8% SDS-PAGE gels. Immunocomplexes separated by SDS-PAGE were transferred to 
nitrocellulose filters. Blots were first blocked with 5% bovine serum albumin in TBST 
(Tris-buffered saline-Tween). After incubation with primary antibody, filters were washed 
in TBST, incubated with appropriate HRP-linked secondary antibodies, and washed again 
with TBST prior to visualization of proteins with enhanced chemiluminescence. Signals on 
X-ray films of immunoblots were quantified using Adobe Photoshop software. Briefly, 
16-bit grayscale images were inverted and a small predefined rectangle was used to 
measure the mean pixel value of relevant signals and background using the histogram 
command. Background signals were subtracted from relevant signals leading to a 
corrected mean pixel value. Values obtained from post-translational modifications were 
then divided by the corrected mean pixel values of the immunoprecipitated material and 
subsequently normalized relative to a given sample.
cells were transiently transfected using Turbofect according to the manufacturer’s 
protocol, while NIH3T3 cells were retrovirally infected with EGFR chimera constructs, as 
described previously for EGFR and EGFR-ERBB2 [10, 20]. 
Receptor downregulation
Receptor downregulation was performed as described by Sorkin and Duex [43]. On day 1, 
cells were seeded at 1.0x105 cells per well of a 24-well dish. On day 3, the cells were 
incubated for various periods of time at 37°C with 100 ng/ml EGF in 0.5 ml DMEM with 
0.1% BSA. The cells were then chilled on ice and rinsed twice with 1 ml ice-cold PBS 
containing 0.1% BSA to remove unbound EGF. Surface-bound unlabeled EGF was removed 
by incubating the cells with sodium acetate buffer (135 mM NaCl, 5 mM HAc, 2.5 mM KCl, 
pH 2.5) for 1 min at 4°C and washed twice with ice-cold PBS with 0.1% BSA to neutralize 
the acid. Subsequently, the cells were incubated for 2 h at 4°C in 0.1 ml 100 ng/ml [125I]-EGF 
containing DMEM with 0.1% BSA. After the incubation, the unbound [125I]-EGF was 
removed by washing the cells three times with 1 ml ice-cold PBS with 0.1% BSA. 
Ligand-induced downregulation was quantified by determining cell-bound radioactivity 
by lysing the cells in 1 ml of 1N NaOH for 1 h at 37°C and measuring in a γ-counter. 
Calculations were performed as described by Sorkin and Duex [43]. 
[125I]-EGF  recycling
[125I]-EGF recycling assay was performed as previously described [43, 44]. On day 1, cells 
were seeded 1.0x105 cells per well in a 24-well dish. On day 3, cells were incubated for 10 
min at 37°C with 5 ng/ml [125I]-EGF in 0.15 ml binding medium (DMEM with 0.1% BSA) to 
allow accumulation of [125I]-EGF-receptor complexes in early endosomes. The cells were 
then chilled on ice and washed three times with 1 ml of ice-cold PBS with 0.1% BSA to 
remove unbound EGF. [125I]-EGF that had not been internalized was removed by incubating 
the cells with sodium acetate buffer (135 mM NaCl, 5 mM HAc, 2.5 mM KCl, pH 4.5) for 2 
min at 4°C, after which the cells were rinsed briefly. The [125I]-EGF-loaded cells were 
subsequently incubated with 100 ng/ml EGF in 0.3 ml binding medium for 45 min at 4°C 
to occupy surface receptors. Cells were then incubated for various lengths of time at 37°C 
with 100 ng/ml EGF in 0.3 ml binding medium to allow trafficking of [125I]-EGF-receptor 
complexes in loaded cells. The cells were subsequently placed on ice, after which 1 ml 
medium was added and the medium was collected. Intact [125I]-EGF was precipitated with 
10% TCA (trichloroacetic acid) plus 2% PTA (phosphotungstic acid) during a 1 h incubation 
at 4°C, and the precipitate was subsequently collected by centrifugation for 10 min at 
5000xg at 4°C. Radioactivity in the supernatant was measured to determine the amount 
of degraded [125I]-EGF. The pellets were dissolved in 1N NaOH to determine the amount of 
intact recycled [125I]-EGF. Surface-bound [125I]-EGF was stripped by incubating the cells for 
5 min with sodium acetate buffer (pH 2.5). This acid wash was collected and the amount 
of surface-bound (recycled) [125I]-EGF was determined by γ-counting. The measured 
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Results
EGFR-ERBB2 chimera is more efficiently recycled than EGFR
It has previously been reported that ERBB2 displays poor ligand-induced downregulation 
and enhanced recycling compared to EGFR [12-14]. Previous studies using EGFR-ERBB2 
chimeras established that poor ERBB2 downregulation is due to the absence of positive or 
the presence of negative sorting signals in the C-terminal cytoplasmic tail of the ERBB2 
receptor, i.e. C-terminal to the kinase domain  [13]. To further locate the sorting signals 
responsible for poor downregulation of the EGFR-ERBB2 chimera and to investigate the 
role of CBL, we made an additional chimera CTC (C-terminal to CBL-site) in which the 
EGFR-ERBB2 boundary is located C-terminal of the EGFR CBL binding site (Fig. 1). Wild-type 
and chimeric receptors were stably expressed in NIH3T3 at similar levels, as determined by 
Western blotting. To investigate the downregulation and recycling of these chimeras, 
[125I]-EGF labeled ligand binding assays were performed. The EGFR-ERBB2 TM chimera 
showed decreased downregulation compared to the wild-type EGFR (Fig. 2a), consistent 
with previous reports [13], while downregulation of the CTC chimera was slightly enhanced 
compared to TM but still much lower than observed for EGFR (Fig. 2A). In line with this, 
EGF-recycling assays demonstrated enhanced recycling of EGFR-ERBB2 TM and CTC 
chimeras compared to wild-type EGFR, (Fig. 2B).  Furthermore, HER14 showed enhanced 
EGF-degradation compared to TM and CTC (Fig. 2C). These findings support and extend 
previous results indicating that upon EGF treatment, the EGFR is efficiently downregulated, 
while the EGFR-ERBB2 TM chimera is more efficiently recycled [13]. Furthermore, we 
Figure 1   EGFR-ERBB2 chimeras used in this study
Schematic drawing of EGFR-ERBB2 chimeras used in this study. HER14 was used as EGFR-expressing 
cells. The EGFR-ERBB2 TM chimera contains the extracellular and transmembrane (TM) domain of 
EGFR, and the intracellular domain of ERBB2. The EGFR-ERBB2 CTC chimera contains only ERBB2 
sequences C-terminal to the CBL binding site. The CBL binding site sequences for EGFR and ERBB2 
are FLQRpY1045SSDPT and PLQRpY1091SEDPT respectively. Numbers indicate amino acids of mature 
receptors.
Figure 2   EGFR-ERBB2 is more efficiently recycled than EGFR
NIH3T3 cells were infected with retrovirus containing EGFR-ERBB2 CTC (triangles) and TM (squares). 
HER14 cells were used as EGFR-expressing cells (diamonds). A, EGF-induced receptor downregulation; 
B, [125I]EGF recycling; C, [125I]EGF degradation. For experimental details, see Materials and Methods. 
Results are mean of 2-3 independent experiments.
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extend these findings by showing that the EGFR-ERBB2 CTC resembles the EGFR-ERBB2 
TM phenotype in downregulation, EGF-recycling and EGF-degradation. Thus, these 
findings demonstrate that poor downregulation and enhanced recycling of EGFR-ERBB2 
TM and CTC is are due to the absence of EGFR sequences or the presence of ERBB2 
sequences C-terminal to the ERBB2 CBL-binding site.
EGF-stimulation of EGFR-ERBB2 does not induce HRS tyrosine 
phosphorylation
We have previously shown that EGFR and EGFR-ERBB2 are both efficiently K63-polyubiq-
uitinated upon EGF treatment [10]. K63-polyubiquitinated EGFR is recognized by the 
UIM-containing ESCRT-0 subunit HRS [23, 25, 26]. Upon activation of EGFR by EGF, HRS is 
tyrosine phosphorylated on residues 329 and 334 by SRC family kinases [23, 31, 32]. Since 
EGFR-ERBB2 displays less efficient downregulation than the EGFR, we tested the hypothesis 
that ERBB2 and HRS do not interact efficiently within the cell. To address whether the 
EGFR-ERBB2 chimera stimulates HRS tyrosine phosphorylation upon EGF-stimulation, we 
treated serum-starved ERBB receptor expressing cell lines with EGF. As shown in Fig. 3, 
EGFR activation results in efficient HRS tyrosine phosphorylation. In contrast, stimulation 
of EGFR-ERBB2 TM results in poor HRS tyrosine phosphorylation (Fig. 3A). Quantification of 
quadruplicate experiments showed that HRS tyrosine phosphorylation is largely abolished 
upon stimulation of the EGFR-ERBB2 TM chimera and the EGFR-ERBB2 CTC chimera (Fig. 
3B). We conclude that EGF activation of the EGFR-ERBB2 TM and CTC chimeras does not 
result in efficient tyrosine phosphorylation of the ESCRT-0 subunit HRS when compared to 
the EGFR. Our findings indicate that enhanced recycling of ERBB2 TM and CTC chimeras is 
accompanied by significantly impaired HRS tyrosine phosphorylation.
AMSH efficiently removes ubiquitin from the activated EGFR, but not 
from the activated EGFR-ERBB2 chimeras
We have previously shown that EGFR and EGFR-ERBB2 are both efficiently K63-polyubiq-
uitinated by CBL. Furthermore we demonstrated that both EGFR and EGFR-ERBB2 TM are 
deubiquitinated by the deubiquitination enzyme USP8, although deubiquitination of 
ERBB2 was less efficient than that of EGFR [10]. Since AMSH is a K63-polyubiquitin 
chain-specific deubiquitination enzyme and it has been shown that AMSH efficiently deu-
biquitinates EGFR [38, 40], we investigated whether AMSH is involved in removing 
ubiquitin from EGFR-ERBB2 chimeras. We performed an in vivo deubiquitination assay for 
which EGFR, EGFR-ERBB2 TM and EGFR-ERBB2 CTC were co-transfected with either AMSH 
wt or catalytically inactive AMSH D348A into HEK293 cells. As expected, EGF-stimulation 
of serum-starved cells resulted in ubiquitination of the EGFR, while co-expression of AMSH 
D348A significantly increased EGFR ubiquitination (Fig. 4A). Strikingly, co-expression of 
EGFR-ERBB2 TM together with AMSH D348A did not result in enhanced receptor 
ubiquitination, indicating that AMSH does not substantially deubiquitinate the EGFR-ERBB2 
Figure 3   EGF-stimulation of EGFR-ERBB2 does not induce HRS tyrosine phosphoryla-
tion 
NIH3T3 were retrovirally infected with EGFR-ERBB2 CTC and TM. HER14 cells were used as EGFR-ex-
pressing cells. A, Cells were serum starved overnight and stimulated for 1 h with 100 ng/ml EGF. 
Whole cell lysates (WCL) were used for anti-HRS immunoprecipitation (IP) and immunoblot (IB) with 
the indicated antibodies. B, Densitometric relative corrected mean pixel values of HRS tyrosine 
phosphorylation were plotted as a mean with standard error of the mean (SEM). Phospho-signals of 
the IPs were related to the amount of precipitated HRS in the second panel and normalized to the 
HER14/EGF group. Data are representative of 4 independent experiments.
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TM chimera (Fig. 4A). To test the hypothesis that recycling receptors show impaired deu-
biquitination by AMSH, we performed a similar experiment for the chimeric EGFR-ERBB2 
CTC. As observed for EGFR-ERBB2 TM, co-expression of EGFR-ERBB2 CTC together with 
AMSH D348A did not significantly increase the ubiquitination signal compared to AMSH 
wt (Fig. 4B). These findings demonstrate that AMSH efficiently removes ubiquitin from the 
activated EGFR, but not from the activated chimeric EGFR-ERBB2 TM and CTC receptors.
TGFα stimulates EGFR K63-polyubiquitination, but does not induce HRS 
tyrosine phosphorylation and AMSH-mediated EGFR deubiquitination
It has been established in a variety of studies that TGFα binding to the EGFR is strongly 
pH-dependent. Consequently, after internalization TGFα dissociates from the EGFR in the 
acidic environment of endosomes [45-47]. As a result, a significant fraction of EGFR is 
recycled back to the cell surface upon TGFα-stimulation and we previously demonstrated 
that this is correlated with decreased steady state ubiquitination levels and decreased 
EGFR degradation [14, 33, 45]. Since EGFR-ERBB2 TM displays efficient recycling, we tested 
if EGF-stimulation of EGFR-ERBB2 TM and TGFα-stimulation of EGFR will show similar char-
acteristics in terms of HRS tyrosine phosphorylation and AMSH-mediated receptor-deu-
biquitination. We have previously shown that EGF-stimulation of EGFR-ERBB2 leads to 
K63-polyubiquitination, albeit slightly less than observed in the wt EGFR [10]. Initially, we 
verified the specificity of the K63 poly-ubiquitin antibody using in vitro synthesized K48- 
and K63-linked polyubiquitin chains (Fig. 5A). Next, we showed that TGFα-stimulation of 
serum-starved stably transfected cell lines does lead to K63-polyubiquitination of the 
EGFR (Fig. 5B), although the steady state level is slightly decreased compared to EGF-stim-
ulation of EGFR. These results demonstrate that, similar to the EGF-stimulated EGFR-ERBB2 
TM chimera, TGFα-stimulated EGFR results in efficient K63-polyubiquitination. These 
findings strongly indicate that enhanced recycling of the EGFR and the EGFR-ERBB2 
chimeras is not due to failure of ligand-induced CBL-mediated K63-linked polyubiquitina-
tion of these receptors.
 EGF-activation of EGFR stimulates both K63-polyubiquitination and HRS tyrosine 
phosphorylation, but we hypothesized that in the case of receptor recycling, ligands may 
induce efficient K63-polyubiquitination without subsequent HRS tyrosine phosphoryla-
tion. Indeed, our data show that TGFα-stimulation of the EGFR hardly resulted in any HRS 
tyrosine phosphorylation, in contrast to the HRS tyrosine phosphorylation detected upon 
EGF-stimulation. However, TGFα-induced activation and tyrosine phosphorylation of 
EGFR were easily detectable (Fig. 5C-D). These findings indicate that upon TGFα-stimula-
tion, the internalized EGFR does not efficiently phosphorylate HRS.
 Since AMSH is a K63-specific deubiquitinating enzyme recruited to the endosomes 
via the ESCRT-0 complex, we investigated whether ubiquitin chains covalently linked to 
TGFα-stimulated EGFR can be removed by AMSH. As expected, coexpression of EGFR 
together with AMSH D348A showed enhanced ligand-induced ubiquitination when 
Figure 4   AMSH efficiently removes ubiquitin from the activated EGFR, but not from the 
activated chimeric EGFR-ERBB2 receptors
HEK293 cells were co-transfected with EGFR, TM (A) or CTC (B) and either AMSH wt or AMSH D348A. 
Serum-starved cells were stimulated for 15 min with or without EGF. WCL were used for anti-EGFR IP 
and IB with the indicated antibodies. Data are representatives of 2 independent experiments.
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Figure 5   TGFα stimulates EGFR K63-polyubiquitination, but does not induce HRS 
tyrosine phosphorylation and AMSH-mediated EGFR deubiquitination
A, 1 µg K48- and K63-linked polyubiquitin chains were separated with SDS-PAGE and detected with 
the K63-polyubiquitin specific antibody. B, HER14 cells were serum-starved overnight and stimulated 
for 15 min with or without 100 ng/ml EGF or TGFα. WCL were used for anti-EGFR IP and IB with the 
indicated antibodies. C, HER14 cells were serum starved overnight and stimulated for 15 min with or 
without 100 ng/ml EGF or TGFα. WCL were used for anti-HRS IP and IB with the indicated antibodies. 
Figure 5   Continued
D, Densitometric relative corrected mean pixel values of HRS tyrosine phosphorylation were plotted 
as a mean with SEM. Phospho-signals of the IPs were related to the amount of precipitated HRS in 
the second panel and normalized to the HER14/EGF group. E, HEK293 cells were co-transfected with 
EGFR and either AMSH wt or AMSH D348A. Serum-starved cells were stimulated for 15 min with or 
without EGF or TGFα. WCL were used for anti-EGFR IP and IB with the indicated antibodies. Data are 
representatives of 2 independent experiments. 
A D
EC
B
4CHAPTER 4 RECYCLING OF EGFR AND ERBB2
118 119
the kinase domain [13]. These studies established that poor ERBB2 downregulation is due 
to the absence of positive or the presence of negative sorting signals in the C-terminal 
cytoplasmic tail of the ERBB2 receptor, i.e. C-terminal to the kinase domain [13]. The 
decreased ERBB2 downregulation may be explained by reduced recruitment of the 
clathrin adapter protein AP2 to drive internalisation [12, 19], the absence of a dileucine 
signal in the cytoplasmic tail of ERBB2 that corresponds to EGFR sequence LL1010/1011 
that promotes lysosomal targeting [19, 20], the presence of an extra 45 amino-acids in the 
ERBB2 cytoplasmic tail [21], and/or the reduced recruitment of CBL E3 ligases to activated 
ERBB2 receptors [22]. However, we previously demonstrated that the ERBB2 CBL binding 
site is functionally active and responsible for ERBB2 K63-polyubiquitination [10, 20]. So far, 
no other studies have been performed on ERBB2 K63-polyubiquitination and the 
ubiquitination sites of ERBB2 have not been determined yet. Recently, using mass 
spectrometry (MS) six ubiquitin-modified lysine residues within the kinase domain of the 
EGFR were identified [11]. Mutation of a single lysines did not alter the ubiquitination status 
of EGFR, but mutation of up to 15 lysine residues resulted in a decrease, but not complete 
abolishment, of EGFR ubiquitination, suggesting that multiple lysine residues are involved 
in EGFR ubiquitination [11, 48]. Furthermore, although MS revealed that more than 40% of 
the ubiquitinated EGFR was in the form of K63-polyubiquitination, the exact sites of 
K63-polyubiquitination on the EGFR have not been determined yet [11]. 
 In this study, we used the EGFR-ERBB2 CTC chimera, in which the EGFR-ERBB2 
boundary is located just C-terminal of the EGFR CBL binding site. Here we show that, using 
the EGFR-ERBB2 CTC chimera, that poor downregulation is largely due to the absence of 
EGFR sequences or the presence of ERBB2 sequences C-terminal to the ERBB2 CBL-binding 
site. For instance, the C-terminal valine of ERBB2 that associates with PDZ-domain proteins 
like Erbin [49, 50] and LIN-7 [51], may be involved in preventing the ERBB2 receptor from 
efficient downregulation. Since downregulation of the EGFR-ERBB2 CTC chimera is 
somewhat decreased compared to EGFR-ERBB2 TM, it seems likely that multiple signals 
are involved in limiting downregulation of ERBB2. Further research must be performed to 
further locate the sorting signals and to elucidate the involvement of various signals that 
are involved in downregulation and recycling of ERBB receptors.
 Our previous studies indicate that ligand-induced lysosomal EGFR degradation is 
associated with proteasome-dependent EGFR deubiquitination [33]. The lysosomal inhibitor 
bafilomycin blocked EGFR degradation and resulted in accumulation of ubiquitinated 
EGFRs, but did not prevent EGFR deubiquitination upon prolonged EGF stimulation. In 
contrast,  the proteasome inhibitor lactacystin had little effect on the ubiquitination status 
of EGFR and caused a slight delay in EGFR degradation. However, addition of bafilomycin 
and lactacystin together resulted in stabilization of the ubiquitinated EGFR, suggesting that 
proteasome activity is required for deubiquitination of the EGFR prior to its degradation in 
lysosomes [33]. We proposed a model in which proteasome-dependent deubiquitination 
facilitates sorting of the EGFR into ILVs of MVBs [33]. Similar results were subsequently 
compared to coexpression with AMSH wt. Upon TGFα-stimulation, however, only a slight 
increase of the ubiquitination status of the EGFR was seen upon coexpression of AMSH 
D348A, but this effect was significantly smaller than observed upon EGF-stimulation (Fig. 
5E). These results indicate that AMSH does not remove K63-polyubiquitin chains efficiently 
from the EGFR upon TGFα-stimulation. 
 Taken together, our results demonstrate that TGFα-stimulation of EGFR and EGF-stim-
ulation of the EGFR-ERBB2 chimera both lead to efficient K63-polyubiquitination. However, 
these conditions are associated with significantly impaired tyrosine phosphorylation of 
the ESCRT-0 complex protein HRS. Furthermore, recycling of EGFR and EGFR-ERBB2 
receptors is associated with substantially decreased receptor deubiquitination by the 
K63-polyubiquitin chain specific deubiquitinating enzyme AMSH. Importantly, the effects 
seen for EGF-stimulated EGFR-ERBB2 resemble those of TGFα-stimulated EGFR, and are 
consistent with the observation that these recycling receptors are not efficiently 
incorporated in the MVB pathway [2]. 
Discussion
Given our previous observation that both EGFR and the EGFR-ERBB2 TM chimera undergo 
CBL-mediated K63-polyubiquitination, we investigated whether activation of this chimera 
is associated with tyrosine phosphorylation of the ESCRT-0 complex subunit HRS and 
AMSH-mediated deubiquitination. Our data show that TGFα stimulation of the EGFR and 
EGF stimulation of EGFR-ERBB2 chimeric receptors, both conditions that are associated 
with enhanced endosomal recycling, correlate with (i) efficient K63-polyubiquitination, (ii) 
significantly impaired tyrosine phosphorylation of HRS and (iii) substantially decreased 
deubiquitination by AMSH. Using an additional EGFR-ERBB2 chimera we demonstrate that 
enhanced recycling, decreased HRS tyrosine phosphorylation and decreased AMSH 
mediated deubiquitination of EGFR-ERBB2 chimeras is primarily due to the absence of 
EGFR sequences or the presence of ERBB2 sequences C-terminal to the CBL-binding sites. 
We conclude that the phenotype observed for EGF-stimulated EGFR-ERBB2 resembles the 
phenotype seen for TGFα-stimulated EGFR, which is consistent with the finding that these 
receptors are not efficiently incorporated in the MVB pathway under these conditions.
 Our data show that EGFR-ERBB2 TM chimera showed decreased downregulation and 
EGF-degradation and enhanced recycling compared to wild-type EGFR. To further locate 
the sorting signals and to investigate the role of CBL, we demonstrate that the phenotype 
of EGFR-ERBB2 CTC chimera largely resembles that observed for EGFR-ERBB2 TM chimera 
(Fig. 2). These results are in line with previous reports showing that ERBB2 displays poor 
ligand-induced downregulation and enhanced recycling compared to EGFR [12, 13]. 
Previous studies used the chimeras EGFR-ERBB2 TM as well as an intermediate EGFR-ERBB2 
COOH chimera, in which the EGFR-ERBB2 boundary is located near the C-terminal end of 
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also suggest that other deubiquitinating enzymes may be involved in deubiquitinating 
K63-polyubiquitinated EGFR-ERBB2 in the recycling pathway. Several DUBs have been 
implicated in deubiquitination of receptors during recycling. Whereas Usp10 has been 
implicated in removal of ubiquitin from CFTR during recycling [57], USP33 and USP20 have 
been proposed to remove ubiquitin from the recycling beta-adrenergic receptor [58] 
while the DUB UCHL3 enables recycling of the epithelial Na+ channel ENaC back to the cell 
surface [59]. These DUBs may have a variety of targets and may possibly also be involved 
in deubiquitination of recycling EGF- or ERBB2 receptors. The idea that MVB sorting and 
endosomal recycling are associated with  deubiquitination by different deubiquitinating 
enzymes is also supported by studies on the endosomal trafficking of the yeast permease 
Gap1 [60]. Whether deubiquitination of ubiquitinated receptors during endosomal 
recycling is proteasome-dependent is currently unclear. 
 We also demonstrate that TGFα-stimulation of the EGFR does not result in detectable 
HRS tyrosine phosphorylation or efficient AMSH-mediated receptor deubiquitination 
(Fig. 5). TGFα binds to the EGFR in a pH-dependent manner, leading to rapid dissociation 
of TGFα from the EGFR in the acidic environment of early endosomes and subsequent 
dephosphorylation of the activated receptor complex [14, 33, 45-47]. Our results indicate 
that TGFα-induced recycling of the EGFR is associated with failure to direct HRS tyrosine 
phosphorylation. This is consistent with our additional finding that the ESCRT-0 associated 
DUB AMSH is not substantially involved in deubiquitination of the K63-polyubiquitin 
chain-modified EGFR following TGFα-stimulation.  
 It is interesting to note that AMSH has been proposed to deubiquitinate cargo 
proteins at an early stage of the endosomal sorting process and to promote recycling of 
receptors, while USP8 activity has been suggested to be essential for effective 
downregulation [37]. However, experimental evidence for this hypothesis is lacking so far. 
AMSH is involved in the MVB pathway by binding the ESCRT-0 protein STAM through a 
non-canonical SH3-binding motif, and with the MIT-domain to several CHMP proteins of 
the ESCRT-III machinery [30, 37, 39, 40]. Recruitment of AMSH towards ESCRT-0 is essential 
for deubiquitination of STAM and HRS, but this deubiquitination does not alter their 
stability. Since HRS and STAM function is dependent on UIM-mediated interactions, this 
may indicate an effect of AMSH on ESCRT complex formation [61]. Binding of AMSH to the 
ESCRT-III components is essential for targeting of AMSH to endosomes [42]. Furthermore, 
AMSH binds clathrin directly and this interaction promotes AMSH recruitment to early 
endosomes [30, 41]. Based on our findings that EGF-stimulation of EGFR-ERBB2 and TG-
Fα-stimulation of EGFR are associated with significantly impaired AMSH-mediated deu-
biquitination, our results do not support the model that AMSH is involved in deubiquitina-
tion of recycling ERBB receptors. Our results support a model that the recycling receptors 
are not efficiently incorporated in the MVB pathway and that the decision for recycling of 
the receptors is made during an early stage of endosomal sorting and prior to interaction 
with the ESCRT-0 complex.
reported for the TrkA receptor tyrosine kinase [52]. For full-length ERBB2, a link between 
proteasome activity and lysosomal degradation has also been reported. The endocytosis -
impaired full-length ERBB2 can be down-regulated by the hsp90 inhibitor Geldanamycin 
(GA), which results in the activation of the E3-ligase CHIP leading to ubiquitination of ERBB2. 
Furthermore, GA induces endocytosis and lysosomal degradation [53-55]. Proteasomal 
activity is not required for GA-induced endocytosis, but proteasomal inhibitors retarded 
degradation of ERBB2 and proteasomal activity is required to sort internalized ERBB2 
to lysosomes [54, 55]. Furthermore, the proteasomal DUB POH1 has been implicated in 
 deubiquitination of ERBB2. Knock-down of POH1 or addition of proteasomal inhibitors resulted 
in increased levels of ERBB2 ubiquitination, but ERBB2 was not detectably accumulated, 
suggesting that the proteasomal pathway is not the major degradative pathway of ERBB2 
[56]. However, in this context, it is important to note that ubiquitination of ERBB- and other 
receptor tyrosine kinases is not limited to constitutive or ligand-induced ubiquitination at 
the plasmamembrane or during endosomal trafficking but may also be the result of 
improper folding of the receptor in the ER membrane resulting in ubiquitination as part of 
the ER associated degradation (ERAD) pathway.
 To further show differences between EGFR and EGFR-ERBB2 sorting, we show that 
EGF-activation of EGFR results in HRS tyrosine phosphorylation. Interestingly, activation of 
EGFR-ERBB2 TM and CTC chimeras show decreased HRS tyrosine phosphorylation (Fig. 3). 
We have previously shown that EGFR and EGFR-ERBB2 are both efficiently K63-polyubiq-
uitinated [10]. Our results support previous findings that K63-polyubiquitinated EGFR is 
recognized by the UIM-containing protein HRS [23, 25, 26] and that HRS is tyrosine 
phosphorylated upon activation of EGFR by EGF [23, 31, 32]. Under these conditions, HRS 
is recruited to early endosomes by Eps15b, the endosomal membrane lipid phosphatidy-
linositol 3-phosphate and clathrin [27-29]. Interestingly, even though EGFR-ERBB2 TM and 
EGFR are efficiently K63-polyubiquitinated upon EGF- and TGFα-activation respectively 
[10], these conditions are not associated with efficient HRS tyrosine phosphorylation. In 
this context it is noteworthy that recycling transferrin receptors also fail to colocalize with 
HRS [24]. Furthermore, a recent study demonstrated that a non-ubiquitinated EGFR 
mutant, which was efficiently recycled to the plasma membrane, was unable to interact 
with HRS and to stimulate HRS tyrosine phosphorylation [44]. Thus, our findings indicate 
that EGFR, EGFR-ERBB2 TM and CTC recycling receptors do not efficiently interact with 
ESCRT-0 complex protein HRS on the endosomal membranes within the cell.
 We also showed that EGF-activation of the EGFR-ERBB2 TM and CTC chimeras is not 
associated with efficient receptor deubiquitination by the K63-polyubiquitin chain-specific 
DUB AMSH, as is observed for the EGFR (Fig. 4). These results are reminiscent of our 
previous findings that the EGFR is a more prominent target for USP8 than the EGFR-ERBB2 
TM chimera [10, 34]. These observations can be explained by the observation that 
EGFR-ERBB2 is more efficiently recycled and that only the fraction that is sorted into ILVs of 
MVBs associates with the ESCRT-0 associated proteins HRS, USP8 and AMSH. These results 
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Conclusion
In conclusion, our results demonstrate that endosomal recycling of the EGFR and ERBB2 
receptors is associated with efficient K63-polyubiquitination, but significantly decreased 
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Abstract
ERBB receptors have an important function in mammalian development and normal 
physiology, but overexpression and poor downregulation of ERBB receptors have been 
associated with malignant growth. Ligand-induced ERBB receptor signaling is terminated 
by clathrin-dependent receptor  endocytosis, followed by incorporation of activated 
receptor complexes into multi-vesicular bodies and subsequent degradation in lysosomes. 
In the case of ERBB1, also known as the EGF receptor, it has been shown that ubiquitination 
serves as a signal to facilitate internalization and subsequent endosomal sorting, but little 
is known about the role of ubiquitination of other ERBB receptors. In the present study we 
investigated the regulation of ubiquitination and deubiquitination of the ERBB4 CYT-1 and 
CYT-2 isoforms in the context of chimeric EGFR-ERBB4 receptors. We demonstrate that 
EGFR-ERBB4 CYT-2 chimera shows decreased ligand-induced downregulation and 
EGF-degradation, as well as enhanced EGF recycling, when compared to EGFR-ERBB4 
CYT-1. Moreover we show that the mutation Y1103F in the binding site for CBL which is 
present in both CYT-1 and CYT-2, does not influence ERBB4 endosomal trafficking. We 
further demonstrate that total ligand-induced ubiquitination of CYT-1 is higher than that 
of CYT-2, whereby CYT-1 ubiquitination is mainly dependent on the PPXY1056 ITCH binding 
site for the E3-ligase ITCH which is only present in CYT-1, while that of CYT-2 is dependent 
on the Y1103 CBL binding site. The E3-ligase c-CBL is more efficiently phosphorylated 
upon EGF stimulation of the CYT-2 than the CYT-1 isoform. Moreover our data show that 
the pY1103 CBL binding site is required for K48-polyubiquitination of both CYT-1 and 
CYT-2, whereas the PPXY1056 ITCH binding site is required for K63-polyubiquitination of 
CYT-1. We further demonstrate that EGF stimulation of EGFR-ERBB4 CYT-1 and CYT-2 does 
not result in efficient binding to and tyrosine phosphorylation of the ESCRT-0 subunit HRS. 
Finally, even though CYT-1 shows ligand-induced K63-polyubiquitination, it is not 
subjected to deubiquitination by the K63 polyubiquitin-specific AMSH deubiquitinating 
enzyme, while CYT-1 is slightly deubiquitinated by USP8. We conclude that CBL and ITCH 
binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, 
respectively.
Introduction
EGFR (ERBB1), ERBB2, ERBB3 and ERBB4 receptors belong to the family of receptor tyrosine 
kinases. Upon binding of EGF-like growth factors, such as EGF and neuregulins, these 
receptors undergo conformational changes which result in receptor dimerization and 
subsequent autophosphorylation of cytoplasmic tail tyrosine residues. These phosphorylation 
events trigger activation of downstream signal transduction pathways that couple ERBB 
receptors to cellular responses, such as proliferation, differentiation, migration, and survival 
[1]. On the other hand, overexpression or mutation of EGFR, ERBB2 and ERBB3 has been 
associated with malignant cellular growth, contributing to enhanced tumor progression 
and poor patient outcome [2]. However, relatively little is known about the role of ERBB4 
in cancer biology. Some reports demonstrate that overexpression of ERBB4 promotes 
breast cancer cell proliferation and transformation of fibroblasts [3, 4]. In contrast, others 
have reported that ERBB4 activation correlates with decreased cell growth and differentiation 
and induces cell cycle arrest or apoptosis [5-7]. 
 The best characterized ERBB receptor, EGFR, has been shown to undergo efficient 
ligand–induced clathrin-dependent endocytosis, followed by incorporation of the 
activated receptor complex into intraluminal vesicles (ILVs) of multi-vesicular bodies 
(MVBs) and subsequent degradation in lysosomes, resulting in an attenuation of receptor 
signaling [8, 9]. Ubiquitination serves as a signal to facilitate internalization of plasma 
membrane receptors such as EGFR [10, 11], whereas both mono-ubiquitination and 
K63-polyubiquitination have been implicated in endosomal sorting and lysosomal 
targeting [12]. In contrast, K48-polyubiquitination has been identified as a signal for 
proteasomal degradation [13]. Following EGF stimulation the E3-ubiquitin ligase CBL is 
recruited to the EGFR and induces ubiquitination of the EGFR [14, 15]. The EGFR is known 
to undergo both mono- and K63-polyubiquitination [16, 17]. We have previously 
demonstrated that the replacement of the EGFR CBL binding site by that of ERBB2 or 
ERBB4 does not impair CBL recruitment or receptor ubiquitination, suggesting that the 
CBL site of ERBB2 and ERBB4 is functionally intact [18]. Indeed, we have shown that EGF 
induces CBL binding site-dependent K63-polyubiquitination of the chimeric EGFR-ERBB2 
receptor [16]. Furthermore, we have demonstrated that CBL-mediated ubiquitin is 
removed by deubiquitination (DUB) enzymes before incorporation of the activated EGFR 
complex into ILVs of MVBs [19]. Indeed, two DUB enzymes are known to be involved in 
EGFR deubiquitination. AMSH is a JAMM-type DUB that is specific for K63-polyubiquitin 
and USP8 is a member of the USP DUBs that remove both K48- and K63-polyubiquitin 
chains. It had already been established that both enzymes are able to deubiquitinate 
EGFR [20-25], but, we have recently demonstrated that USP8, but not AMSH, is capable of 
deubiquitination of ERBB2 [16]. However, no information is currently available about the 
role of the E3 ligase CBL and the DUB enzymes USP8 and AMSH on the ubiquitination 
status of ERBB4. 
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total ligand-induced ubiquitination is more prominent in CYT-1 than CYT-2. The CBL 
binding site is responsible for K48-polyubiquitination of both CYT-1 and CYT-2, while 
K63-polyubiquitination is dependent on the ITCH binding site in CYT-1. Furthermore, we 
investigated the effect of deubiquitination enzymes USP8 and AMSH on ERBB4 CYT-1 
isoforms and demonstrate that USP8 but not AMSH slightly affects the ubiquitination 
status of CYT-1.  
Materials and methods
Reagents
The following antibodies were used in this study: a-EGFR monoclonal antibody (mAb) 
528, a-EGFR polyclonal antibody (pAb) 1005, a-ERBB4 pAb C18, a-GFP pAb FL, a-HRS pAb 
M79, a-ubiquitin mAb P4D1 (Santa Cruz), a-phosphotyrosine mAb 4G10, a-K63 ubiquitin 
mAb Apu3 (Upstate Biotechnology), a-ubiquitin pAb U5379, a-tubulin mAb and a-FLAG 
mAb M2 (Sigma). Immunoprecipitation of EGFR was performed using mAb528, while 
pAb1005 was used for EGFR detection on Western blots. Secondary goat anti-rabbit 
(GARPO) and goat anti-mouse (GAMPO) mAbs, both linked to horseradish peroxidase, 
were purchased from Signal Transduction Laboratories. Other reagents used in this study 
included Sepharose beads coupled to protein A (Amersham Biosciences), Turbofect™ 
(Fermentas) and mouse receptor grade EGF (BD Bioscience). All PCR primers were obtained 
from Sigma.
Recombinant DNA technology and constructs
pcDNA3 EGFR and pcDNA3 EGFR Y1045F were kindly provided by Dr. Y Yarden (Weizmann 
Institute, Israel) and pZIPneo EGFR-ERBB4 CYT-2 was kindly provided by M.H. Kraus 
(Vanderbilt University School of Medicine, USA) [26]. EGFR-ERBB4 CYT-2 was removed 
from the pZIPneo vector by SpeI and AgeI digestion, and subsequently inserted into a 
modified pcDNA3.1 vector using NheI and AgeI restriction sites. pcDNA3.1 EGFR-ERBB4 
CYT-1 was generated using PCR-mediated primer overlap extension of pcDNA3.1 
EGFR-ERBB4 CYT-2 using PmeI and NheI sites. The Y1103F mutation in pcDNA3.1 
EGFR-ERBB4 CYT-1 and CYT-2, as well as the P1054A mutation in pcDNA3.1 EGFR-ERBB4 
CYT-1 were introduced by PCR-mediated primer overlap extension using the PmeI and 
NheI restriction sites. The retroviral pLXSN EGFR constructs have been described previously 
[16, 18]. EGFR-ERBB4 CYT-2 was removed from the pZIPneo vector and subsequently 
inserted into a modified pLXSN vector using SpeI and BglII restriction sites. pLXSN 
EGFR-ERBB4 CYT-1 was generated using PCR-mediated primer overlap extension of 
pcDNA3.1 EGFR-ERBB4 CYT-2 using AgeI and BsmI sites. The Y1103F mutation in PLXSN 
EGFR-ERBB4 CYT-1 and CYT-2 and the P1054A mutation in pLXSN EGFR-ERBB4 CYT-1 were 
introduced by PCR-mediated primer overlap extension using the AgeI and BsmI restriction 
 It has been established that downregulation of ERBB2, ERBB3 and ERBB4 is significantly 
lower than that of EGFR [26], but the molecular basis for this difference in behavior remains 
poorly understood. Previous studies suggested that the difference may result from the 
absence of positive or the presence of negative sequences in the cytoplasmic domains of 
these various receptors [26, 27]. For example, it has been proposed that reduced 
recruitment of CBL to ERBB2, ERBB3 and ERBB4 receptors may be responsible for poor 
ligand-induced downregulation of these receptors [28]. However, we have demonstrated 
that the replacement of the EGFR CBL binding site by that of ERBB2 and ERBB4 did not 
affect CBL recruitment, receptor ubiquitination, -degradation, -downregulation or ligand 
degradation of EGFR, suggesting that poor downregulation of ERBB2 and ERBB4 is not 
due to sequence variations in the CBL binding site of these receptors [18].  
 Research on ERBB4 is made complex by the existence of four structurally and 
functionally different isoforms, generated by tissue-specific alternative mRNA splicing 
from a single ERBB4 gene [29]. ERBB4 juxtamembrane (JM) isoforms (JM-a and JM-b) differ 
in a stretch of amino acids at the extracellular JM domain of the receptor, whereby JM-a 
contains 23 unique amino acids and confers susceptibility to ecto-domain shedding, 
while JM-b contains 13 alternative amino acids which are non-cleavable [30]. Following 
activation of ERBB4 by neuregulin, JM-a is cleaved in the extracellular JM domain by TACE 
(tumor necrose factor-α converting enzyme), a member of the transmembrane ADAM 
metalloprotease family also known as ADAM17 [31]. Subsequently, the remaining truncated 
receptor (designated m80) undergoes intramembrane proteolysis by γ-secretase, resulting 
in a soluble intracellular domain known as s80 [32, 33]. These catalytically active tyrosine 
kinase s80 domains have been suggested to translocate to the nucleus and act as a tran-
scriptional regulator [32, 34, 35]. 
 ERBB4 cytoplasmic (CYT) isoforms differ by including (CYT-1) or excluding (CYT-2) a 
16-amino acid stretch in the cytoplasmic tail of the receptor [36]. The insert contains two 
important and overlapping consensus sequences: an YXXM and a PPXY motif, which share 
the common Y1056. The YXXM motif in CYT-1 is a known consensus binding motif for the 
SH2 domain of the p85 subunit of phosphoinositide 3-kinase (PI3-K) and as a result CYT-1, 
in contrast to CYT-2, can activate the (PI3-K)-Akt pathway, which is associated with cell 
survival and chemotaxis [36, 37]. However, both isoforms can activate the Shc/Ras/MAPK 
pathway and mediate cell proliferation [37]. The presence of PPXY motifs in ERBB4 is 
unique in the ERBB family, such that the CYT-1 isoform contains three PPXY motifs whereas 
CYT-2 contains only two. The PPXY motif is the binding site for WW domain containing 
proteins, such as Nedd-like ubiquitin ligases including the E3 ligase Aip4/ITCH [38-40]. 
Indeed, ITCH has been identified to bind and ubiquitinate both the CYT-1 and CYT-2 
isoform of ERBB4, although to a different extent [39, 41]. 
 In this study we investigated whether the CBL binding site in ERBB4 CYT-1 and CYT-2 
and the ITCH binding site in ERBB4 CYT-1 isoform are functionally active and regulate 
ligand-induced ERBB4 ubiquitination. Using EGFR-ERBB4 chimeras we demonstrate that 
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trafficking of [125I]-EGF-receptor complexes in loaded cells. The cells were subsequently 
placed on ice, after which 1 ml of medium was added and subsequently  collected. Intact 
[125I]-EGF was precipitated with 10% TCA (trichloroacetic acid) plus 2% PTA (phosphotung-
stic acid) during a 1 hr incubation at 4°C, after which the precipitate was collected by 
centrifugation for 10 min at 5000xg at 4°C. Radioactivity in the supernatant was measured 
to determine the amount of degraded [125I]-EGF. The pellets were solved in 1N NaOH to 
determine the amount of intact recycled [125I]-EGF. Surface-bound [125I]-EGF was stripped 
by incubating the cells for 5 min with sodium acetate buffer (pH 2.5). This acid wash was 
collected and the amount of surface-bound (recycled) [125I]-EGF was determined by 
γ-counting. The measured [125I]-EGF was corrected for non-specific binding after which 
total recycled [125I]-EGF was calculated by summing the surface-bound [125I]-EGF and intact 
recycled [125I]-EGF, as previously described [42, 43].
Cell stimulation and cell lysis
Cell stimulation and cell lysis were performed as described previously [19]. Near confluent 
transfected HEK293 cells were incubated with serum-free medium for 18 h. Growth factors 
were then resuspended in DMEM to a final concentration of 100 ng/ml. After the 
incubation period cells were washed twice with ice-cold PBS and adherent cells were 
lysed during a 20-min incubation at 4°C in lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1% 
Brij97, 5 mM EDTA pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 
1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml pepstatin). Cell lysates were subsequently 
transferred to Eppendorf tubes and centrifuged for 10 min at 4°C at 10000xg in an 
Eppendorf centrifuge to remove nuclei and cell debris. Samples were prepared for 
SDS-PAGE analysis by adding Laemmli sample buffer to cleared whole cell lysates and 
then heated for 5 min at 95 °C prior to loading SDS-PAGE gels under reducing conditions. 
Immunoprecipitation, immunoblotting and densitometry
Immunoprecipitation, immunoblotting and densitometry were performed as described 
previously [18, 19]. Anti-Flag M2 antiserum was used to immunoprecipitate USP8. 
Antibodies were first coupled to protein G-Sepharose beads for 30–60 min at 4 °C. Cleared 
cell lysates were then added to the antibody-absorbed beads and incubated for at least 3 
hr at 4 °C. Unbound cellular proteins were then removed by washing twice with ice-cold 
lysis buffer and once with ice-cold phosphate-buffered saline. Immunocomplexes were 
then resuspended in 2x Laemmli sample buffer. Samples were heated for 5 min at 95 °C 
and kept at –20 °C or loaded directly onto 8% SDS-PAGE gels. Immunocomplexes 
separated by SDS-PAGE were transferred to nitrocellulose filters. Blots were first blocked 
with 5% BSA in TBST (Tris-buffered saline-Tween). After incubation with primary antibodies, 
filters were washed in TBST, incubated with appropriate HRP-linked secondary antibodies, 
and washed again with TBST prior to visualization of proteins with enhanced chemilumi-
nescence. Signals on X-ray films of immunoblots were quantified using Adobe Photoshop 
sites. The generation of the pEGFP C1 USP8 construct has been described previously [16]. 
Primer sequences are available upon request. All constructs were verified by DNA 
sequencing. 
Cell lines and recombinant expression
Parental NIH3T3 cells, HER14 cells (NIH3T3 cells stably expressing human EGFR), both kindly 
provided by Dr. J. Schlessinger (Yale University, New Haven, CT), and human embryonic 
kidney cells (HEK293 cells) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% newborn calf serum (NCS; Hyclone). HEK293 cells were 
transiently transfected using Turbofect according to the manufacturer’s protocol and 
NIH3T3 cells were retrovirally infected with EGFR chimera constructs, as described 
previously for EGFR and EGFR-ERBB2 [16, 18]. 
Receptor downregulation
Receptor downregulation was performed as described by Sorkin and Duex [42]. On day 1, 
cells were seeded at 1.0x105 cells per well of a 24-well dish. On day 3, the cells were 
incubated for various periods of time at 37°C with 100 ng/ml EGF in 0.5 ml DMEM with 
0.1% BSA. The cells were then chilled on ice and rinsed twice with 1 ml ice-cold PBS 
containing 0.1% BSA to remove unbound EGF. Surface-bound unlabeled EGF was removed 
by incubating the cells with sodium acetate buffer (135 mM NaCl, 5 mM HAc, 2.5 mM KCl, 
pH 2.5) for 1 min at 4°C and washed twice with ice-cold PBS with 0.1% BSA to neutralize 
the acid. Subsequently, the cells were incubated for 2 h at 4°C in 0.1 ml of 100 ng/ml 
[125I]-EGF containing DMEM with 0.1% BSA. After the incubation, the unbound [125I]-EGF 
was removed by washing the cells three times with 1 ml ice-cold PBS with 0.1% BSA. 
Ligand-induced downregulation was quantified by determining cell-bound radioactivity 
by lysing the cells in 1 ml of 1N NaOH for 1 h at 37°C and measuring [125I]-EGF in a γ-counter. 
Calculations were performed as described by Sorkin and Duex [42]. 
[125I]-EGF recycling
[125I]-EGF recycling assay was performed as previously described [42, 43]. On day 1, cells 
were seeded at 1.0x105 cells per well in a 24-well dish. On day 3, cells were incubated for 10 
min at 37°C with 5 ng/ml [125I]-EGF in 0.15 ml binding medium (DMEM with 0.1% BSA) to 
allow accumulation of [125I]-EGF-receptor complexes in early endosomes. The cells were 
then chilled on ice and washed three times with 1 ml of ice-cold PBS with 0.1% BSA to 
remove unbound EGF. [125I]-EGF that had not been internalized was removed by incubating 
the cells with sodium acetate buffer (135 mM NaCl, 5 mM HAc, 2.5 mM KCl, pH 4.5) for 2 
min at 4°C, after which the cells were rinsed briefly. The [125I]-EGF-loaded cells were 
subsequently incubated with 100 ng/ml of unlabeled EGF in 0.3 ml binding medium for 
45 min at 4°C to occupy surface receptors. Cells were then incubated for various periods 
of time at 37°C with 100 ng/ml of unlabeled EGF in 0.3 ml binding medium to allow 
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software. Briefly, 16-bit grayscale images were inverted and a small predefined rectangle 
was used to measure the mean pixel value of relevant signals and background using the 
histogram command. Background signals were subtracted from relevant signals leading 
to a corrected mean pixel value. Values obtained from post-translational modifications 
were then divided by the corrected mean pixel values of the immunoprecipitated material 
and subsequently normalized relative to a given sample.
Results
EGFR-ERBB4 CYT-2 chimera recycles more efficiently than EGFR-ERBB4 
CYT-1
It has previously been reported that ERBB4 displays ligand-induced internalization and 
downregulation [26, 39, 41], albeit to a lower extent than observed for EGFR [26]. 
Unfortunately, in studies comparing EGFR and EGFR-ErbB4 chimeras only the CYT-2 
isoform was used [26] and as a result little is known about isoform-specific downregulation 
and (de-)ubiquitination of ERBB4. Nevertheless it has been shown that the E3 ligase ITCH 
binds and ubiquitinates the CYT-1 isoform of ERBB4 more prominently than the CYT-2 
isoform, due to the presence of an additional PPXY motif in the CYT-1 isoform. This results 
in more pronounced, localization in intracellular vesicles and enhanced degradation of 
CYT-1 [39, 41]. ERBB4 CYT-1 and CYT-2 also contain a putative CBL E3 ligase bindings site 
(pY1103) and we previously demonstrated that replacement of the EGFR CBL binding site 
by that of ERBB4 does not affect CBL recruitment, EGFR-ubiquitination, -degradation, 
-downregulation or ligand degradation [18]. 
 In order to investigate whether the pY1103 CBL binding site in the CYT-1 and YT-2 
isoforms of ERBB4 is functionally active and responsible for CBL recruitment, CBL tyrosine 
phosphorylation and ERBB4 ubiquitination, we used retroviral cell lines containing 
chimeric constructs consisting of the extracellular and transmembrane domains of the 
EGFR fused to the CYT-1 or CYT-2 intracellular domains of ERBB4. Furthermore, we 
generated mutants in which either the CBL-binding site (Y1103F) or the ITCH-binding site 
(P1054A) of ERBB4 is mutated. We first confirmed that chimeric receptors were expressed 
at comparable levels in these retroviral cell lines (Fig. 1A, middle panel). Next, we showed 
that the tyrosine kinase activity of the receptors was activated in response to EGF 
stimulation, confirming that all the chimeric EGFR-ERBB4 constructs were functionally 
active (Fig. 1A, top panel). 
 To investigate the kinetics of downregulation and recycling of the various EGFR-ERBB4 
chimeras, [125I]-EGF-labeled ligand binding assays [42, 43] were performed. The EGFR-ERBB4 
CYT-2 showed reduced EGF-induced downregulation compared to EGFR-ERBB4 CYT-1 
(Fig. 1B), consistent with previous reports [39, 41]. Moreover, EGFR-ERBB4 CYT-2 showed 
enhanced ligand-induced recycling (Fig. 1C) and decreased EGF degradation (Fig. 1D) 
Figure 1   EGFR-ERBB4 CYT-2 chimera recycles more efficiently than EGFR-ERBB4 CYT-1
NIH3T3 cells were retrovirally infected with EGFR-ERBB4 CYT-1 WT, CYT-1 Y1103F, CYT-1 P1054A, 
CYT-2 WT or CYT-2 Y1103F. A, Cells were serum starved overnight and stimulated for 15 min with 100 
ng/ml EGF. Whole cell lysates (WCL) were immunoblotted (IB) with the indicated antibodies. Data 
are representative of two independent experiments. B-D, [125I]-EGF labeled ligand binding assays 
using NIH3T3 cells expressing EGFR-ERBB4 CYT-1 WT (diamonds), CYT-1 Y1103F (squares), CYT-2 WT 
(triangles) or CYT-2 Y1103F (crosses). B, EGF-induced receptor downregulation. C, [125I]-EGF recycling. 
D, [125I]-EGF degradation. For experimental details, see section 2. Results are mean and standard 
deviation of two independent experiments.
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CBL is more efficiently tyrosine phosphorylated upon stimulation of 
ERBB4 CYT-2 than of CYT-1
To test whether CBL is activated upon stimulation of ERBB4 CYT-1 or CYT-2 expressing cell 
lines, we analyzed the extent of CBL tyrosine phosphorylation upon EGF stimulation of 
chimeric receptors. Figure 2A shows that EGF stimulation of CYT-1 results in tyrosine phos-
phorylation of CBL which can be coprecipitated with the activated receptor. CBL tyrosine 
phosphorylation was not appreciably reduced in the CYT-1 CBL-binding site mutant 
Y1103F. Similar observations have previously been made for the EGFR Y1045F CBL binding 
site mutant and most likely results from a multivalent interaction of CBL with ERBB 
receptors [16]. Interestingly, the level of EGF-induced CBL tyrosine phosphorylation and 
coprecipitation with the activated ERBB4 receptor was clearly higher for ERBB4 CYT-2 than 
for CYT-1. In contrast to CYT-1, however, mutation of the CBL binding site in CYT-2 strongly 
reduced EGF-induced CBL tyrosine phosphorylation and receptor-coprecipitation (Fig. 
2A). Quantification of duplicate experiments confirmed these results (Fig. 2B). These data 
indicate that CBL is more efficiently activated by EGF stimulation of the EGFR-ERBB4 
chimera CYT-2 than CYT-1, while in addition CBL recruitment to CYT-2 is pY1103 dependent. 
Ligand-induced ubiquitination of EGFR-ERBB4 CYT-1 is predominantly 
ITCH binding site-dependent, whereas ligand-induced ubiquitination of 
CYT-2 is CBL binding site-dependent
We subsequently determined whether the pY1103 ERBB4 CBL binding site is functionally 
active and responsible for ligand-induced ubiquitination of EGFR-ERBB4 CYT-1 and CYT-2. 
Figure 3A shows that EGFR-ERBB4 CYT-1 displays prominent EGF-induced ubiquitination, 
while stimulation of EGFR-ERBB4 CYT-2 resulted in less efficient ligand-induced 
ubiquitination. Moreover, mutation of the CBL binding site resulted in only a slight 
decrease in the ligand-induced ubiquitination of CYT-1, while a similar mutation in CYT-2 
almost completely abolished ligand-induced ubiquitination (Fig. 3A). These findings 
demonstrate that the CBL binding site in ERBB4 CYT-2 is functionally active and mediates 
ligand-induced CBL recruitment, CBL tyrosine phosphorylation and ERBB4 receptor 
ubiquitination. Moreover, these findings demonstrate that ligand-induced EGFR-ERBB4 
ubiquitination is mainly CBL-mediated for the CYT-2 but not the CYT-1 isoform.
 It has been reported that the E3 ligase ITCH is responsible for ubiquitination of ERBB4 
CYT-1 in particular, since CYT-1 has an additional binding site for ITCH (PPXY1056) which is 
missing in the ERBB4 CYT-2 isoform [38-40]. Indeed, the P1054A mutation has previously 
been shown to abolish ITCH binding and ITCH-mediated ubiquitination of the CYT-1 
isoform, both in the presence and absence of ligand [39]. To confirm that the PPXY1056 ITCH 
binding site is responsible for most of the observed ligand-induced ubiquitination of 
CYT-1, we generated an ERBB4 CYT-1 P1054A mutant. While mutation of the CBL binding 
site in CYT-1 only slightly decreased ubiquitination of CYT-1 (Fig. 3A), mutation of the ITCH 
binding site almost completely abolished ligand-induced ERBB4 CYT-1 ubiquitination (Fig. 
compared to EGFR-ERBB4 CYT-1. Finally, mutation of the Y1103F CBL binding site (Y1103F) 
did not affect EGFR-ERBB4 downregulation, EGFR-ERBB4 recycling or EGF-induced 
degradation, neither in the CYT-1 nor in the CYT-2 isoform (Fig. 1B-D). Our findings support 
and extend previous results indicating that CYT-1 is internalized and degraded more 
efficiently than CYT-2 in response to NRG-1 stimulation [39, 41]. Our finding that mutation 
of the ERBB4 Y1103 CBL binding site does not affect endosomal trafficking as assessed by 
radiolabeled ligand-binding assays is reminiscent of our previous finding that mutation of 
the CBL binding site does not affect endosomal trafficking in the EGFR and EGFR-ERBB2 
models systems [16, 18, 44].
Figure 1   Continued
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3B). These findings also indicate that CYT-1 is much more efficiently ubiquitinated upon 
ligand-binding than CYT-2. Furthermore, ligand-induced ubiquitination of ERBB4 CYT-1 is 
predominantly mediated by the ITCH binding site PPXY1056 with only a minor contribution 
of the pY1103 CBL binding site, while ligand-induced ubiquitination of ERBB4 CYT-2 is 
predominantly mediated by the pY1103 CBL binding site.
Figure 2   CBL is more efficiently tyrosine phosphorylated upon stimulation of ERBB4 
CYT-2 than of CYT-1
NIH3T3 cells were retrovirally infected with EGFR-ERBB4 CYT-1 WT, CYT-1 Y1103F, CYT-2 WT or CYT-2 
Y1103F. A, Cells were serum starved overnight and stimulated for 15 min with 100 ng/ml EGF. Whole 
cell lysates (WCL) were used for anti-CBL immunoprecipitation (IP) and immunoblotting (IB) with the 
indicated antibodies. B, Densitometric analysis whereby relative corrected mean pixel values of CBL 
tyrosine phosphorylation were plotted as mean with standard deviation. Phospho-signals of the IPs 
were related to the amount of precipitated CBL in the second panel and normalized to the CYT-1 
WT/EGF group. Data are representative of two independent experiments. 
Figure 3   Ligand-induced ubiquitination of EGFR-ERBB4 CYT-1 is predominantly ITCH 
binding site-dependent, whereas ligand-induced ubiquitination of CYT-2 is 
CBL binding site-dependent
A and B, NIH3T3 cells were retrovirally infected with EGFR-ERBB4 CYT-1 WT, CYT-1 Y1103F, CYT-1 
P1054A, CYT-2 WT or CYT-2 Y1103F. Cells were serum starved overnight and stimulated for 15 min 
with 100 ng/ml EGF. WCL were used for anti-EGFR IP and IB with the indicated antibodies. Data are 
representative of five (A) and two (B) independent experiments.
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CYT-2 is less efficiently downregulated and more efficiently recycled than CYT-1. To test 
the hypothesis that EGFR-ERBB4 CYT-2 shows less efficient MVB targeting than CYT-1, we 
tested the efficiency by which EGFR-ERBB4 CYT-1 and CYT-2 interact with HRS. As shown 
in Figure 5A, EGFR activation results in efficient HRS tyrosine phosphorylation and copre-
Ligand-induced K48-linked polyubiquitination of EGFR-ERBB4 CYT-1 and 
CYT-2 isoforms is CBL-binding site dependent, while ligand-induced 
K63-linked polyubiquitination of CYT-1 is ITCH-binding site dependent
We previously demonstrated that CBL is responsible for K63-polyubiquitination of the 
EGFR and an EGFR-ERBB2 chimera [16]. Although a previous study suggested that ITCH 
catalyzes mono-ubiquitination of ERBB4 CYT-1 [39], studies addressing the type of (poly-)
ubiquitination for CYT-2 and the role of CBL in ERBB4 ubiquitination have not been 
performed yet. To address these questions, we used K48- and K63-specific antibodies to 
identify the type of ubiquitin that is covalently linked to ERBB4. The specificity of these 
antibodies has previously been validated by us [44]. Figure 4A (top panel) shows that both 
EGFR-ERBB4 CYT-1 and CYT-2 are K48-polyubiquitinated upon stimulation with EGF and 
that mutation of the CBL binding site largely abolished ligand-induced K48-polyubiquiti-
nation. As shown in Fig. 4B, not only EGFR-ERBB4 CYT-1 and EGFR-ERBB4 CYT-2, but also 
the CYT-1 P1054A ITCH binding site mutant displayed efficient ligand-induced K48-poly-
ubiquitination, (Fig. 4B, first panel). Total ligand-induced ubiquitination of EGFR-ERBB4 
CYT-1 was increased compared to CYT-2 (Fig. 3), but this difference was not seen for the 
K48-polyubiquitination signal of EGFR-ERBB4 CYT-1 when compared to CYT-2 (Fig. 4). Even 
though total ligand-induced ubiquitination of EGFR-ERBB4 CYT-1 was hardly affected by 
mutation of the CBL binding site (Fig. 3A), our results demonstrate that CBL is involved in 
K48-polyubiquitination of EGFR-ERBB4 CYT-1 (Fig. 4A). 
 Moreover, Figure 4A (second panel) shows that EGFR-ERBB4 CYT-1 is also efficiently 
K63-polyubiquitinated upon EGF treatment, while EGFR-ERBB4 CYT-2 hardly showed any 
K63-polyubiquitin signal. Mutation of the CBL binding site did not influence the level of 
ligand-induced K63-polyubiquitination of CYT-1 (Fig. 4A, second panel). Interestingly, 
mutation of the ITCH binding site resulted in abolishment of the K63-polyubiquitination 
signal of the EGFR-ERBB4 CYT-1 (Fig. 4B, second panel). Taken together, these results 
demonstrate that most of the ligand-induced total ubiquitination seen for EGFR-ERBB4 
CYT-1 is mediated through the PPXY1056 ITCH binding site and results in K63-polyubiquiti-
nation. Our data also demonstrate that the CBL binding site is involved in K48-polyubiq-
uitination of both EGFR-ERBB4 CYT-1 and CYT-2. 
EGF stimulation of EGFR-ERBB4 CYT-1 and CYT-2 isoforms does not 
induce HRS tyrosine phosphorylation and AMSH-mediated 
deubiquitination
The internalization and downregulation of ERBB4 CYT-2 is significantly lower than that 
observed for ERBB4 CYT-1 (Fig. 1) and EGFR [26]. We previously demonstrated that EGFR is 
efficiently K63-polyubiquitinated [16] and in Figure 4 we showed that EGFR-ERBB4 CYT-1, 
but not CYT-2, is efficiently K63-polyubiquitinated upon EGF treatment. K63-polyubiquiti-
nated EGFR is recognized by the UIM-containing ESCRT-0 subunit HRS [45-47]. Upon 
activation of EGFR by EGF, HRS is tyrosine phosphorylated [46, 48, 49]. As seen in Figure 1, 
Figure 4   Ligand-induced K48-linked polyubiquitination of EGFR-ERBB4 CYT-1 and 
CYT-2 isoforms is CBL-binding site dependent, while ligand-induced 
K63-linked polyubiquitination of CYT-1 is ITCH-binding site dependent
A and B, NIH3T3 cells were retrovirally infected with EGFR-ERBB4 CYT-1 WT, CYT-1 Y1103F, CYT-1 
P1054A, CYT-2 WT or CYT-2 Y1103F. Cells were serum starved overnight and stimulated for 15 min 
with 100 ng/ml EGF. WCL were used for anti-EGFR IP and IB with the indicated antibodies. Data are 
representative of three independent experiments.
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cipitation with the activated receptor. In contrast, EGF stimulation of neither EGFR-ERBB4 
CYT-1 nor CYT-2 resulted in HRS tyrosine phosphorylation or ERBB4 coprecipitation with 
HRS (quantified in in Fig. 5B) , this in spite of the fact that CYT-1 is more efficiently 
downregulated than CYT-2. 
 AMSH is a K63-polyubiquitin specific deubiquitination enzyme and it has been 
shown to efficiently deubiquitinate EGFR [24, 25], and to a lesser extent also ERBB2 [50]. 
Since CYT-1 but not CYT-2 undergoes K63-polyubiquitin modification, we investigated 
whether AMSH is involved in removing ubiquitin from K63-polyubiquitin attached to 
EGFR-ERBB4 CYT-1. As expected, EGF-stimulation of serum-starved cells resulted in 
ubiquitination of the EGFR, while co-expression of AMSH D348A significantly increased 
EGFR ubiquitination. In contrast, no effect of cotransfection of AMSH D348A was observed 
on the level of ubiquitination of EGFR-ERBB4 CYT-1, indicating that AMSH does not 
substantially deubiquitinate the K63-polyubiquitin-modified EGFR-ERBB4 CYT-1 (Fig. 5C, 
second panel). As expected, the non-K63-ubiquitinated EGFR-ERBB4 CYT-2 isoform was 
also not deubiquitinated by AMSH (results not shown). These findings suggest that 
EGFR-ErbB4 is not efficiently sorted towards the MVB pathway. The latter observation is 
reminiscent of our previous finding that the EGFR-ERBB2 chimera displays ligand-induced 
K63-polyubiquitination but no AMSH-mediated deubiquitination [44].
EGFR-ERBB4 CYT-1 is a poor substrate for USP8-mediated 
deubiquitination
We previously demonstrated that ligand-(in)dependent ubiquitination of EGFR and 
EGFR-ERBB2 can be counterbalanced by the deubiquitination enzyme USP8 [16, 20]. 
Moreover, we have shown that USP8 tyrosine phosphorylation and deubiquitination 
activity was less efficient for EGFR-ERBB2 than for the EGFR, suggesting that only the 
fraction of EGFR-ERBB2 that is targeted to lysosomes interacts with USP8. The 
downregulation of EGFR-ErbB2 was decreased and the recycling of EGFR-ErbB2 was 
increased compared to EGFR. We hypothesized that EGFR-ErbB4 might also be only partly 
subjected to USP8 regulation. To test this hypothesis, we first analyzed USP8 tyrosine 
phosphorylation upon EGF stimulation of EGFR-ErbB4 CYT-1. EGF stimulation of 
EGFR-ErbB4 CYT-1 results in coprecipitation of USP8 with activated receptor and USP8 
tyrosine phosphorylation. Although the intensity of the signals was clearly lower than 
observed for EGFR (results not shown), our results show that ligand-induced USP8 copre-
cipitation and USP8 tyrosine phosphorylation are increased upon coexpression of the 
EGFR-ERBB4 CYT-1 chimera with the catalytically inactive USP8 C748A mutant (Fig. 6A). 
These observations are in line with those on EGFR of EGFR-ERBB2, and suggest that 
impaired USP8-mediated deubiquitination traps the internalized receptor on the 
endosomal membrane [16]. The Y1103F mutation of the CBL binding site did not affect 
USP8 tyrosine phosphorylation of the EGFR-ERBB4 CYT-1 receptor (Fig. 6A), as confirmed 
by quantitative analysis (Fig. 6B). These results show that EGF stimulation of EGFR-ERBB4 
Figure 5   EGF stimulation of EGFR-ERBB4 CYT-1 and CYT-2 isoforms does not induce 
HRS tyrosine phosphorylation and AMSH-mediated deubiquitination
A, HEK293 cells were transfected with EGFR, EGFR-ERBB4 CYT-1 WT or CYT-2 WT. Serum-starved cells 
were stimulated for 1 h with or without EGF. WCL were used for anti-HRS IP and IB with the indicated 
antibodies. B, Densitometric analysis of relative corrected mean pixel values of HRS tyrosine phos-
phorylation, plotted as mean with standard deviation. Phospho-signals of the IPs were related to the 
amount of precipitated HRS in the second panel and normalized to the EGFR/EGF group. C, HEK293 
cells were co-transfected with EGFR or EGFR-ERBB4 CYT-1 WT and either AMSH WT or AMSH D348A. 
Serum-starved cells were stimulated for 15 min with or without EGF. WCL were used for anti-EGFR IP 
and IB with the indicated antibodies. Data are representatives of two independent experiments. 
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CYT-1 triggers USP8 tyrosine phosphorylation and demonstrate that USP8 is part of the 
ERBB4 signaling cascade. These results are reminiscent of our previous results obtained for 
EGFR-ERBB2 [16]. 
 In order to test whether EGFR-ERBB4 CYT-1 is subject to USP8 mediated deubiquitination, 
we tested the effect of USP8 deubiquitination activity on EGFR and CYT-1.. As expected, 
coexpression of inactive USP8 C748A together with EGFR resulted in an increase of 
ubiquitination signal on EGFR even in the absence of ligand (Fig. 6C). As reported before, 
there appears to be a difference in a low and a high molecular weight ubiquitination 
signal, possibly representing mono- and polyubiquitination signals respectively [16]. 
Coexpression of the inactive USP8 C748A with EGFR seems to constitutively increase the 
low molecular weight ubiquitination signal. Coexpression of USP8 C748A together with 
EGFR-ERBB4 CYT-1 also results in a slight increase in low molecular weight ubiquitination 
signal, albeit much less compared to the EGFR ubiquitination signal (Fig. 6C). These 
results demonstrate that EGFR-ERBB4 CYT-1 is constitutively subjected to USP8 mediated 
deubiquitination and suggest that ERBB4 CYT-1 is less efficiently targeted to the MVB 
degradation pathway when compared to the EGFR.
Figure 6   EGFR-ERBB4 CYT-1 is a poor substrate for USP8-mediated deubiquitination
A, HEK293 cells were transiently transfected with EGFP-Flag-USP8 WT or C748A, as well as with 
EGFR-ERBB4 CYT-1 WT or Y1103F. Serum-starved cells were stimulated for 1 h with or without EGF. 
WCL were used for anti-flag IP and IB with the indicated antibodies. B, Densitometric analysis of 
relative corrected mean pixel values of USP8 tyrosine phosphorylation plotted as mean with 
standard deviation. Phospho-signals of the IPs were related to the amount of precipitated USP8 in 
the second panel and normalized to the CYT-1/EGF group. C, HEK293 cells were co-transfected with 
EGFR or EGFR-ERBB4 CYT-1 WT and either USP8 WT or USP8 C748A. Serum-starved cells were 
stimulated for 15 min with or without EGF. WCL were used for anti-EGFR IP and IB with the indicated 
antibodies. Data are representative of 2 experiments.
Figure 5   Continued
C A
B
5CHAPTER 5 CBL AND ITCH BINDING SITES IN ERBB4 MEDIATE K48- AND K63-POLYUBIQUITINATION
146 147
for NRG-induced ERBB4 activation [39] giving rise to decreased ligand-induced internal-
ization of CYT-2 compared to CYT-1 [39]. Our present observation that the Y1103F CBL 
binding site does not influence endosomal trafficking of either ERBB4 isoform, is 
reminiscent of our previous finding that mutation of the CBL binding site does not affect 
endosomal trafficking of EGFR and EGFR-ERBB2 chimeric receptors [16, 18, 44]. Nevertheless, 
CBL is tyrosine phosphorylated and recruited upon ligand stimulation of both EGFR-ERBB4 
CYT-1 and CYT-2 receptor, although these recruitment and CBL tyrosine phosphorylation 
were found to be more abundant for the CYT-2 isoform. In this context, it is noteworthy 
that CYT-1 may be subject to enhanced constitutive downregulation compared to CYT-2 
[51], which could explain the more efficient coupling of the CYT-2 isoform to steady state 
CBL recruitment and CBL tyrosine phosphorylation than the CYT-1 isoform. Alternatively, 
CBL protein levels are regulated by proteasomal degradation through ubiquitination by 
the E3-ligase ITCH or NEDD4 [52], which could indicate that CBL is degraded in the context 
of the ERBB4 CYT-1 but not the CYT-2 receptor that lacks the PPXY ITCH binding site. 
Our results demonstrate that CBL is involved in ligand-induced K48-polyubiquitination of 
both ERBB4 CYT-1 and CYT-2 isoforms and that the total ligand-induced ubiquitination of 
CYT-2 is regulated by CBL. These results support our previous findings that replacement of 
the EGFR CBL binding site by that of ERBB4 results in efficient CBL tyrosine phosphoryla-
tion, CBL recruitment or receptor ubiquitination [18]. Interestingly, a role for CBL in 
K48-ubiquitination in addition to mono- and K63-polyubiquitination has not previously 
been shown for ERBB receptors, although CBL has been implicated in K48-polyubiquitina-
tion of other receptor tyrosine kinases such as the insulin-like growth factor I receptor [53] 
and Flt3 [54]. It is currently unclear how CBL might stimulate distinct types of (poly-)
ubiquitination. One possible explanation might be that distinct CBL proteins are 
responsible for a different type of ubiquitination, although so far no data has been 
published that supports this hypothesis. Alternatively,  E2 ubiquitin-conjugating enzymes 
can determine the length and topology of ubiquitin chains [55], and therefore CBL may 
associate with different E2 ubiquitin conjugating enzymes to stimulate the formation of 
different types of receptor (poly-)ubiquitination. Indeed, c-CBL is known to interact with 
UbcH7 (UBE2L3) [56-58], Ubc4/5 and UbcH5 (UBE2D) [58-60]. Moreover, specific E2s with 
dedicated roles in ubiquitin chain initiation and linkage-specific polyubiquitin elongation 
have been identified [55]. The UBE2D family of E2s lacks specificity for a lysine residue in 
the substrate, which allows them to initiate chain formation on a variety of substrates 
using multiple E3s [61]. One possibility is that UBE2D participates in ubiquitin chain 
initiation while another E2 mediates chain elongation, resulting in multiple types of po-
ly-ubiquitination. Indeed, UbcH5 has been described as a chain initiator for both K48- and 
K63-polyubiquitination [62, 63]. This model might explain the finding that CBL can 
stimulate mono-, K48- as well as K63-polyubiquitination.   
 Our data showing that total ligand-induced ubiquitination of EGFR-ERBB4 CYT-1 is 
more abundant than that of CYT-2, is in line with previous reports [64]. We further 
Discussion
In this study we demonstrate that EGFR-ERBB4 CYT-2 chimera displays decreased 
downregulation and enhanced EGF recycling, when compared to EGFR-ERBB4 CYT-1. 
However, the Y1103F CBL binding site does not appear to be involved in the endosomal 
trafficking of either ERBB4 isoforms. Both EGFR-ERBB4 CYT-1 and CYT-2 are efficiently 
ubiquitinated, but total ligand-induced ubiquitination of CYT-1 is more abundant than 
that of CYT-2. Ligand-induced ubiquitination of CYT-1 was mainly regulated by the PP1054XY 
E3-ligase ITCH binding site, with only a minor contribution of the pY1103 E3 ligase CBL 
binding site, while ligand-induced ubiquitination of CYT-2 was CBL-binding site mediated. 
The E3-ligase CBL is more efficiently activated upon stimulation of the CYT-2 isoform and 
the CBL binding site is responsible for K48-polyubiquitination of both CYT-1 and CYT-2. In 
contrast, the ITCH binding site leads to K63-polyubiquitination of CYT-1 only. We further 
demonstrate that stimulation of CYT-1 and CYT-2 does not result in efficient binding to or 
tyrosine phosporylation of the ESCRT-0 subunit HRS. Finally, CYT-1 is not subjected to deu-
biquitination by the K63 polyubiquitin-specific AMSH DUB enzyme, while CYT-1 is slightly 
deubiquitinated by USP8. We conclude that CBL is the main E3-ligase for ligand-induced 
ubiquitination of ERBB4 CYT-2, while the ITCH binding site is the key regulator for 
ligand-induced CYT-1 ubiquitination and that the CBL and ITCH binding sites in ErbB4 
CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively.
 Our data, showing that EGFR-ERBB4 CYT-2 chimera displays decreased downregulation 
and enhanced EGF recycling compared to EGFR-ERBB4 CYT-1, resemble those described 
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previous observations for ERBB2 [44]. These findings suggest the possibility that targeting 
of ERBB4 into the MVB pathway is less efficient than observed for the EGFR and/or that 
other deubiquitination enzymes may be involved in deubiquitination of ERBB4 prior to 
MVB targeting. Overall, our results support the model that CYT-1 is targeted towards both 
the proteasome and lysosome for degradation, while CYT-2 is primarily degraded by the 
proteasome.
 It is currently unclear why ERBB4 might have various degradation pathways. Some 
studies have been performed on degradation of the cleavable JM-a and uncleavable JM-b 
isoforms. Following activation of ERBB4, JM-a is cleaved at the extracellular JM by TACE, 
resulting in a truncated membrane bound m80 receptor [31]. Subsequently, the m80 
receptor undergoes intramembrane proteolysis by γ-secretase, resulting in the soluble 
intracellular domain s80 [32, 33]. The CYT-2 m80 receptor then becomes ubiquitinated and 
is far more susceptible to proteasomal degradation than full-length ERBB4 [67]. 
Furthermore, following cleavage at the JM site, CYT-2 has been shown to translocate more 
efficiently to the nucleus than CYT-1 [40, 64, 67]. Moreover, the Y1054A mutation which 
results in inhibition of both the PI3 kinase and WW domain-binding motifs, has been 
shown to result in enhanced ERBB4 nuclear translocation [38]. In combination with our 
present findings this raises the interesting possibility that ligand-induced CBL-mediated 
K48-polyubiquitination of ERBB4 directs the JM-cleaved nuclear CYT-1 and CYT-2 isoforms 
towards the proteasomal degradation pathway, while the full-length non-cleaved and 
non-translocated ERBB4 CYT-1 receptors are directed towards the lysosomal degradation 
pathway, under the influence of ITCH-binding site dependent K63-polyubiquitination. 
Conclusion
Taken together, we here demonstrate that the EGFR-ERBB4 CYT-2 chimera shows 
decreased downregulation and enhanced EGF recycling compared to EGFR-ERBB4 CYT-1 
and that the Y1103F CBL binding site does not influence ERBB4 endosomal trafficking. We 
provide evidence for CBL-mediated K48-polyubiquitination of both CYT-1 and CYT-2 and 
ITCH-mediated K63-polyubiquitination of CYT-1. Finally, we demonstrate that the CBL 
binding site is the main E3-ligase for CYT-2, while the ITCH binding site is the key regulator 
of CYT-1 ubiquitination. 
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demonstrate that total ubiquitination of CYT-1 is mostly regulated by the PPXY1056 motif to 
which WW-domains of the Nedd-like E3 ligase family can bind [38-40], and that this motif 
is responsible for K63-polyubiquitination of EGFR-ERBB4 CYT-1. These results are in line 
with previous reports showing that members of this WW-domain containing Nedd-like E3 
ligases family are responsible for ubiquitination of CYT-1 [38-41, 65]. Sundvall et al. have 
suggested that ITCH catalyzes mono-ubiquitination to ERBB4 CYT-1 [39], but our studies 
demonstrate that the ITCH binding site is involved in ligand-induced K63-polyubiquitina-
tion of CYT-1. Nedd-family E3 ligases ITCH and Nedd4 have been previously implicated in 
K63-polyubiquitination [66], but we cannot exclude the possibility that CYT-1 is also mo-
no-ubiquitinated by ITCH. Indeed, coexpression of the CYT-1 isoform with the USP8 C748A 
inactive mutant slightly enhanced the fraction of constitutive, low molecular weight ubiq-
uitin-modified ERBB4 (Fig. 6C). In contrast to the experiments performed by Sundvall et al., 
we used specific antibodies recognizing K63-polyubiquitin, rather than antibodies that 
either detect poly- versus total ubiquitin [39]. Furthermore, our results demonstrate that 
CYT-1 is both K48- and K63-polyubiquitinated. In line with this observation, Sundvall et al. 
demonstrated that total ubiquitination was still detectable when using K48R and K63R 
mutants [39]. So even though our results demonstrate the involvement of the ITCH 
binding site in K63 polyubiquitination of ERBB4 CYT-1 isoform, we cannot rule out the 
possibilities that ERBB4 CYT-1 is also mono-ubiquitinated and that ITCH may have a dual 
role in mono- and polyubiquitination of ERBB4 CYT-1. 
 Our results furthermore show that EGFR-ERBB4 CYT-1 is K48- and K63-polyubiquiti-
nated, while CYT-2 is mainly K48-ubiquitinated. While mono-ubiquitination and K63-poly-
ubiquitination have been implicated in endosomal sorting and lysosomal targeting [12], 
K48-polyubiquitination is known to serve as a signal for proteasomal degradation [13]. 
Indeed, previous studies have demonstrated that CYT-1 undergoes both lysosomal and 
proteasomal degradation [38, 40, 41], while inhibition of the proteasomal degradation 
pathway showed increased CYT-2 levels, suggesting that the proteasomal pathway is the 
main degradation pathway for CYT-2 [41]. Moreover, the CYT-1 isoform was more efficiently 
endocytosed and more rapidly degraded than the CYT-2 isoform [39, 67]  whereas the 
CYT-1 isoform colocalized in endocytic vesicles with Rab5 and Rab7, markers of early and 
late endosomal vesicles, respectively. This indicates that CYT-1 trafficks via early endosomes 
to late endosomes/lysosomal structures [39]. Furthermore, in a previous study it has 
demonstrated that ERBB4 is constitutively subjected to proteasomal degradation in the 
presence or absence of ITCH, while in the presence of ITCH ERBB4 is degraded by the 
lysosome [41]. Based on the observations described above, one would expect that K63 
polyubiquitin modified CYT-1 interacts with the ESCRT-0 subunit HRS within the MVB 
pathway. However, we could not substantiate such an interaction, nor could we detect an 
effect of AMSH deubiquitination activity towards ERBB4. The failure to detect an interaction 
between HRS and ERBB4 as well as the failure to detect activity of the K63 polyubiquitin 
specific AMSH enzyme towards K63 polyubiquitin modified ERBB4 is reminiscent of our 
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Abstract
The ERBB1-ERBB4 receptors belong to a family of receptor tyrosine kinases that trigger a 
network of signaling pathways after  ligand binding, thereby regulating cellular growth, 
differentiation and development. Ligand-induced signaling through ERBB1, also known as 
EGFR, is attenuated by the clathrin-dependent receptor-mediated endocytosis and RING 
E3-ligase CBL-mediated receptor ubiquitination, which is followed by incorporation into 
multi-vesicular bodies (MVBs) and subsequent degradation in lysosomes. Before 
incorporation into MVBs, the EGFR is deubiquitinated by USP8. We previously demonstrated 
that USP8 is tyrosine phosphorylated in an EGFR- and SRC-kinase dependent manner. In 
the present study we show that overexpression of constitutively active SRC enhances 
constitutive and ligand-induced USP8 tyrosine phosphorylation. We also show that 
enhanced endosomal recycling of the EGFR induced by TGFα stimulation is associated 
with decreased USP8 tyrosine phosphorylation. We therefore hypothesize that tyrosine 
phosphorylation of USP8 could regulate the function of USP8. To identify USP8 tyrosine 
phosphorylation site(s), we used USP8 deletion constructs, site-directed mutagenesis of 
nine individual USP8 tyrosine residues and mass spectrometry (MS) analysis. Our results 
demonstrate that the MIT-domain is necessary for ligand-induced tyrosine phosphoryla-
tion of USP8 1-504. However, mutation of three MIT domain tyrosine residues did not 
abolish USP8 tyrosine phosphorylation. Similar results were obtained upon mutation of six 
exposed tyrosine residues in the Rhod domain and linker region. Repeated MS analysis of 
both USP8 WT and C748A mutants readily detected serine phosphorylation, including the 
S680 14-3-3 binding site, but did not reveal any phospho-tyrosine residues. Notably, 
mutation of the tyrosine residue in the USP8 14-3-3 binding motif (Y679) did not abolish 
phosphoserine-dependent binding of 14-3-3 to USP8. Our findings are most consistent 
with the model that MIT domain-dependent recruitment of USP8 to endosomal 
membranes is important for low stoichiometry SRC-mediated tyrosine phosphorylation of 
multiple USP8 tyrosines. Our findings demonstrate that USP8 is a target for the post-trans-
lational serine and tyrosine phosphorylation, most likely characterized by low abundant 
tyrosine phosphorylation on multiple residues, and high abundant serine phosphoryla-
tion on several residues.  
Introduction
Phosphorylation and ubiquitination are key post-translational protein modifications which 
play an important role in signaling cascades. Phosphorylation is the reversible addition of 
a phosphate group to a serine, threonine or tyrosine residue of a substrate protein, which 
results in a fast, reversible, specific and often temporary modification. Phosphorylation 
can be present on multiple residues in a target protein. Phosphorylation can modulate 
protein functions, induce or abolish enzyme activity, change protein conformations, or 
target proteins for destruction [1]. Furthermore, phospho-tyrosine (pY) is a specific binding 
site for cytoplasmic proteins with SH2 (SRC homology 2) and PTB (phospho-tyrosine 
binding) domains [2]. Phospho-threonine (pT) and phospho-serine (pS) can also recruit 
specific proteins and domains, including 14-3-3 proteins (pS), WW domains (pS or pT) and 
forkhead-associated (FHA) domains (pT) [3]. Phosphorylation is performed by over 500 
different protein kinases within human cells [4] while phosphate groups can be actively 
removed by over 100 different phosphatases [5]. 
 Ubiquitination is the attachment of the 76 amino acid polypeptide ubiquitin via its 
C-terminal glycine residue to the substrate lysine residue. Ubiquitination is more complex 
compared to phosphorylation, since ubiquitin attachment can occur in the form of mono- 
ubiquitination, multi-ubiquitination or even poly-ubiquitination through at least eight 
different linkages. Mono-ubiquitination is the attachment of a single ubiquitin to a  substrate 
lysine residue, whereas multi-ubiquitination is mono-ubiquitination on multiple substrate 
lysine residues. Poly-ubiquitination occurs when a ubiquitin lysine residue functions as an 
acceptor for another ubiquitin molecule, resulting in the formation of polyubiquitin chains. 
Poly-ubiquitin chains can either be linear, or form branches, whereby each of its seven different 
lysine residues (e.g. K48 and K63) can be involved [6]. From a functional perspective, mono- 
and multi-ubiquitination have been shown to trigger internalization of cell-surface receptors 
and subsequent degradation in lysosomes [7]. Moreover, K48-polyubiquitination leads to 
proteasomal degradation of its substrate protein [8], whereas K63-polyubiquitination serves as a 
signal for non-proteasomal processes such as DNA repair, kinase activation, translation regulation 
and endosomal sorting [9]. The ubiquitination reaction is performed by a three-step enzymatic 
cascade. First, a ubiquitin-activating enzyme (E1) forms a thiol-ester bond with the carboxy- 
terminal glycine of ubiquitin in an ATP-dependent process. Then, the E1 attaches the ubiquitin 
C-terminus to the catalytic cysteine residue of the ubiquitin-conjugating enzyme (E2). Finally, 
a ubiquitin protein ligase (E3) catalyses the transfer of activated ubiquitin from the E2 enzyme 
to the substrate lysine residue. There are two ubiquitin-activating E1 enzymes, 37 ubiquitin- 
conjugating E2 enzymes and >600 ubiquitin E3 ligases in the human genome [10]. 
Ubiquitination can be reversed by approximately 90 different deubiquitination enzymes 
(DUBs), which can be subdivided into five families: the UCHs (Cys proteases ubiquitin C-terminal 
hydrolases), USPs (ubiquitin-specific proteases), OTUs (ovarian tumor proteases), the JAMMs 
(JAB1/MPN/MOV34 zinc metalloenzymes) and Josephins [11].
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USP8 has been demonstrated to undergo posttranslational modifications. It has been 
reported to undergo ubiquitination following EGF stimulation [25]. We have demonstrated 
that USP8 is tyrosine phosphorylated in an EGFR- and SRC-kinase dependent manner 
following EGF-stimulation [17, 21]. However, the site of tyrosine phosphorylation and the 
functional significance of USP8 tyrosine phosphorylation are as yet unknown. Furthermore, 
it has been shown that USP8 can be phosphorylated on threonine 907 (T907) in an 
Akt-dependent manner in response to neuregulin-stimulation. This phosphorylation 
contributes to the stabilization of USP8 protein levels, suggesting a role for Akt in the 
regulation of USP8 function [33]. Phosphorylation of serine 680 (S680) within the RSYSSP 
sequence of USP8 leads to association with 14-3-3 proteins [34-38]. Binding of 14-3-3 
protein to phosphorylated target proteins can alter their enzymatic activity, subcellular 
localization, protein-protein interactions, phosphorylation state, and/or regulate the cell 
cycle [39]. During M-phase of the cell cycle, USP8 is dephosphorylated at S680, resulting in 
dissociation from 14-3-3 and enhanced USP8 function during cell division [35]. Furthermore, 
mutation of S680 resulted in enhanced USP8 activity towards EGFR, although the 
EGFR-USP8 interaction itself was not affected by S680 mutation. Stimulation of cells with 
EGF does not change the levels of S680 phosphorylation and 14-3-3 binding of USP8 [35]. 
Moreover, USP8 colocalizes with ubiquitinated proteins at the mid-body during cytokinesis 
[40] consistent with the finding that various ESCRT proteins function at the mid-body [41, 
42], suggesting a role of USP8 in the regulation of endosomal function during cell division. 
However, the exact mechanism whereby these posttranslational modifications regulate 
USP8 function, remains unclear. 
 It can be hypothesized that USP8 tyrosine phosphorylation regulates USP8 activity by 
affecting the function of the MIT domain, the Rhod domain, the interaction with 14-3-3 or 
its enzymatic activity. As a first step towards addressing this question, we aimed to identify 
the tyrosine phosphorylation site(s) of USP8. Several strategies, including deletion 
mapping, site-directed mutagenesis of accessible tyrosine residues and mass spectrometry 
 The ERBB1-ERBB4 receptors belong to the family of receptor tyrosine kinases. Binding 
of ligands to their receptors triggers a network of signaling pathways, resulting in cellular 
growth, differentiation and development. Overexpression or poor downregulation of 
these receptors can result in enhanced signaling and cancerous growth. Therefore, it is 
critical that receptor signaling is terminated in an efficient manner [12]. Following 
activation, the ERBB signaling is attenuated by the clathrin-dependent pathway of recep-
tor-mediated endocytosis, followed by incorporation in multi-vesicular bodies (MVBs) and 
subsequent degradation in lysosomes. Ubiquitination serves as a signal to facilitate inter-
nalization and endosomal sorting of plasma membrane receptors [13, 14]. Upon ligand 
binding to ERBB1, also known as EGFR, the E3-ubiquitin ligase CBL is recruited directly to 
EGFR phosphotyrosine 1045 (pY1045) or indirectly through GRB2, which binds EGFR 
pY1068 and pY1086, in both cases resulting in ubiquitination of the receptor [15, 16]. We 
and others demonstrated that CBL induces both mono-, multi- and K63-polyubiquitina-
tion of EGFR [17, 18]. More recently, we also demonstrated that the CBL binding site is 
required for ligand-induced K63 and K48 polyubiquitination of ERBB2 and ERBB4, 
respectively [17, 19].
 We have previously demonstrated that, following ligand-induced CBL-mediated 
ubiquitination, the EGFR is deubiquitinated before lysosomal degradation [17, 20, 21]. 
Indeed, two DUBs have been shown to deubiquitinate the EGFR before incorporation of 
the activated receptor complex in MVBs. AMSH is a JAMM-type DUB that is specific for 
K63-polyubiquitination and has been shown to deubiquitinate the EGFR [22-24]. USP8  is a 
member of the USP DUBs that removes both K48- and K63-polyubiquitination and which 
is known to be involved in EGFR deubiquitination [21, 25-27]. While one report suggests 
that USP8 inhibits EGFR degradation [25], we and others have demonstrated that USP8 
promotes EGFR degradation [21, 26]. We recently showed that USP8 also deubiquitinates 
ERBB2, albeit to a much lesser extent than EGFR [17]. Both AMSH and USP8 bind 
components of the endosomal sorting complex for transport (ESCRT) which are involved 
in targeting ubiquitinated cargo receptors for incorporation into intraluminal vesicles 
(ILVs) of MVBs. AMSH and USP8 bind with their PxxP motif to the non-canonical SH3-binding 
motif of ESCRT-0 protein STAM, and with their MIT (Microtubule Interacting and Trans-
port)-domain to several CHMP proteins of the ESCRT-III machinery [23, 27-30]. Furthermore, 
USP8 contains a Rhod (Rhodanese-like) domain, but this domain is catalytically inactive 
due to the absence of the active-site Cys residue (for domain structure, see Fig. 1). Still, the 
USP8 Rhod domain is known to interact with the ubiquitin E3 ligase NRDP1 that stimulates 
ERBB3 and ERBB4 ubiquitination. Stimulation of cells with the ERBB3 ligand neuregulin-1 
increases USP8 levels, which in turn stabilizes NRDP1. Knockdown of genes for NRDP1 or 
USP8 has been shown to result in suppressed neuregulin-induced ERBB3 ubiquitination 
and degradation [31-33].
Figure 1   Domain structure of USP8
Amino acid boundaries of individual domains are indicated on top of the figure. MIT: Microtubule 
Interacting and Transport domain; DUB: catalytic deubiquitination domain with active site C748; 
Rhod: Rhodanese-like domain; pS680: binding motif 14-3-3 proteins; residues 405-413 and 700-708: 
Stam/Hbp SH3 binding domains; residues 310-740: linker domain.
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Y85F, Y86F and Y85/86F were generated using Pfl23II and Eco88I sites. The mutations 
Y679F and S680A were introduced in USP8 using Bpu1102I and SacI sites and Y641F was 
generated using SpeI and Bpu1102I sites. Human SRC Y527A (Upstate Biotechnology) was 
a gift from E. Danen (Leiden University MC, Leiden, The Netherlands). pGEX 2T-14-3-3ζ was 
kindly provided by M. Nellist (Erasmus MC, Rotterdam, The Netherlands). Primer sequences 
are available upon request. All mutations were verified by DNA sequencing.
Cell stimulation and cell lysis
Stimulation of cells with growth factors and cell lysis were performed as described 
previously [20]. Near confluent transfected HEK293 cells were incubated with serum-free 
medium for 18 h. Growth factors were then resuspended in DMEM to a final concentration 
of 100 ng/ml. Following the incubation period, cells were washed twice with ice-cold PBS 
and adherent cells were lysed during a 20-min incubation at 4°C in lysis buffer (150 mM 
NaCl, 25 mM Tris pH 7.5, 1% Brij97, 5 mM EDTA pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml pepstatin). 
Cell lysates were subsequently transferred into Eppendorf tubes and centrifuged for 10 
min at 4°C at 10000xg in an Eppendorf centrifuge to remove nuclei and cell debris. 
Samples were prepared for SDS-PAGE analysis by adding Laemmli sample buffer to 
cleared whole cell lysates, and then heated for 5 min at 95 °C prior to loading SDS-PAGE 
gels under reducing conditions. 
Immunoprecipitation, immunoblotting and densitometry
Immunoprecipitation, immunoblotting and densitometric analyses of the blots were 
performed as described previously [20, 43]. Anti-Flag M2 antiserum was used to immuno-
precipitate USP8. Antibodies were first coupled to protein G-Sepharose beads for 30–60 
min at 4 °C. Cleared cell lysates were then added to the antibody-absorbed beads and 
incubated for at least 3 h at 4 °C. Unbound cellular proteins were then removed by washing 
twice with ice-cold lysis buffer and once with ice-cold phosphate-buffered saline. Immu-
nocomplexes were then resuspended in 2x Laemmli sample buffer. Samples were heated 
for 5 min at 95 °C and kept at –20 °C or loaded directly onto 8% SDS-PAGE gels. Immuno-
complexes separated by SDS-PAGE were transferred to nitrocellulose filters. Blots were 
first blocked with 5% bovine serum albumin in TBST (Tris-buffered saline-Tween). After 
incubation with primary antibody, filters were washed in TBST, incubated with appropriate 
HRP-linked secondary antibodies, and washed again with TBST prior to visualization of 
proteins with enhanced chemiluminescence. Signals on X-ray films of immunoblots were 
quantified using Adobe Photoshop software. Briefly, 16-bit grayscale images were inverted 
and a small predefined rectangle was used to measure the mean pixel value of relevant 
signals and background using the histogram command. Background signals were 
subtracted from relevant signals leading to a corrected mean pixel value. Values obtained 
from post-translational modifications were then divided by the corrected mean pixel 
analysis did not result in the identification of single phosphorylated tyrosine residue, even 
though serine phosphorylation sites, including the pS680 14-3-3 binding site, were readily 
detected. Nevertheless, our results support the model that the USP8 MIT domain is 
important for endosomal recruitment and allows low stoichiometry SRC family kinase-me-
diated USP8 tyrosine phosphorylation of multiple tyrosine residues. 
Material and methods
Cell culture and reagents
Human embryonic kidney cells (HEK293 cells) were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% newborn calf serum (NCS; Hyclone) and 
transiently transfected using Turbofect™ (Fermentas) according to the manufacturer’s 
protocol. The following antibodies were used in this study: a-EGFR polyclonal antibody 
(pAb) 1005, a-GFP pAb FL (Santa Cruz), a-phosphotyrosine mAb 4G10 (Upstate 
Biotechnology), α-FLAG mAb M2, a-tubulin mAb (Sigma), α-phospho-(Ser) 14-3-3 Binding 
Motif (Cell Signaling). Immunoprecipitation of USP8 was performed using α-FLAG mAb 
M2, while both α-FLAG mAb M2  and a-GFP pAb FL were used for USP8 detection on 
Western blots. Horseradish peroxidase-labeled secondary antibodies goat anti-rabbit 
(GARPO) and goat anti-mouse (GAMPO) mAbs were purchased from Signal Transduction 
Laboratories. Other reagents used in this study included Sepharose beads coupled to 
protein G (Amersham Biosciences), mouse receptor grade EGF (BD Bioscience), 
recombinant human TGFa (R&D systems), and Glutothione Sepharose beads (GSH) 
(Sigma). All PCR primers were obtained from Biolegio.
Recombinant DNA technology and constructs
pcDNA3 EGFR was kindly provided by Dr. Y.Yarden (Weizmann Institute, Israel). pEGFP C1 
vector (Clontech), pEGFP C1 flag-tagged wild-type and C748A mUSP8, as well as USP8 
1-504, USP8 141-504, USP8 504-640 and USP8 640-1080 have been previously described 
[17, 21]. For an overview of the domain structure of mUSP8, see Fig. 1. Construction of USP8 
Δ140, Δ90 and Δ74, in which respectively the N-terminal 140, 90 and 74 amino acids are 
removed, was performed by overlap extension PCR of pEGFP C1 USP8 WT with a 
temporarily removed NotI site, and subsequent cloning using the NotI and Acc65I sites. 
USP8 Δ140 was subsequently cloned in frame in the USP8 C748A construct using Bpu1102I 
and Bsp1407I sites. USP8 141-731 was constructed by PCR of USP8 WT with primers 
containing an additional stop codon and SpeI restriction site, cloned into Bpu1102I and 
SpeI sites of USP8 WT, and subsequently USP8 Δ140 was cloned into this construct using 
Bpu1102I and Bsp1407I sites. All single nucleotide mutations were introduced using 
PCR-mediated primer overlap extension. USP8 Y12F was introduced using XhoI and PauI 
sites, USP8 Y189F, Y255F, Y306F and Y336F were generated using XhoI and Pfl23II sites and 
6CHAPTER 6 POST-TRANSLATIONAL PHOSPHORYLATION OF USP8
160 161
trypsin (P00761, porcine), keratin K22E (P35908, human), keratin K1C9 (P35527, human), 
keratin K2C1 (P04264, human) and keratin K1CI (P35527, human). The “label-free 
quantification” as well as the “match between runs” (set to 2 min) options were enabled. 
De-amidated peptides were allowed to be used for protein quantification and all other 
quantification settings were kept at default settings.
Results
Constitutively active SRC enhances constitutive and ligand-induced 
USP8 tyrosine phosphorylation
Using specific tyrosine kinase inhibitors and kinase-dead ERBB mutants, we previously 
demonstrated that the DUB USP8 is a substrate for EGFR- and ERBB2-activated SRC-family 
tyrosine kinases and that USP8 tyrosine phosphorylation is EGFR- (or ERBB2-) and 
SRC-kinase dependent [17, 21]. To address the question of the functional significance of 
USP8 tyrosine phosphorylation, it is crucial to elucidate the regulation of USP8 tyrosine 
phosphorylation and to identify the USP8 tyrosine residues that are phosphorylated upon 
activation of EGFR. To increase the USP8 tyrosine phosphorylation signal, we co-expressed 
USP8 WT or the catalytically inactive USP8 C748A mutant in the presence or absence of a 
constitutively active SRC Y527A mutant construct, which prevents formation of an 
inhibitory intra-molecular interaction between the SRC SH2 domain and the 
phosphorylated pY527 residue in the C-terminus of SRC. As a result of the Y527A mutation, 
the SRC catalytic domain is tyrosine phosphorylated leading to constitutive activation 
[47]. Consistent with our previously published results [17], ligand-induced USP8 tyrosine 
phosphorylation was enhanced in USP8 C748A compared to USP8 WT (Fig. 2A-B). 
Moreover, co-expression of constitutively active SRC Y527A with EGFR and either USP8 WT 
or C748A substantially increased basal and ligand-induced USP8 tyrosine phosphorylation 
(Fig 2A-B). On the other hand, co-precipitation of the activated tyrosine phosphorylated 
EGFR was not appreciably increased (Fig. 2A). These results strengthen our previous results 
that USP8 is a substrate for SRC-family tyrosine kinases. 
USP8 tyrosine phosphorylation is decreased upon TGFα stimulation 
To investigate how USP8 tyrosine phosphorylation is regulated, we tested whether TGFα 
stimulation of EGFR leads to efficient USP8 tyrosine phosphorylation. TGFα binds the EGFR 
in a pH-dependent manner and this leads to dissociation of TGFα from the EGFR in the 
acidic environment of endosomes [48-50]. Consequently, a significant fraction of EGFR is 
recycled back to the cell surface upon TGFα-stimulation and we previously demonstrated 
that this is correlated with decreased steady state ubiquitination, decreased EGFR 
degradation and decreased deubiquitination by AMSH [20, 48, 51, 52]. We therefore tested 
whether enhanced recycling of EGFR in response to TGFα stimulation leads to efficient 
values of the immunoprecipitated material and subsequently normalized relative to a 
given sample. Significance was calculated according to the student t-test.
Mass Spectrometry
Protein samples were separated by electrophoresis on a 8% SDS-PAGE gel, followed by gel 
staining  using colloidal Coomassie blue after which the bands were excised. Protein 
preparation and mass spectrometry were performed as described previously [44]. In-gel 
digestion was performed as follows: The SDS gel was destained by two washes with 
water. Cysteine reduction was performed by adding 100 µl of 50 mM DTT (dithiothreitol) 
in 50 mM NH4HCO3. Samples were then sonicated for 1 min and incubated for 1 h at 60°C 
without shaking. Alkylation was performed when samples had reached room temperature, 
by replacing DDT by 100 µl of 50 mM iodoacetamide in 50 mM NH4HCO3. Samples were 
then sonicated for 1 min after which alkylation took place at room temperature for 1 h in 
the dark. The gel pieces were washed three times with 100 µl of 50 mM NH4HCO3. For 
proteolytic digestion, samples were treated overnight with 100 µl of trypsin (10 ng/µl in 50 
mM NH4HCO3, sequencing grade, Boehringer Mannheim) at room temperature. Gel 
fragments were removed by centrifugation and the proteolytic peptides were recovered 
in the supernatant fraction (25 µl), after which 10% trifluoroacetic acid was added to lower 
the pH below 4. Finally all extracts were measured by LC-MS/MS. Protein samples were 
analyzed by injecting 18 µl of the various samples over a 0.10 by 32 mm Prontosil 
300-5-C18H (Bischoff, Germany) pre-concentration column (prepared in house) at a flow 
rate of 6 µl/min for 5 min, equipped to the Proxeon EASY nLC system. Tryptic peptides 
were eluted from the pre-concentration column onto a 0.10 by 250 mm Prontosil 
300-3-C18H analytical column (prepared in house) by applying an acetonitrile gradient at 
a flow of 0.5 µl/min. The gradient consisted of a linear increase from 9% acetonitrile/0.1% 
formic acid to 34% acetonitrile/0.1% formic acid within 50 min, followed by a steep 
increase to 80% acetonitrile/0.1% formic acid within 3 min as a column cleaning step. 
Between the run on the pre-concentration and the analytical column, an electrospray 
potential of 3.5 kV was applied directly to the eluent through a solid 0.5 mm platina 
electrode fitted into a P777 Upchurch microCross. Full scan positive mode FT-MS spectra 
were measured between m/z 380 and 1400 at resolution 60,000 on an LTQ-Orbitrap 
(Thermo electron, San Jose, CA) /MSMS scans of the four most abundant double or triple 
charged peaks in the FTMS scan were recorded in the data-dependent mode in a linear 
trap (MSMS threshold = 10,000). Data were acquired using Xcalibur software. LCMS runs 
with all MSMS spectra obtained were analyzed with MaxQuant 1.2.2.5 [45] using default 
settings for the Andromeda search engine [46] except that extra variable modifications 
were set for de-amidation of N and Q and phosphorylation of S, T and/or Y.  A Mus 
musculus database downloaded from Uniprot (http://www.uniprot.org) was used 
together with a contaminant database that contains sequences of common contaminant 
as for instance: BSA (P02769, bovine serum albumin precursor), trypsin (P00760, bovine), 
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USP8 tyrosine phosphorylation. As shown in Figure 3, USP8 is less efficiently tyrosine 
phosphorylated upon stimulation of EGFR by TGFα than by EGF (Fig. 3). Moreover, copre-
cipitation of USP8 with EGFR is largely decreased upon stimulation with TGFα (Fig. 3A-B). 
These results support our previous findings that ligand-induced recycling of ERBB 
receptors is associated with decreased interaction with and tyrosine phosphorylation of 
USP8, and suggest that only the fraction of ERBB molecules that is targeted for lysosomal 
degradation interacts with USP8 within the MVB pathway of the cell [17]. 
The N-terminal 504 amino acids of USP8 are sufficient for USP8 tyrosine 
phosphorylation
To identify the USP8 tyrosine residues that are phosphorylated upon EGF-stimulation of 
EGFR, we first addressed the question which part of USP8 is essential for binding to the 
EGFR and for subsequent tyrosine phosphorylation. We co-transfected HEK293 cells with 
EGFR and various EGFP-Flag-USP8-deletion constructs (for the USP8 domain structure, see 
Figure 2   Constitutively active SRC Y527A enhances constitutive and ligand-induced 
USP8 tyrosine phosphorylation
A, HEK293 cells were transiently transfected with pcDNA3 EGFR and pEGFPC1 USP8 WT or pEGFPC1 
USP8 C748A, in the presence or absence of SRC Y527A. Serum-starved cells were stimulated with or 
without 100 ng/ml EGF for 1 h. Subsequently, whole cell lysates (WCL) were used for anti-flag immu-
noprecipitation (IP) and immunoblot (IB) with the indicated antibodies. B, densitometric relative 
corrected mean pixel value of USP8 tyrosine phosphorylation, plotted as mean with standard 
deviation. Phospho-signal of the IPs was related to the amount of precipitated USP8 in the second 
panel and normalized to the USP8 WT/EGF group. Significance of selected pairwise comparisons is 
indicated as p<0.05. Data are representative of 3 experiments.
Figure 3   USP8 tyrosine phosphorylation is decreased upon TGFα stimulation 
A, HEK293 cells were transiently co-transfected with EGFR in the presence of pEGFPC1 vector or 
pEGFPC1 USP8 WT. Lanes 1 and 4 are non-transfected controls. Serum-starved cells were stimulated 
for 1 h with 100 ng/ml EGF or 100 ng/ml TGFα and WCL were used for anti-flag IP and IB with the 
indicated antibodies. In panel 4 signals of both anti-flag and anti-EGFR are shown due to consecutive 
immunoblotting with anti-Flag (panel 3) and anti-EGFR (panel 4). B, densitometric relative corrected 
mean pixel value of USP8 tyrosine phosphorylation plotted as mean with standard deviation. 
Phospho-signal of the IPs was related to the amount of precipitated USP8 in the second panel and 
normalized to the USP8 WT/EGF group. Significance is indicated as p<0.05. Data are representative 
of 3 experiments.
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Fig. 1). We previously demonstrated that the USP8 construct 1-504, in which the MIT and 
Rhod domain and the N-terminal SH3 binding motif are present, and USP8 construct 
640-1080, in which the C-terminal SH3 binding motif and the DUB domain are present, 
co-precipitate with the EGFR. These results suggested that association of USP8 with the 
EGFR occurs via at least two separate interactions [21]. In line with this, EGFR co-precipita-
tion was observed for all USP8 constructs used in this study, including USP8 1-504 and 
USP8 640-1080, although co-precipitation was most prominent with the USP8 WT 
construct (Fig. 4A, upper panel, upper arrow). Furthermore, the USP8 construct 141-731, 
from which both the MIT and the DUB domain have been removed, still co-precipitates 
with the EGFR, albeit to a lesser extent than WT USP8 (Fig. 5A, lanes 7 & 8, upper arrow). 
Our results indicate that at least one binding sequence for EGFR is present in the USP8 
constructs 1-504 and 640-1080. Overall, these results support and extend our previous 
model that USP8 and EGFR associate via multiple molecular interactions. 
 As previously shown, USP8 WT is tyrosine phosphorylated upon EGF-stimulation of 
serum-starved transfected cells (Fig. 4). The USP8 construct 1-504, which includes the 
MIT-domain and Rhod-domain, is also tyrosine phosphorylated, albeit less than USP8 WT. 
This tyrosine phosphorylation is largely abolished in the USP8 construct 141-504, in which 
the MIT-domain has been deleted. Furthermore, hardly any tyrosine phosphorylation was 
detected in the USP8 construct 640-1080 construct, which contains the DUB domain (Fig. 
4A & 4B). Our results furthermore showed that stimulation of the EGFR results in tyrosine 
phosphorylation of USP8 construct 141-731, although the decrease compared to USP8 WT 
was not statistically significant (Fig. 5A-B). Taken together, these results demonstrate that 
USP8 is tyrosine phosphorylated upon EGF-stimulation of the EGFR on at least one tyrosine 
in the first 504 N-terminal amino acids. 
Optimal USP8 tyrosine phosphorylation is MIT-domain dependent
The MIT-domain of USP8 interacts with CHMP proteins of the ESCRT-III complex and is 
important for endosomal recruitment [30]. Furthermore, the MIT-domain is required for 
EGFR degradation [27, 30], which suggests that this domain is essential for USP8 function. 
As we have demonstrated before, deletion of the MIT-domain in USP8 results in decreased 
EGF-induced USP8 tyrosine phosphorylation [17]. Here, we strengthen these results by 
showing that deletion of the N-terminal MIT-domain from USP8 construct 1-504, resulting 
in USP8 141-504, almost completely abolished tyrosine phosphorylation (Fig. 4), whereas 
deletion of the MIT domain in USP8 WT significantly reduced USP8 tyrosine phosphoryla-
tion (Fig. 5 & 6). These results show that the MIT domain is essential for optimal USP8 
tyrosine phosphorylation. It has previously been demonstrated that a catalytically inactive 
mutant of USP8 (C748A) displays enhanced binding to EGF-stimulated EGFR, which has 
been attributed to substrate-trapping that immobilizes substrate proteins and the enzyme 
itself on the endosomal membrane [25, 53]. In addition, we previously showed that 
enhanced co-precipitation of USP8 C748A with EGF-stimulated EGFR is associated with 
Figure 4   The N-terminal 504 amino acids of USP8 are sufficient for USP8 tyrosine phos-
phorylation
A, HEK293 cells were transiently transfected with pcDNA3 EGFR and a pEGFPC1 vector or pEGFPC1 
USP8 construct. Serum-starved cells were stimulated with or without 100 ng/ml EGF for 1 h and WCL 
were used for anti-flag IP and IB  with the indicated antibodies. B, densitometric relative corrected 
mean pixel value of USP8 tyrosine phosphorylation plotted as mean with standard deviation. 
Phospho-signal of the IPs was related to the amount of precipitated USP8 in the second panel and 
normalized to the USP8 WT/EGF group. Significance of selected pairwise comparisons is indicated 
as p<0.05 or not significant (n.s.). Data are representative of 3 experiments.
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increased tyrosine phosphorylation of the USP8 C748A mutant [17]. To determine whether 
the MIT domain is also necessary for the enhanced tyrosine phosphorylation of USP8 
C748A, we tested the effect of ΔMIT USP8 C748A on tyrosine phosphorylation. 
Co-expression of the ΔMIT USP8 C748A mutant partly recovered the decrease in USP8 
tyrosine phosphorylation seen upon deletion of the MIT-domain and was comparable to 
USP8 WT tyrosine phosphorylation, suggesting that the MIT-domain is necessary for the 
enhanced tyrosine phosphorylation of the USP8 C748A mutant on the endosomal 
membrane (Fig. 5). Our results demonstrate that the MIT domain is required for optimal 
tyrosine phosphorylation of USP8, which is in line with previous results that the MIT 
domain is necessary for endosomal recruitment [30].
Mutation of exposed tyrosines in the USP8 MIT domain does not abolish 
USP8 tyrosine phosphorylation
Although the MIT domain is necessary for endosomal recruitment [30], we cannot rule out 
that USP8 tyrosine phosphorylation occurs within the MIT domain. To address this 
question, we generated several MIT domain deletion constructs and mutated several MIT 
domain tyrosine residues that are predicted to be accessible for phosphorylation based 
on the USP8 MIT domain crystal structure [32]. First, we tested two additional deletion 
constructs, in which α-helices within either the first 74 or the first 90 amino acids of USP8 
were completely removed. As already shown in Fig. 5A-B, deletion of the complete 
MIT-domain (USP8 Δ140) resulted in substantially decreased USP8 tyrosine phosphoryla-
tion (Fig. 6A-B). Deletion of the N-terminal 90 amino acids (USP8 Δ90) resulted in an almost 
comparable decrease in USP8 tyrosine phosphorylation (Fig. 6). Indeed, the intensity of 
the USP8 phospho-tyrosine signal relative to the EGFR phospho-tyrosine signal is 
substantially decreased for USP8 Δ140 and USP8 Δ90 when compared to USP8 WT. In 
contrast, the intensity of the USP8 phospho-tyrosine signal relative to the EGFR was similar 
for USP8 Δ74 and USP8 WT. Although the phospho-tyrosine signal for USP8 and EGFR 
appears to be decreased in USP8 Δ74 transfected cells (Fig 6A, lane 8), relative to USP8 WT 
transfected cells (Fig 6A lane 2), this can be attributed to the lower expression of the Δ74 
construct (Fig. 6A, panel 2). Taking this into account, the tyrosine phosphorylation is 
completely restored in USP8 Δ74 (Fig. 6A), as confirmed by quantitative analysis of triplicate 
experiments (Fig. 6B). The efficiency of co-immunoprecipitation of the EGFR with USP8 
was hardly affected by deletion of a part of the MIT domain, suggesting that a complete 
MIT-domain is not essential for USP8 binding to the EGFR. Our results suggest that the 
N-terminal 74 amino acids are not essential for the MIT function of USP8 and do not 
contain tyrosines that are a substrate for EGF-induced phosphorylation. Nevertheless, 
these results strengthen our conclusion that an intact MIT domain is essential for optimal 
USP8 tyrosine phosphorylation.
 In Fig. 4 we demonstrated that at least one tyrosine is phosphorylated in the first 
N-terminal 504 amino acids. However, since the tyrosine phosphorylation in the 1-504 
Figure 5   Optimal USP8 tyrosine phosphorylation is MIT-domain dependent
A, HEK293 cells were transiently transfected with pcDNA3 EGFR and an pEGFPC1 USP8 construct. 
Serum-starved cells were stimulated with or without 100 ng/ml EGF for 1 h and WCL were used for 
anti-flag IP and IB with the indicated antibodies. B, densitometric relative corrected mean pixel value 
of USP8 tyrosine phosphorylation plotted as mean with standard deviation. Phospho-signal of the 
IPs was related to the amount of precipitated USP8 in the second panel and normalized to the USP8 
WT/EGF group. Significance of selected pairwise comparisons is indicated as p<0.05 or not significant 
(n.s.). Data are representative of 3 experiments.
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construct was decreased compared to USP8 WT, it is likely that more than a single tyrosine 
residue of USP8 is phosphorylated. In total, USP8 contains 35 tyrosines, of which 15 are 
located within the first N-terminal 504 amino acids. To address the question whether a 
phosphorylated tyrosine is present within the MIT domain, we analyzed the surface 
exposure of all 9 tyrosines within the known crystal structure of the mouse MIT domain. 
Y12 is the only tyrosine of which the hydrophobic phenyl ring is not completely buried in 
the crystal structure and is therefore predicted to be accessible for a tyrosine kinase. 
Furthermore, Y12 is absolutely conserved in vertebrates. To test whether Y12 could be a 
site for USP8 tyrosine phosphorylation, we generated a Y12F mutant. However, no effect 
on total USP8 tyrosine phosphorylation was observed upon mutation of Y12 (Fig. 6C-D), 
suggesting that Y12 is not solely responsible for USP8 tyrosine phosphorylation. Our 
previous observation that the decreased tyrosine phosphorylation for USP8 Δ140 and 
USP8 Δ90 is largely restored in USP8 Δ74, suggests that a relevant USP8 tyrosine phosphor-
ylation site could be present between USP8 amino acids 74 and 90. Indeed, tyrosines are 
present on both positions 85 and 86. In order to investigate the contribution of these 
residues, we generated two single mutants (USP8 Y85F and USP8 Y86F) and one double 
mutant (USP8 Y85/86F). Our results showed, however, that USP8 tyrosine phosphorylation 
was not decreased in any of these mutants (Fig. 6C-D), demonstrating that these two 
tyrosines are not solely responsible for the USP8 tyrosine phosphorylation in EGF 
stimulated cells. Taken together, our results do not support the model that USP8 is tyrosine 
phosphorylated within the MIT domain but rather support the hypothesis that the MIT 
domain is required to recruit USP8 to the endosomal membrane to undergo SRC kinas-
es-dependent tyrosine phosphorylation.
Mutation of exposed tyrosines in the USP8 Rhod and linker domain does 
not abolish USP8 tyrosine phosphorylation
To further identify tyrosine residues that are involved in USP8 tyrosine phosphorylation, 
we investigated several tyrosine residues within the Rhod (residues 185-310) and linker 
domain (residues 310-740) of USP8. Besides the 9 tyrosine residues in the MIT domain, the 
USP8 construct 1-504 contains six additional tyrosine residues. The Rhod domain within 
this construct contains 5 tyrosines, none of which appears to be involved in the interaction 
with NRDP1 [32]. The hydrophobic phenyl ring of three of these tyrosines (Y189, Y255, 
Y308) is not buried and therefore potentially accessible for a kinase. Of these three 
tyrosines, Y189 is conserved in mammals, but replaced by Phe in non-mammalian 
vertebrates, while Y255 is absolutely conserved in mammals and vertebrates, and in 
addition Y308 is absolutely conserved, except for replacement by Phe in chicken (data not 
shown). Y336, which is part of the linker-domain of USP8, is also absolutely conserved in 
vertebrates. Our results show that mutation of either Y189, Y255, Y308 or Y336 did not 
significantly decrease the total USP8 tyrosine phosphorylation level observed  upon EGF 
stimulation (Fig. 6C-D, lanes 11 & 12 and Fig. 7). We subsequently tested two additional 
Figure 6   Mutation of exposed tyrosines in the USP8 MIT domain does not abolish USP8 
tyrosine phosphorylation
A and C, HEK293 cells were transiently transfected with pcDNA3 EGFR and a pEGFPC1 USP8 
construct. Serum-starved cells were stimulated with or without 100 ng/ml EGF for 1 h and WCL were 
used for anti-flag IP and IB with the indicated antibodies. B and D, densitometric relative corrected 
mean pixel value of USP8 tyrosine phosphorylation plotted as mean with standard deviation. 
Phospho-signal of the IPs was related to the amount of precipitated USP8 in the second panel and 
normalized to the USP8 WT/EGF group. B, Significance of selected pairwise comparisons is indicated 
as p<0.05 or not significant (n.s.). D, Differences between USP8 WT/EGF compared to mutant/EGF 
groups were all not significant. Data are representative of 3 (A-B) and 2 (C-D) experiments.
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tyrosine residues in the linker domain, Y641 and Y679. Y641 is absolutely conserved among 
vertebrates and is located in a highly conserved domain with an as yet unknown function. 
Y679 is located within the 14-3-3 binding motif and precedes the S680 phosphorylation 
site of USP8 [35]. Again, mutation of Y641 or Y679 did not result in a decrease of the total 
USP8 tyrosine phosphorylation level (Fig. 7). Taken together, these results show that Y189, 
Y255, Y308, Y336, Y641 and Y679 are not solely responsible for the total USP8 tyrosine 
phosphorylation detected upon EGF stimulation of EGFR, and therefore support the 
model that more than a single USP8 tyrosine is phosphorylated. 
Figure 7   Mutation of exposed tyrosines in the USP8 Rhod and linker domain supports 
the model that more than one tyrosine in USP8 is phosphorylated
A, HEK293 cells were transiently transfected with pcDNA3 EGFR and pEGFPC1 USP8 WT or an USP8 
mutant. Serum-starved cells were stimulated with or without 100 ng/ml EGF for 1 h and WCL were 
used for anti-flag IP and IB with the indicated antibodies. B, densitometric relative corrected mean 
pixel value of USP8 tyrosine phosphorylation plotted as mean with standard deviation. 
Phospho-signal of the IPs was related to the amount of precipitated USP8 in the second panel and 
normalized to the USP8 WT/EGF group. Differences between USP8 WT/EGF compared to mutant/
EGF groups were all not significant. Data are representative of 2 experiments.
Figure 6   Continued
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binds to GST14-3-3 with the same affinity as USP8 WT and USP8 C748, while binding of 
USP8 S680A to 14-3-3 was largely abolished (Fig. 10A and 10C). These results show that 
phosphorylation of Y679 does not affect binding of 14-3-3 to USP8.
 It has previously been reported that mutation of S680 results in enhanced USP8 
activity towards EGFR, although EGF stimulation did not affect the level of S680 phos-
phorylation and 14-3-3 binding of USP8 [35]. We therefore investigated whether USP8 
Mass Spectrometry analysis reveals USP8 serine but no tyrosine 
phosphorylation
To further investigate which tyrosines are phosphorylated upon EGFR stimulation, we 
used mass spectrometry (MS) analysis. MS analysis of USP8 WT and USP8 C748A was 
performed in duplicate. Protein samples were separated by electrophoresis, followed by 
gel staining using Coomassie blue and excision of the bands (Fig. 8A). Tyrosine phosphor-
ylation of USP8 was confirmed on a parallel western blot (Fig. 8B). As shown in Fig. 8C, MS 
analysis of USP8 WT revealed an almost complete sequence coverage, although several 
tyrosine-containing peptides were not detected in these analyses, among which a 
peptide containing Y255. However, site-directed mutagenesis of Y255 did not result in a 
detectable decrease in total USP8 tyrosine phosphorylation (Fig. 7). MS analysis did not 
reveal any evidence for USP8 tyrosine phosphorylation, although it clearly revealed the 
presence of several phosphorylated serine residues including pS153, pS392, pS680 and 
pS722 in USP8 WT (Fig. 8C). pS153, pS392 and pS680 were also observed in USP8 C748A. In 
conclusion, in spite of the use of several complementary strategies for identification of 
phosphorylated tyrosine residues in USP8, including the use of deletion constructs, 
site-directed mutagenesis and MS analysis, we have so far been unable to identify a 
specific USP8 tyrosine that is phosphorylated. On the other hand, several USP8 serine 
phosphorylation sites were identified using MS analysis. 
Mutation of Y679 does not influence 14-3-3 binding and S680 is not 
involved in the regulation of USP8 tyrosine phosphorylation
To address the functionality of S680 phosphorylation, we tested whether binding of 
14-3-3 proteins to USP8 depends on phosphorylation of S680. Using a GST14-3-3 pull-down 
experiment, we demonstrate here that USP8 WT and USP8 640-1080 interact with 14-3-3 
proteins (Fig. 9A and 9D). Furthermore, USP8 constructs 140-504 and 540-640 were unable 
to interact with GST14-3-3 (Fig. 9A). Specific antibodies which recognize phosphorylated 
14-3-3 binding motifs (p(Ser)14-3-3 Binding Motif), indeed recognized both USP8 WT and 
USP8 construct 640-1080 (Fig. 9B). In contrast, mutation of S680 completely abrogated 
binding of antibodies specific for 14-3-3 binding motifs (Fig. 9B and 9E). Furthermore, the 
USP8 mutant S680A was not able to interact with GST14-3-3 proteins (Fig. 9C and 9F), 
showing that phosphorylated S680 is responsible for binding of USP8 to 14-3-3 proteins. 
Catalytically inactive USP8 also efficiently interacted with 14-3-3, showing that the deubiq-
uitinating activity of USP8 is not necessary for binding of USP8 to 14-3-3 proteins (Fig. 9C 
and 9F). 
 The RSYSSP 14-3-3 protein binding motif in USP8 contains the conserved Y679 which 
upon phosphorylation could possibly interfere with 14-3-3 binding. Although we obtained 
no direct evidence for phosphorylation of USP8 Y679 in the site-directed mutagenesis 
study (Fig. 7) and the MS experiments (Fig. 8), we addressed whether phosphorylation of 
Y679 could potentially regulate 14-3-3 binding. Our experiment showed that USP8 Y679F 
Figure 8   Mass Spectrometry analysis reveals USP8 serine but no tyrosine  
phosphorylation sites
A-B, HEK293 cells were transiently transfected with pcDNA3 EGFR and pEGFPC1 USP8 C748A. 
Serum-starved cells were stimulated with or without 100 ng/ml EGF for 1 h and WCL were used for 
anti-flag IP and Coomassie staining (A) or IB with the indicated antibodies (B). C, table containing the 
results of the four mass spectrometry analyses. Analyses 1-2: USP8 WT, analyses 3-4: USP8 C748A
A
C
B
MS 
analysis
pSerines Tyrosines  
not covered 
1-504
Tyrosines  
not covered  
total
Sequence 
covered  
1-504
Sequence 
coverage  
total
1 392, 680 255 255, 806 65% 73%
2 153, 392, 680 255 255, 806, 946 69% 72%
3 392, 680, 722 210, 255 210, 255, 630, 631, 641, 749,  
766, 806, 1013, 1022, 1030,  
1033, 1064, 1068
62% 57%
4 153, 392, 680, 
722
36, 60, 63, 
210, 255,  
301, 308
36, 60, 63, 210, 255, 301,  
308, 336, 630, 631, 641, 749,  
766, 772, 806, 913,
39% 34%
946, 978, 1002, 1013, 1022,  
1030, 1033, 1064, 1068
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Figure 9   USP8 binds 14-3-3 proteins in a phosphoserine 680-dependent manner
A-C, HEK293 cells were transiently transfected with pEGFP C1 vector, pEGFPC1 USP8 WT or an USP8 
mutant. WCL were used for affinity precipitation with GST vector or GST 14-3-3 followed by IB with 
the indicated antibodies. D-F, densitometric relative corrected mean pixel value plotted as mean 
with standard deviation. Signals were related to the amount of transfected GFP in the second panel 
and normalized to the USP8 WT group. Significance of selected pairwise comparisons is indicated as 
p<0.05 or not significant (n.s.). Data are representative of 3 experiments.
Figure 9   Continued
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S680A showed altered tyrosine phosphorylation levels upon EGF stimulation. Our results 
showed that in EGF treated cells the tyrosine phosphorylation level of USP8 S680A was 
comparable to that of USP8 WT, while increased tyrosine phosphorylation was detected 
for USP8 C748A (Fig. 10B and 10D). Overall, these results show that 14-3-3 proteins bind to 
USP8 in a pS680-dependent manner and that mutation of Y679 in the binding motif does 
not affect 14-3-3 binding. Our results are consistent with previously published results that 
phosphorylation of S680 in amino acid sequence RSYSSP in USP8 leads to binding of 
14-3-3 proteins to USP8 [34-38]. Furthermore, we demonstrate that S680 is not involved in 
the regulation of USP8 tyrosine phosphorylation. 
Figure 10   Mutation of Y679 does not influence 14-3-3 binding and S680 is not involved 
in the regulation of USP8 tyrosine phosphorylation 
A, HEK293 cells were transiently transfected with pEGFP C1 vector, pEGFPC1 USP8 WT or an USP8 
mutant. WCL were used for anti-GST14-3-3 affinity precipitation and IB with the indicated antibodies. 
B, HEK293 cells were transiently transfected with EGFR and pEGFPC1, USP8 WT or an USP8 mutant. 
Serum-starved cells were stimulated with or without 100 ng/ml EGF for 1 h. Subsequently, WCL were 
used for anti-flag IP and IB with the indicated antibodies. C-D, densitometric relative corrected mean 
pixel value plotted as mean with standard deviation. Signals were related to the amount of 
transfected GFP in the second panel and normalized to the USP8 WT group. Significance of selected 
pairwise comparisons is indicated as p<0.05 or not significant (n.s.). Data are representative of 3 
experiments.
Figure 10   Continued 
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endosomal recruitment which is required for EGFR degradation [27, 30]. These findings are 
consistent with the model that USP8 is tyrosine phosphorylated upon MIT-dependent 
recruitment of USP8 to endosomal membranes [17, 21]. This model is supported by our 
results that the MIT-domain is involved in the substrate-trap of USP8 C748A on endosomal 
membranes (Fig. 5A-B). We cannot rule out that removal of the MIT-domain results in a 
conformational effect resulting in reduced USP8 tyrosine phosphorylation, but this is less 
likely since this mutant has been extensively studied before [30]. Even though the MIT 
domain is essential for tyrosine phosphorylation of the truncated USP8 construct 1-504 
(Fig 4), removal of the MIT domain does not completely abolish tyrosine phosphorylation 
of USP8 WT (Fig. 5 & 6), suggesting that USP8 might also be recruited to endosomal 
membranes through alternative mechanisms. It cannot be excluded that the tyrosine 
phosphorylation that remains in the ΔMIT mutant may be due to phosphorylation of 
USP8 by activated SRC-kinases in the cytoplasm. With the additional MIT-deletion mutants 
Δ90 and Δ74, we demonstrate that the first 74 amino acids of the MIT-domain of USP8 are 
not essential for proper MIT-domain function that results in USP8 tyrosine phosphoryla-
tion (Fig. 6A-B). Finally, we cannot rule out the possibility that USP8 is tyrosine 
phosphorylated within its MIT domain. Site-directed mutagenesis of Y12, Y85 and Y86 did 
not reveal a substantial reduction in USP8 phosphotyrosine content (Fig. 6C-D), as detected 
by immunoblotting. It remains possible that one of the other tyrosines in the MIT domain 
is accessible in the cell perhaps due to conformational changes. Apart from the MIT 
domain tyrosine residues, the USP8 construct 1-504 contains six additional tyrosine 
residues, five of which are located within the Rhod domain and one in the linker-domain 
(residues 310-740). Y336 is located within a conserved motif L[N/T/D]F[S/T]YPSLE with an 
unknown function. Using the ELM server [54], this site is also listed as a putative CK2 phos-
phorylation site (S338) and a YxxΦ endosomal sorting motif that binds to clathrin APs 
(http://elm.eu.org/), and it therefore would be an interesting candidate as a potential 
tyrosine phosphorylation site. However, neither site-directed mutagenesis (Fig. 7) nor MS 
analysis (Fig. 8) revealed evidence in favor of phosphorylation of these six tyrosine residues. 
 Overall, we have provided strong evidence for ligand-induced ERBB- and SRC family 
kinase–dependent tyrosine phosphorylation of USP8 1-504. The finding that site-directed 
mutagenesis did not reveal any evidence in favor of tyrosine phosphorylation may be due 
to the fact that we did not mutate all tyrosines in this region or to the possibility that 
mutation of a single tyrosine residue does not sufficiently affect total USP8 tyrosine phos-
phorylation. The finding that we did detect phospho-serine but no phospho-tyrosine 
residues by MS analysis suggests that the stoichiometry of USP8 tyrosine phosphorylation 
may be very low and therefore not detectable by MS. Our data support the model 
whereby EGF stimulation of the EGFR leads to MIT-domain dependent recruitment of 
USP8 towards the activated receptor-complex at the endosomes where also the SRC 
kinases are present that phosphorylate USP8. We speculate that only a relatively small 
fraction of cellular USP8 is recruited from the cytoplasm towards endosomes, resulting in 
Discussion
Given our previous observation that USP8 is tyrosine phosphorylated in an EGFR- and 
SRC-kinase dependent manner following EGF-stimulation, we aimed to identify the phos-
phorylation sites in USP8 and the functional significance of such tyrosine phosphoryla-
tion. Using USP8 deletion constructs, our results demonstrate that USP8 is efficiently 
tyrosine phosphorylated on at least one tyrosine residue in the N-terminal 504 amino 
acids of USP8, as detected by immunoblotting with anti-phosphotyrosine  and that the 
MIT-domain is necessary for ligand-induced tyrosine phosphorylation of USP8 1-504. 
However, site-directed mutagenesis of selected USP8 tyrosine residues that are predicted 
to be accessible for phosphorylation, did not reveal any evidence for phosphorylation of 
individual tyrosines. Repeated MS analysis of both USP8 WT and the USP8 C748A mutant 
did not reveal any tyrosine phosphorylation, even though almost all tyrosines of the USP8 
1-504 construct were recovered in the MS analysis. In contrast, MS analysis did result in the 
identification of several serine phosphorylation sites, including the S680 14-3-3 binding 
site, and subsequent experiments showed that this site is responsible for phosphorylation 
dependent binding of 14-3-3 to USP8. Our findings demonstrate that USP8 is a target for 
the post-translational serine and tyrosine phosphorylation, most likely characterized by 
low abundant tyrosine phosphorylation on multiple residues, and high abundant serine 
phosphorylation on a several residues.  
 Our studies indicate that both constitutive and ligand-induced USP8 tyrosine phos-
phorylation signal can be increased by co-expression of constitutively active SRC Y527A 
together with USP8 and EGFR (Fig. 2) and that TGFα stimulation of EGFR decreased USP8 
tyrosine phosphorylation (Fig. 3). These results strengthen our previous findings that (i) 
USP8 is a target for SRC-family tyrosine kinases [17, 21], (ii) ligand-induced recycling of ERBB 
receptors is associated with decreased interaction with and tyrosine phosphorylation of 
USP8 and (iii) that only the fraction of ERBBs that is targeted for lysosomal degradation, 
interacts with USP8 within the MVB pathway of the cell [17].   
 We previously demonstrated that the USP8 constructs 1-504 and 640-1080 
co-precipitate with the activated EGFR, and based on that observation we proposed a 
bivalent interaction model of USP8 with the EGFR [21]. Our results support and extend our 
previous findings that association of USP8 with the EGFR involves a multivalent interaction, 
since we now show that even in the absence of the MIT and DUB domain USP8 can 
coprecipitate with the EGFR (Fig. 4-5). Furthermore, we demonstrate that optimal USP8 
tyrosine phosphorylation is not necessary for binding of USP8 to EGFR. Our data suggest 
that USP8 is tyrosine phosphorylated upon EGF-stimulation of the EGFR on at least one 
tyrosine in the first 504 N-terminal amino acids, in which the MIT-domain and Rhod-domain 
are present (Fig. 4).
 Removal of the MIT-domain abolished the tyrosine phosphorylation of USP8 1-504. 
The MIT-domain of USP8 interacts with ESCRT-III proteins and is therefore important for 
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a role during mitosis [35, 63, 64]. Whereas phosphorylation of S680 and T907 has an effect 
on USP8 activity and stability [33, 35], it cannot be excluded that tyrosine and serine phos-
phorylation on other sites may influence USP8 activity and stability as well.
Conclusion
In summary, our data demonstrates that USP8 is a target for SRC-mediated tyrosine phos-
phorylation in the N-terminal 504 amino acids upon EGF stimulation of EGFR. Furthermore, 
serine phosphorylation on several sites was detected, including the phosphorylated S680 
to which 14-3-3 efficiently bind. 
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a low stoichiometry of tyrosine phosphorylated USP8. This model is supported by our 
current findings that TGFα stimulation of EGFR and EGF stimulation of ERBB2 [52], 
conditions that are associated with enhanced endosomal recycling and decreased MVB 
targeting, resulted in less coprecipitation of USP8 with the activated receptor and 
decreased USP8 tyrosine phosphorylation. Overall, our data clearly show that USP8 is 
tyrosine phosphorylated. However, the tyrosine phosphorylation site of USP8 and the 
precise role of USP8 tyrosine phosphorylation remain to be elucidated. 
 The MS analysis revealed  the presence of phospho-serine residues in USP8. In total 
four serine phosphorylation sites were detected, in particular serines 153, 392, 680 and 722 
(Fig. 8). pS153 (RpSVENLLDSK) is located in a conserved motif (amino-acids 153-161) with an 
unknown function in mammals in between the USP8 MIT domain and the Rhod domain. 
Similarly, pS392 (AEApSPIIQPAPATK) is located in a conserved motif in mammals in the 
linker region in close proximity to the STAM/Hbp SH3 binding site (405-413). pS680 
(SYpSSPDITQALQEEEK) was found in all four MS analyses and is part of the 14-3-3 binding 
motif RSYSSP in USP8 [34-38]. pS722 (LSApSQIR) is located in a conserved region in 
between the C-terminal Hbp SH3 binding motif and the DUB domain. pS722 was only 
found in EGF-stimulated cells containing USP8 C748A, which could indicate that this serine 
is involved in substrate trapping. In a previous study, MS analysis was used to demonstrate 
that USP8 is phosphorylated on serines 108, 153 and 680, depending on the tissue of 
origin [55]. Furthermore, USP8 can be phosphorylated on T907 in response to neuregT-
ulin-stimulation of ERBB3 [33], although we did not find evidence for pT907 in our MS 
analysis. This can possibly be explained by the difference in model system that was used, 
as Cao et al. used neuregulin stimulated ERBB3 receptors [33]. Phosphorylated S680 was 
detected in all our analyses. Phosphorylation of S680 in the vertebrate conserved amino 
acid sequence RSYSSP in USP8 leads to binding of 14-3-3 proteins to USP8 [34-38]. Indeed, 
our data demonstrate that USP8 binds to 14-3-3 proteins in a phosphorylated 
S680-dependent manner (Fig. 9). We have also shown that enzymatic activity of USP8 is 
not necessary for binding to 14-3-3 proteins and that phosphorylation of Y679 in the 
binding motif is not involved in 14-3-3 binding (Fig. 10). Further research is necessary to 
elucidate the role of the other serine phosphorylation sites. 
 Several DUB enzymes have been shown to undergo posttranslational modification, 
including ubiquitination as well as serine and tyrosine phosphorylation. Although the 
physiological role of USP25 remains to be explored, the tyrosine kinase SYK has been 
found to tyrosine phosphorylate USP25. The protease activity of USP25 was not affected 
by its tyrosine phosphorylation, but its protein level was decreased [56]. Several DUB 
enzymes are regulated by serine phosphorylation, including TNFAIP3 (A20) whose DUB 
activity is increased upon phosphorylation [57], In contrast, serine phosphorylation of 
CYLD and OTUB1 is associated with decreased DUB activity [58-60]. Furthermore, the 
stability of ATXN3 (Ataxin-3) and USP10 is influenced upon serine phosphorylation [61, 62]. 
As with USP8 phosphorylation of S680, serine phosphorylation of USP16 and USP44 plays 
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1. Aim of the thesis and summary of results
The ERBB receptors are critical regulators of normal development, but they are also 
frequently involved in the formation of solid tumors, as a result of enhanced, prolonged or 
ligand-independent signaling. Attenuation of ERBB receptor signaling is mediated by the 
clathrin-dependent pathway of receptor-mediated endocytosis and subsequent sorting 
of the activated ligand-receptor complex through the MVB pathway to lysosomes for 
degradation. Most studies on this topic have been performed on the EGFR, for which 
ubiquitination by the E3 ligase CBL has been suggested to play an important role in EGFR 
internalization and lysosomal targeting. Knowledge about the ubiquitination and deubiq-
uitination of the other ERBB receptors may help to elucidate more about ERBB receptor 
downregulation pathways.
 In this thesis, we aimed to unravel the mechanisms underlying ubiquitination and 
deubiquitination of, in particular, ERBB2 and ERBB4. In order to investigate this process and 
to allow a comparison between the various ERBB receptors, we used chimeric receptors 
containing the extracellular and transmembrane domains of the EGFR and the cytoplasmic 
tail of either ERBB2 or ERBB4 as a model system. In chapter 2 we demonstrated that 
replacement of the EGFR CBL binding site by that of ERBB2 or ERBB4 did not affect CBL 
recruitment, receptor ubiquitination, degradation, or downregulation, as well as ligand 
degradation. Subsequently, we demonstrated that the naturally occurring CBL binding 
site is functionally active in both ERBB2 (chapter 3) and ERBB4 (chapter 5). Interestingly, we 
demonstrated that EGFR and ERBB2 are efficiently K63-polyubiquitinated by CBL (chapter 
3), while in contrast ERBB4 is K48-polyubiquitinated by CBL and K63-polyubiquitinated by 
ITCH (chapter 5). Furthermore, we demonstrated that ligand-dependent recycling of 
EGFR, ERBB2 and ERBB4 is associated with impaired HRS tyrosine phosphorylation and 
decreased deubiquitination by AMSH (chapter 4 and 5). In contrast, EGFR, ERBB2 and the 
ERBB4 isoform CYT-1 are deubiquitinated by USP8 under both ligand-dependent and –
independent conditions (chapter 3 and 5). In the case of ERBB2, enhanced recycling, 
decreased HRS tyrosine phosphorylation and decreased AMSH-mediated deubiquitina-
tion of EGFR-ERBB2 chimeras was found to be primarily due to the presence of ERBB2 
sequences or the absence of EGFR sequences in the region C-terminal of the CBL binding 
site (chapter 4). Finally, in chapter 6 we demonstrated that USP8 is post-translationally 
modified by tyrosine and serine phosphorylation. 
 In this general discussion we will integrate and discuss our results about ubiquitination 
and deubiquitination of the ERBB receptors. First, we will discuss the observation that 
ERBB2 and ERBB4 are less efficiently downregulated than EGFR. Second, we will propose 
models for the observation that CBL is involved in both K48- and K63-polyubiquitination 
of ERBB receptors. Third, we will discuss that - in contrast to the EGFR -  ERBB2 and ERBB4 
do not efficiently interact with HRS within the cell and show enhanced recycling. Fourth, 
we will discuss the function of AMSH and USP8 in deubiquitination of ERBB receptors 
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chimera is somewhat decreased compared to EGFR-ERBB2 TM, it seems likely that multiple 
signals are involved in limiting downregulation of ERBB2. In search for molecular differences 
in the C-terminal region of the receptors, we observed that, in contrast to the EGFR, the 
C-terminal valine of ERBB2 and ERBB4 associates with PDZ-domain proteins. Thus, whereas 
ERBB2 interacts with Erbin, PICK1 (13, 14) and LIN-7 (15), ERBB4 interacts with the PSD-95 
family of PDZ domain-containing proteins (16). Interestingly, Erbin, PICK1 and LIN-7 have 
been suggested to be involved in maintaining ERBB2 to the membrane (13, 14). The 
binding of PDZ domain containing proteins is an interesting difference between EGFR 
versus ERBB2 and ERBB4. And might play an essential role in limiting downregulation of 
ERBB2 and ERBB4. Still, the mechanisms of internalization and recycling of ERBB2, ERBB3 
and ERBB4 have scarcely been studied, and further research is required to further locate 
the sorting signals and to elucidate the involvement of various signals that are involved in 
downregulation and recycling of ERBB receptors. 
3. CBL interaction with ERBB receptors
3.1 Binding of CBL to ERBB receptors
The CBL protein family consists of three different proteins, i.e. C-CBL, CBLB and CBLC (17). 
CBL proteins associate with their N-terminal tyrosine kinase binding (TKB) domain to a 
consensus RYXXDP CBL binding site that is present in EGFR, ERBB2 and ERBB4, but not in 
ERBB3 (chapter 2). Previously, it has been shown that the CBL binding site in wild-type 
EGFR and ERBB2 receptors is functionally active (18-20). Moreover, we have found that 
modification of the EGFR CBL binding site into one that resembles the ERBB2 or ERBB4 CBL 
binding site does not affect CBL recruitment, CBL-mediated EGFR ubiquitination, EGFR 
downregulation, EGFR degradation or EGF ligand degradation (chapter 2), suggesting that 
the CBL binding sites in ERBB2 and ERBB4 are indeed functionally active. In this thesis, we 
also provide evidence that the RYXXDP CBL binding site is functionally active in the 
context of chimeric EGFR-ERBB2 and EGFR-ERBB4 receptors, because CBL is recruited and 
activated upon activation of EGFR-ERBB2 and EGFR-ERBB4, albeit less efficient when 
compared to the EGFR (chapter 3 and 5). 
3.2 CBL tyrosine phosphorylation
While all three CBL proteins can be tyrosine phosphorylated and recruited towards the 
activated EGFR (21, 22), association of CBL proteins with other ERBB receptors has previously 
been been confirmed only for the recruitment of C-CBL to an oncogenic ERBB2 mutant or 
mAb-bound ERBB2 (18, 23, 24). Until now, no data have been published on the (functional) 
interaction of ERBB2 with CBLB or CBLC proteins, or between ERBB4 receptors and any of 
the CBL proteins. Although our findings demonstrate that C-CBL is tyrosine phosphorylated and 
recruited to the receptors following activation of chimeric EGFR-ERBB2 and EGFR-ERBB4 
during downregulation and recycling, as well as the posttranslational regulation of 
 deubiquitination enzymes.
2. Endosomal sorting of ERBB receptors 
Most studies regarding ligand-induced ERBB trafficking have been performed using the 
EGFR as a model. It has previously been demonstrated that, compared to EGFR, the other 
ERBB receptors show impaired ligand-induced internalization and downregulation (1, 2). 
The molecular basis for the difference in internalization and downregulation efficiency of 
ERBB2, ERBB3 and ERBB4 receptors remains poorly understood. In an early study using 
ERBB chimeras, Baulida et al. demonstrated that EGFR-ERBB2 and EGFR-ERBB4 were 
internalized 3-fold slower than EGFR despite the activation of the kinase and phosphory-
lation of the ERBB2 and ERBB4 intracellular domain (2). Here, we confirmed that the 
EGFR-ERBB2 chimeric receptor showed decreased downregulation and enhanced 
recycling compared to the EGFR (chapter 4). The poor downregulation of ERBB2 has been 
attributed to reduced recruitment into clathrin-coated pits (1, 3, 4), impaired lysosomal 
targeting or increased recycling back to the cell surface (5, 6). When comparing the 
molecular structure of EGFR and ERBB2, impaired downregulation of ERBB2 may result 
from (i) reduced recruitment of the clathrin adapter protein AP2µ to drive internalization 
(2, 7, 8), (ii) the absence of a dileucine signal in the cytoplasmic tail of ERBB2 that corresponds 
to EGFR LL1010/1011 which associates with AP2β to promote lysosomal targeting of the 
EGFR (9), (iii) the presence of a unique 45 amino acid insert in the cytoplasmic tail of ERBB2 
(10) and/or (iv) impaired recruitment of CBL E3 ligases (11, 12). ERBB4 also fails to form a 
complex with AP-2 (2) and the dileucine motif is also absent in ERBB4 (chapter 2). Moreover, 
it has been proposed that reduced recruitment of CBL to ERBB2, ERBB3 and ERBB4 
receptors may be responsible for poor ligand-induced downregulation of these receptors 
(11). However, our results (chapter 2) show that replacement of the EGFR CBL binding site 
by that of ERBB2 and ERBB4 does not affect CBL recruitment, receptor ubiquitination, 
degradation, downregulation or ligand degradation of EGFR, indicating that poor down- 
regulation of ERBB2 and ERBB4 is not due to sequence variations in the CBL binding site of 
these receptors. 
 It has been hypothesized in earlier studies that the difference in downregulation may 
result from the absence of positive or the presence of negative sequences in the 
cytoplasmic domains of the various receptors (1, 2). To further locate the molecular basis 
for the difference in trafficking of EGFR versus EGFR-ERBB2, we used the EGFR-ERBB2 CTC 
chimera, in which the EGFR-ERBB2 boundary is located just C-terminal of the EGFR CBL 
binding site. Based on those studies we concluded that the poor downregulation is largely 
due to the absence of EGFR sequences or the presence of ERBB2 sequences C-terminal to 
the ERBB2 CBL-binding site (chapter 4). Since downregulation of the EGFR-ERBB2 CTC 
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are required in the formation of distinct linkage-specific polyubiquitin chains. In the third 
model, distinct E2 enzymes cooperate with CBL proteins to mediate ubiquitin chain 
initiation versus (linkage specific) ubiquitin chain elongation. These models will be 
described and discussed in more detail in the following sections. 
4.1 Distinct CBL proteins in ERBB ubiquitination
With respect to the first model, it is known from overexpression studies that C-CBL, CBLB 
and CBLC can support ligand-induced EGFR ubiquitination (19-21, 29, 30), indicating that 
different CBL proteins are able to support the ubiquitination of EGFR. In addition, several 
groups have used mouse embryonic fibroblast cells obtained from CBL gene knock-out 
mice or RNA interference analysis to investigate whether, in particular, C-CBL and/or CBLB 
are required for EGFR ubiquitination. Duan et al. used C-CBL deficient mouse embryonic 
fibroblast cell lines that simultaneously expressed reduced amounts of CBLB and very little 
CBLC to show that that the impaired ligand-induced ERBB receptor ubiquitination could 
be restored by human C-CBL expression (25). However, two other reports showed that 
only efficient knock-down of both C-CBL and CBLB resulted in substantial inhibition of 
EGFR ubiquitination (31, 32). Similarly, using RNA interference techniques Pennock et al 
reported that cells with >90% downregulation of either C-CBL or CBLB retained substantial 
EGF-induced EGFR ubiquitination, although with altered kinetics (33). Overall, these 
findings indicate that C-CBL and CBLB act redundantly in terms of EGF-induced EGFR 
ubiquitination and EGFR downregulation. Whether C-CBL and CBLB have distinct roles in 
ubiquitination and degradation of ERBB2 and ERBB4 has not (yet) been investigated. For 
ERBB2, only C-CBL has been shown to support ERBB2 receptor ubiquitination (18, 23, 24), 
but no data are available on a possible functional interaction between ERBB2 and CBLB or 
CBLC. Similarly, the involvement of any CBL protein in mediating ERBB4 ubiquitination and 
degradation has not been investigated yet. Thus, additional overexpression and/or 
knock-out/knock down studies are required to determine whether distinct CBL proteins 
are required for the ligand-induced ubiquitination and degradation of - in particular - 
ERBB2 and ERBB4. In summary, there is currently no clear evidence to support the model 
that distinct CBL proteins direct the ubiquitination of distinct ERBB receptors.
4.2 CBL proteins in linkage-specific ubiquitination
The second model postulates that distinct CBL proteins are required for the formation of 
distinct linkage-specific polyubiquitin chains. In general, CBL proteins have thus far been 
implicated in the formation of mono/multi-ubiquitin (34, 35), K33 polyubiquitin chains 
(36), K48 poly-ubiquitin chains (37, 38)(this thesis), and K63 poly-ubiquitin chains (31)(this 
thesis) of various receptor tyrosine kinases in intact cells. Initial reports using specific 
antibodies recognizing mono- versus total ubiquitination and/or ubiquitin mutants 
deficient in polyubiquitination suggested that the EGFR is only monoubiquitinated (34, 
35). However, Huang et al. demonstrated by Mass Spectrometry (MS) analysis that the 
receptors, our results do not rule out the possibility that CBLB and CBLC are tyrosine 
phosphorylated and recruited to the activated chimeric receptors as well. Moreover, 
although we demonstrated that the ERBB2- and ERBB4- CBL binding sites are required for 
ligand-induced poly-ubiquitination, our results do not allow us to determine which CBL 
protein is responsible for ligand-induced (poly-)ubiquitination of these chimeric ERBB2 
and ERBB4 receptors. In order to draw such conclusions, our studies need to be repeated 
in cells from CBL knock-out animals or CBL knock-down cell lines (25), or by overexpressing 
wild-type or dominant-negative CBL proteins.
 We demonstrated that mutation of the consensus CBL binding site in the EGFR does 
not significantly affect C-CBL tyrosine phosphorylation (chapter 3). We obtained similar 
results for C-CBL tyrosine phosphorylation following activation of chimeric EGFR-ERBB2 
and EGFR-ERBB4 receptors (chapter 3 and 5). This observation can probably be explained 
by the multivalent interaction of CBL proteins with EGFR and, most likely, ERBB2 and ERBB4 
receptors as well. For instance, besides the interaction of the CBL TKB domain with the 
phosphorylated CBL consensus binding site motif, C-CBL and CBLB proteins also interact 
by means of their proline-rich domain with the SH3 domain of GRB2, which is known to 
associate with the activated and tyrosine-phosphorylated EGFR, ERBB2 and ERBB4 via its 
SH2 domains. Although the functional significance of the CBL-GRB2 interaction for 
recruitment to the EGFR has been previously documented (26-28), similar studies have not 
yet been performed for ERBB2 and ERBB4. In addition, C-CBL and CBLB proteins are also 
known to associate with many other proteins that might provide multivalent interaction 
with ERBB receptors including SRC-family kinases, PLCγ1 and many more (17). Variation in 
the affinity, multivalency and steady state kinetics of CBL protein interaction with various 
ERBB receptors may provide the mechanism why the steady state interaction of CBL 
proteins with ERBB2 and ERBB4 receptors is decreased relative to EGFR, as has been 
proposed previously (11).
4. CBL-mediated ubiquitination of ERBB receptors
Using poly-ubiquitin specific mAbs, we demonstrated that the CBL binding site in EGFR 
and ERBB2 is required for K63-polyubiquitination (chapter 3), while the CBL binding site in 
ERBB4 is required for K48-polyubiquitination (chapter 5). Although our findings implicate 
the involvement of the CBL binding site in EGFR, ERBB2 and ERBB4 in the formation of 
K63-linked and K48-linked polyubiquitin chains, various models can be proposed to 
explain the role of CBL proteins in ERBB receptor mono- and poly-ubiquitination. In this 
context it is important to note that mono-ubiquitination is a prerequisite for subsequent 
poly-ubiquitination. In the first model, distinct CBL proteins are involved in (poly-)
ubiquitination of different ERBB receptors or, alternatively, a single CBL protein might have 
various functions in different ERBB receptors. In the second model, different CBL proteins 
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dimerization of C-CBL is required for optimal interaction with substrate proteins, optimal 
C-CBL tyrosine phosphorylation and optimal substrate ubiquitination (43). The functional 
significance of ubiquitin recognition by the CBLB UBA domain remains to be determined. 
We suggest that it is possible that the CBL UBA domains are involved in (i) substrate 
selection, (ii) regulation of mono- or linkage specific poly-ubiquitination, (iii) subcellular 
localization, or (iv) other regulatory protein-protein interactions. In summary, no data are 
available yet that confirm the model that distinct CBL proteins are responsible for the 
generation of linkage-specific poly-ubiquitin chains. Thus, additional overexpression and/
or knock-out/knock down studies are required to determine whether distinct CBL proteins 
are responsible for the generation of linkage-specific poly-ubiquitin chains. 
4.3 Interaction of CBL proteins with E2 enzymes
The formation of linkage-specific poly-ubiquitin chains that are associated with ERBB 
receptors may also, at least in part, be determined by E2 enzymes that associate with the 
E3 ligases involved in ERBB receptor ubiquitination. Thus, distinct CBL proteins may 
associate with different E2s to stimulate the formation of various types of ERBB receptor 
ubiquitination. This would lead to a model similar to the one described in the previous 
paragraph. However, each CBL protein may also interact with multiple distinct E2 enzymes 
during different stages of ERBB receptor ubiquitination. Indeed, binding of C-CBL to 
various E2 enzymes has been described (48). Initial reports described interaction of C-CBL 
with UbcH7 (UBE2L3) (30, 48, 49). However, others have used Ubc4 in an in vitro 
ubiquitination assay to identify the E3 ligase activity of C-CBL (29). Furthermore, in vitro 
ubiquitination of EGFR can be mediated by both UbcH5B and UbcH5C (19). In addition, the 
RING finger of C-CBL has been shown to interact with Ubc4/5 (UBE2D) family proteins 
(Ubc4, UbcH5B and UbcH5C) and to colocalize with these proteins in the plasma 
membrane and in the endosomes (48, 50). The amino acid residues in UbcH7 that contact 
the RING domain of C-CBL are conserved in Ubc4/5 (49, 50), which makes it likely that 
C-CBL can interact with both UbcH7 and Ubc4/5. 
 As explained above, CBL might function together with different initiating and 
elongating E2 enzymes. Indeed, the UBE2D family of E2s are the smallest E2 proteins, 
containing only the UBC core, and are able to cooperate with multiple E3s to initiate 
ubiquitin chain formation in a diverse set of substrates. These E2s do not confer linkage 
specificity and mediate ubiquitin chain formation of all linkages in vitro (51). Since UBE2D 
has been described as an E2 which in concert with CBL is able to induce EGFR ubiquitination 
(29, 48, 50), it is possible that UBE2D is the initiator of ubiquitin chain formation and another 
E2 enzyme is required for chain elongation leading to K48- or K63-polyubiquitination. 
Indeed, UBE2D has been described as a chain initiator in both K48- and K63-polyubiquiti-
nation (37, 52-54). However, no specific elongating E2s have been described so far for 
CBL-mediated ubiquitination. Several E2 enzymes with chain elongation activity have 
been described to display specificity for K48- or K63-polyubiquitination. These E2 enzymes 
EGFR is also efficiently K63-polyubiquitinated and identified six ubiquitin-modified lysine 
residues within the kinase domain of the EGFR (31). Mutation of single lysines did not alter 
the ubiquitination status of EGFR, but mutation of in total 15 lysine residues resulted in a 
substantial decrease, but not complete abolishment, of EGFR ubiquitination, demonstrating 
that multiple lysine residues in EGFR are modified by ubiquitin (31, 39). Furthermore, MS 
analysis revealed that 50% of the ubiquitin attached to the EGFR was in the form of mo-
no-ubiquitination, 40% consisted of K63-poly-ubiquitin chains, while only 7% of total 
ubiquitin attached to the EGFR was in the form of K48-poly-ubiquitin chains. However, the 
exact location of the various forms of polyubiquitin chains within EGFR have not been 
determined yet (31). Moreover, so far it remains unclear which type of linkages results from 
CBL-mediated ubiquitination. Using poly-ubiquitin specific mAbs, we demonstrated that 
the CBL binding site in EGFR and ERBB2 is required for K63-polyubiquitination (chapter 3), 
while the CBL binding site in ERBB4 is required for K48-polyubiquitination (chapter 5). 
However, these results do not allow us to determine whether the CBL binding site is 
required for mono/multi-ubiquitination, polyubiquitination, or both. Moreover, mutation 
of the CBL binding site results in disruption of binding of all CBL proteins, and therefore it 
is not known which CBL protein is involved in the formation of the K48- or K63-polyubiq-
uitin chains. Together with the NEDD4 family member ITCH, CBLB has recently also been 
implicated in the formation of K33-linked polyubiquitin chains attached to the T-cell 
receptor ζ-chain (36). It should be noted, however, that the contribution of individual ITCH 
and CBLB proteins in TCRζ K33 poly-ubiquitin chain formation has not been investigated. 
Therefore, it remains uncertain whether CBLB is involved in either mono-ubiquitination 
(i.e. initiation) or in the formation of K33-linked poly-ubiquitin chains (i.e. elongation), or in 
both. 
 If C-CBL, CBLB and CBLC mediate the formation of distinct linkage-specific 
poly-ubiquitin chains, this is most likely due to structural differences between the CBL 
proteins. Such differences include the presence (C-CBL and CBLB) or absence (CBLC) of an 
ubiquitin associated (UBA) domain at the C-terminal end (40). The CBL UBA domains are 
known to be involved in C-CBL/CBLB homo- and hetero-dimerization (41, 42). Additional 
structural and functional analysis of the C-CBL and CBLB UBA domains has confirmed that 
the CBL UBA domain is required for CBL homo- and hetero-dimerization, optimal CBL 
tyrosine phosphorylation as well as optimal CBL-mediated substrate ubiquitination (43, 
44). The UBA domain is not required for the E3 ligase activity of C-CBL or CBLB, but deletion 
of the UBA domain disrupts CBL dimerization and (thereby) reduces CBL tyrosine phos-
phorylation in response to EGFR activation and association with activated EGFR (41). 
However, deletion of the UBA domain of either C-CBL or CBLB did not significantly affect 
EGFR downregulation or degradation (45, 46). Interestingly, the UBA domain of CBLB but 
not C-CBL shows increased affinity for free polyubiquitin chains (either K29-, K48- or K63-) 
over monoubiquitin in vitro (47), while the C-CBL UBA domain coprecipitates with 
ubiquitinated proteins in vivo (46). Overall, it seems that the CBL UBA domain-mediated 
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impaired ligand-induced downregulation compared to EGFR (1, 2). In this thesis, we 
demonstrated that ERBB2 and ERBB4 are linked to DUB enzymes in the MVB pathway, 
albeit to a lesser extent than EGFR. Our results show that the CYT-1 isoform of ERBB4 is 
both K48- and K63-polyubiquitinated, which suggests that CYT-1 is targeted towards both 
the proteasomal and lysosomal degradation pathways, while the CYT-2 isoform is primarily 
degraded by the proteasome. This hypothesis is in line with previous studies demonstrating 
that CYT-1 undergoes both lysosomal and proteasomal degradation (60-62), while 
inhibition of the proteasomal degradation pathway showed increased CYT-2 levels, 
suggesting that the proteasomal pathway is the main degradation pathway for CYT-2 (60). 
 It is currently unclear why multiple pathways are involved in degradation of ERBB4, 
but this may relate to the existence of four alternatively spliced isoforms of this receptor, 
JMa, JMb, CYT-1 and CYT-2. Following ligand-induced activation of ERBB4, JM-a is cleaved 
at the extracellular juxtamembrane domain by TACE, resulting in a truncated membrane 
bound m80 receptor (63). Subsequently, this truncated receptor undergoes intramembrane 
proteolysis by γ-secretase, resulting in a soluble intracellular domain designated s80 (64, 
65). The CYT-2 m80 receptor then becomes ubiquitinated and is far more susceptible to 
proteasomal degradation than full-length ERBB4 (66). Furthermore, following cleavage at 
the JM site, CYT-2 has been shown to translocate more efficiently to the nucleus than 
CYT-1 (62, 66, 67). Enhanced nuclear location of ERBB4 can also be obtained by the Y1056A 
mutation, which results in inhibition of both the PI3 kinase and WW domain-binding 
motifs, and has been shown to result in enhanced ERBB4 nuclear translocation (61). In 
combination with our finding that CYT-2 is more efficiently K48-polyubiquitinated than 
CYT-2 are, this raises the interesting possibility that ligand-induced CBL-mediated 
K48-polyubiquitination of ERBB4 directs the JM-cleaved nuclear CYT-1 and CYT-2 isoforms 
towards the proteasomal degradation pathway, while the full-length non-cleaved and 
non-translocated K63-polyubiquitinated receptors are directed towards the lysosomal 
degradation pathway.
 The reason why ERBB4 regulation differs from that of EGFR and ERBB2 remains a topic 
for further research. Additional overexpression and/or knock-out/knock down studies in 
the various ERBB4 isoforms are required to determine what the functional significance is 
of CBL and ITCH mediated K48- and K63-polyubiquitination of distinct ERBB4 isoforms.
6. Involvement of HRS in ERBB degradation and recycling
In early endosomes the activated ligand-receptor complex is sorted to be recycled back 
to the cell surface or targeted for lysosomal degradation by incorporation into ILVs of 
MVBs (68). Lysosomal targeting is mediated by the ESCRT complexes. Ubiquitinated 
receptors are recognized by the UIM of HRS and STAM, which are both part of the ESCRT-0 
complex (69, 70). It has been shown that HRS preferentially binds to mono- and K63-ubiq-
interact with the ubiquitin that is attached to the substrate by the initiating E2 and 
mediate a specific polyubiquitin linkage, like UBE2K (HIP2) and UBE2G2 (UBC7) for 
K48-polyubiquitination (53). UBC13 (UBE2N) is an E2 specific for K63-polyubiquitin chain 
formation and acts in concert with UEV1A (UBE2V1) or MMS2 (UBE2V2), which both lack 
the active-site Cys residue (55). UBC13-UEV1A is involved in NF-kB activation, while 
UBC13-MMS2 is involved in DNA-damage responses (56). Notably, Duex et al., (57) reported 
that RNAi-mediated knock-down of UEV1B, a splice variant of UEV1 locus that is known to 
associate with UBC13 to direct the formation of K63-linked poly-ubiquitin chains, promotes 
EGFR degradation. Moreover, UEV1B overexpression inhibits EGFR degradation. In contrast, 
RNAi-mediated knock-down of UBC13 or MMS2 did not inhibit EGFR degradation (57). The 
authors suggested a model in which UEV1B mediated its effect by inhibition of HRS 
function rather than affecting the downregulation of the EGFR directly. However, they did 
not evaluate the presence of linkage-specific polyubiquitin chains on the EGFR in UBC13 
or UEV1B knock-down cells. Obviously, it will be very important to test the contribution of 
specific E2 enzymes in the formation of ligand-induced CBL binding site dependent 
mono- and/or linkage-specific polyubiquitin chains on various ERBB receptors. This can 
be investigated by using E2 knock-down/knock-out cell lines or overexpression of 
catalytically inactive E2  enzymes.
 In conclusion, the third model is a model whereby different E2s act in concert with a 
CBL protein and lead to K48- and K63-polyubiquitination in ERBB4 versus EGFR and ERBB2 
respectively. Based on the limited information currently available, UBE2D may be a 
ubiquitin chain initiator for EGFR substrate molecules, while the E2 elongator decides 
whether the chain will be extended towards K48- or K63-polyubiquitin chains. To test this 
hypothesis, an in vitro ubiquitination assay should be performed whereby distinct E2 
enzymes are added. Alternatively or additionally, distinct E2 enzymes can be 
downregulated or upregulated in a heterologous expression system followed by 
evaluation of linkage-specific EGFR ubiquitination using mass spectrometry or mAbs that 
recognize linkage specific.polyubiquitin chains. 
5. K48- and K63-polyubiquitination of ERBB4 
Whereas K48-linked poly-ubiquitination serves as a signal for proteasomal degradation 
(58), K63-linked poly-ubiquitination has been shown to regulate non-proteosomal 
processes such as DNA repair, kinase activation, translational regulation and endosomal 
sorting (59). Our results demonstrate that EGFR and ERBB2 are efficiently K63-polyubiquitu-
inated by CBL (chapter 3), while ERBB4 is K48-polyubiquitinated by CBL and K63-polyubiq-
uitinated by ITCH (chapter 5). These findings raise the question why  the various ERBB 
receptors behave in a different manner. Stimulation of EGFR leads to efficient 
downregulation and lysosomal degradation, whereas ERBB2, ERBB3 and ERBB4 show 
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of HRS with activated EGFR-ERBB4, it is possible that SRC family kinases are not activated 
upon EGFR-ERBB4 activation. However, it is also possible that a small fraction of HRS is not 
detectably phosphorylated for the part of ERBB4 that is targeted towards the lysosome, as 
suggested above for ERBB2. HRS preferably binds to K63-polyubiquitined chains and 
therefore SRC family kinases may only be activated to phosphorylate HRS in the presence 
of CBL-mediated K63-polyubiquitination. Indeed, expression of a dominant-negative form 
of CBL inhibits EGF-dependent HRS phosphorylation (77) and overexpression of CBL 
increases HRS phosphorylation (72). Moreover, a CBL binding site mutant of the MET 
receptor tyrosine kinase was unable to induce HRS tyrosine phosphorylation, whereas the 
wild-type receptor did (78). Thus, CBL-mediated K63 polyubiquitination of ERBB receptors 
may facilitate interaction of these receptors with the ESCRT-0 complex, thereby facilitating 
SRC family kinase-mediated HRS tyrosine phosphorylation. Importantly, CBL-mediated 
K63 polyubiquitination of ERBB receptors may not be enough for efficient interaction with 
the ESCRT-0 complex as ERBB2 is efficiently K63 poly-ubiquitinated but does not results in 
efficient HRS tyrosine phosphorylation. Similarly, even though TGFa stimulated EGFR 
shows substantial K63 poly-ubiquitination (chapter 4), this may not be enough to result in 
substantial SRC-kinase mediated HRS tyrosine phosphorylation. This model may also 
explain the finding that CBL-mediated K48-polyubiquitination of EGFR-ERBB4 receptor 
does not result in detectable HRS tyrosine phosphorylation. 
 Additional research must be performed to determine whether HRS is functionally 
involved in the ERBB2 and ERBB4 downregulation and the recycling pathway. Over- 
expression and/or knock down studies, as well as studies involving mutation of the 
tyrosine phosphorylation sites of HRS should be performed to determine the functional 
role of HRS in ERBB2 and ERBB4 downregulation and recycling. 
7. Deubiquitination by USP8 and AMSH
Before incorporation of the activated EGFR complex in ILVs of MVBs, the attached ubiquitin 
is removed by deubiquitination (DUB) enzymes (79). It has been established that the deun-
biquitination enzymes USP8 and AMSH are able to deubiquitinate EGFR (80-85). USP8 
removes both K48- and K63-polyubiquitin chains, while AMSH is specific for K63-linked 
polyubiquitin. Both AMSH and USP8 interact with ESCRT-0 and ESCRT-III proteins within 
the MVB downregulation pathway (83, 85-87).   Our results show that AMSH and USP8 are 
responsible for EGFR deubiquitination following EGF stimulation (chapter 3 and 4). Given 
the observation that that ERBB2 and ERBB4 become K63-polyubiquitinated, we were 
surprised to find that AMSH does not detectably remove ubiquitin from ligand-stimulated 
ERBB2 and ERBB4 chimeras, even though ERBB2 and ERBB4 are deubiquitinated by USP8 
(chapter 4 and 5). It is interesting to note that AMSH has been proposed to deubiquitinate 
cargo proteins at an early stage of the endosomal sorting process thereby promoting 
uitinated EGFR (50, 69, 71) and we have confirmed by the use of K63-polyubiquitin specific 
mAbs that EGFR is K63-polyubiquitinated (chapter 3). Our finding that EGF-induced 
activation of EGFR results in HRS tyrosine phosphorylation is consistent with previous 
findings that HRS is phosphorylated on tyrosine residues 329 and 334 by SRC family 
kinases following EGF stimulation (69). Mutation of these phosphorylation sites resulted in 
suppressed EGFR degradation (69, 72, 73), suggesting that HRS tyrosine phosphorylation 
is required for efficient lysosomal targeting of EGFR. Although our results show that 
EGFR-ERBB2 and EGFR-ERBB4 chimeras are K63-polyubiquitinated as well, we hardly 
detected HRS tyrosine phosphorylation upon ligand binding to these receptors (chapter 
4 and 5). These findings suggest that ERBB2 and ERBB4 do not detectably support 
(SRC-family kinase-mediated) HRS tyrosine phosphorylation.  
 Since HRS phosphorylation upon EGF activation of EGFR is mediated by SRC, this 
raises the possibility that SRC is not activated upon activation of ERBB2 and ERBB4. It has 
previously been shown, however, that SRC family kinases are also activated upon ligand 
binding to EGFR-ERBB2 chimeric receptors (74, 75). Thus, ERBB2 receptor-mediated 
SRC-family kinase activation may not be sufficient to direct HRS tyrosine phosphorylation, 
in spite of the presence of significant amounts of K63 poly-ubiquitin modified ERBB2. We 
further found that EGFR-ERBB2 is less efficiently downregulated and more efficiently 
recycled than EGFR (Chapter 4). Our observation that, TGFα-induced recycling of  EGFR is 
also associated with failure to direct HRS tyrosine phosphorylation, suggests that recycling 
receptors do not efficiently interact with HRS and therefore show impaired HRS tyrosine 
phosphorylation. Thus, TGFα-stimulated EGFR and EGF stimulated EGFR-ERBB2 chimeras 
may be directed towards the recycling compartment before receptor-activated SRC-family 
kinases may interact with and phosphorylate HRS. It is unclear so far how exactly the 
mechanism of recycling is regulated and if HRS plays a role in this process. In this context 
it is noteworthy that recycling transferrin receptors also fail to colocalize with HRS (70). 
Furthermore, a recent study demonstrated that a non-ubiquitinated EGFR mutant in 
which 15 lysines are mutated (15KR), is efficiently recycled to the plasma membrane and is 
unable to interact with HRS and to stimulate HRS tyrosine phosphorylation. The EGFR 
15KR mutant receptor appeared to recycle to the plasmamembrane via the same pathway 
as the transferrin receptors (76). Since, HRS is essential for lysosomal targeting of activated 
receptors (72), a small portion of phosphorylated HRS may be involved in targeting a small 
fraction of ERBB2 receptors to the lysosome. It should also be noted that we cannot rule 
out the possibility that a small portion of HRS is undetectably phosphorylated. Possibly, 
only the fraction of ERBB2 that will be downregulated via the MVB pathway is recognized 
by HRS. Nevertheless, our findings are consistent with the model that HRS sorts 
ubiquitinated receptors towards the MVB lysosomal targeting pathway thereby preventing 
the recycling to the cell surface. 
 Activation of SRC family kinase has been described for EGFR and ERBB2 (74, 75), but not 
for ERBB4. Because we did not detect any HRS tyrosine phosphorylation or coprecipitation 
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absence of ligand. The existence of a constitutive ERBB receptor ubiquitination pathway 
that can only be revealed in the presence of catalytically inactive USP8 enzymes is 
consistent with the finding that ERBB receptors cycle constitutively, although slowly, 
through endosomal compartments (88).
 In contrast to previous reports which demonstrate that USP8 is involved in removing 
K48- and K63 polyubiquitin linkages, we suggest that USP8 is also involved in removing 
the low MW ubiquitination signal of EGFR, ERBB2 and ERBB4. We hypothesise that this 
lower signal represents the mono- and oligo-ubiquitination signals. This agrees with 
previous suggestions that USP8 may disassemble mono- and oligo-ubiquitin chains, in 
addition to K63- and K48-linked chains (81, 82). However, the role of USP8 in removal of 
monoubiquitin adducts has not yet been confirmed experimentally, neither in vitro nor in 
vivo.
 The above results indicate that both AMSH and USP8 might be involved in removing 
ubiquitin from receptors that are targeted towards the lysosomal pathway. AMSH might 
remove the K63-polyubiquitin signal from the EGFR while USP8 might remove the mono- 
and oligo-ubiquitin signals from ERBB receptors. We further hypothesize that other DUBs 
will be involved in deubiquitination of ERBB2 and ERBB4 during recycling and/or lysosomal 
targeting, since neither USP8 nor AMSH appears to be responsible for efficient removal of 
K48- and/or K63-polyubiquitin chains from ERBB2 and ERBB4. Interestingly, two other deu-
biquitination enzymes, USP2a and Cezanne-1, appear also to be involved in deubiquitina-
tion of EGFR (89, 90). Indeed, USP2a localizes to early endosomes and associates with EGFR, 
while Cezanne-1 interacts with EGFR although its localization has not been investigated 
so far (89, 90). These enzymes may act in concert with or may have overlapping functions 
with AMSH and USP8, since Usp2a and Cezanne-1 both cleave K48- as well as K63-poly-
ubiquitin linkages (89, 91). It remains to be investigated if these two enzymes may also 
have deubiquitination activity towards the other ERBB receptors. In addition, a number of 
other deubiquitinating enzymes have been implicated in deubiquitination of plasma 
membrane receptors during their recycling process, including USP20 and USP33 for the 
b2-adrenergic receptor (92), USP10 for the CFTR (93), UCH-L3 for the Epithelial Na Channel 
(94), and DUB2A for the CSF3 receptor (95). Thus, a variety of DUB enzymes has been 
implicated in deubiquitination of plasmamembrane receptors during endosomal 
recycling, suggesting that separate DUBs are involved in deubiquitination of distinct 
cargo during lysosomal targeting versus recycling pathways. 
 In conclusion, we propose a model whereby AMSH is responsible for removing 
K63-polyubiquitin from EGFR within the MVB downregulation pathway, while USP8 is 
responsible for removing mono/oligo-ubiquitin adducts from EGFR, ERBB2 and ERBB4 
during the MVB downregulation pathway. Other deubiquitination enzymes may also 
participate in the removal of K48- and K63-polyubiquitin chains from ERBB receptors 
during recycling and/or lysosomal targeting (figure 1). 
recycling of receptors, while USP8 activity has been suggested to be essential for effective 
lysosomal targeting (83). The model that AMSH promotes recycling has been based on 
the observation that AMSH interacts with both clathrin and the ESCRT-0 component 
STAM. Moreover, siRNA knockdown of AMSH results in an enhanced degradation rate of 
stimulated EGFR as well as internalized receptor-bound EGF. The model that USP8 is 
essential for effective lysosomal targeting is based on the finding that USP8 translocates 
to endosomes following EGF stimulation and that multiple components of the MVB 
sorting pathway are targets of USP8 (83). However, direct experimental evidence for the 
hypothesis that AMSH promotes recycling of receptors is lacking so far. Our results do not 
support a model in which AMSH is involved in deubiquitination of recycling ERBB 
receptors. Indeed, our data show that AMSH does not detectably deubiquitinate recycling 
EGFR, ERBB2 and ERBB4 receptors (chapter 4 and 5). Therefore, our findings better support 
a model in which AMSH is responsible for removing K63-polyubiquitin from ERBB receptor 
after the lysosomal targeting event has taken place. To further support this model, AMSH 
knockdown experiments might give more information on ERBB recycling and/or 
downregulation in routing assays.  
 As stated above, it has been suggested that USP8 activity is essential for effective 
lysosomal targeting (83). Indeed, USP8 interacts with components of both the ESCRT-0 
and ESCRT-III complexes and our data show that USP8 is able to deubiquitinate EGFR, 
ERBB2 and ERBB4 (chapter 3 and 5). Our finding that USP8 is less active in deubiquitinating 
ERBB2 and ERBB4 than EGFR suggests that targeting of ERBB2 and ERBB4 into the MVB 
pathway is less efficient than observed for EGFR. It is possible that only the fraction of ERBB 
receptors that is destined to be sorted into ILVs of MVBs associates with USP8. Additionally, 
USP8 might also play a role in removal of ubiquitin from recycling receptors. ERBB2 and 
ERBB4 are less efficiently downregulated than EGFR, but all these receptors are deubiquiti-
nated by USP8, raising the possibility that USP8 plays a role in the recycling process. 
Although our data do not directly confirm this hypothesis, we can also not rule out this 
possibility at this moment. Additional knockdown studies of USP8 in combination with 
recycling and downregulation assays must be performed to identify the exact role(s) of 
USP8 in ERBB trafficking. 
 The observation that USP8 deubiquitinates ERBB receptors both in the presence and 
absence of ligand indicates that EGFR, EGFR-ERBB2 and EGFR-ERBB4 are constitutively 
ubiquitinated and deubiquitinated. This supports the hypothesis that ERBB receptor 
ubiquitination is the net result of E3 ligase-mediated ubiquitination and DUB-mediated 
deubiquitination (50). Moreover, CBL binding site mutants of EGFR (Y1045F) and 
EGFR-ERBB2 (Y1091F) are also deubiquitinated by USP8 either in the presence or absence 
of EGF stimulation. We therefore propose that USP8 is not solely counteracting 
CBL-mediated ubiquitination but also counteracts ligand- and CBL binding site-independ-
ent ERBB receptor ubiquitination. This model proposes that additional yet unidentified E3 
ligases may be involved in mediating constitutive ERBB receptor ubiquitination in the 
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8. Post-translational modifications of USP8
An interesting finding is our observation that USP8 is post-translationally modified upon 
stimulation of ERBB receptors (chapter 6). We find that USP8 is tyrosine phosphorylated 
upon EGF-induced activation of EGFR, ERBB2 and ERBB4, while in addition USP8 is serine 
phosphorylated upon activation of EGFR. Furthermore, threonine phosphorylation of 
USP8 upon ligand-induced activation of ERBB3 has been shown before in an earlier study 
(96). We hypothesize that  posttranslational modification of deubiquitination enzymes 
may affect the functional activity of these enzymes. Indeed, Akt-dependent T907 phos-
phorylation of USP8 occurs in response to neuregulin-stimulation. T907 phosphorylation 
contributes to the stabilization of USP8 protein levels, suggesting a role for Akt in the 
regulation of USP8 function (96). It should be noted that we did not detect any USP8 
threonine phosphorylation in MS analysis following EGFR stimulation (chapter 6). It should 
be investigated if this results from the different model system used, as Cao et al. used 
neuregulin-stimulated ERBB3 receptors (96). 
 Furthermore, serine phosphorylation of USP8 upon EGF stimulation of EGFR was 
confirmed by our MS analysis (chapter 6). Four serine phosphorylation sites were detected 
(i.e. S153, S392, S680, S722), of which only S680 has been studied before. Phosphorylation 
of USP8 S680 facilitaties the binding of 14-3-3 proteins (97-101). During the M-phase of the 
cell cycle, S680 of USP8 becomes dephosphorylated, resulting in dissociation of 14-3-3 
and enhanced USP8 function activity during cell division (98). The role of the other serine 
phosphorylation sites of USP8 has not been investigated so far. Possibly they also have an 
important function in USP8 deubiquitination activity, stability, regulation or localization. 
Overall, these findings demonstrate that USP8 is post-translationally modified by tyrosine, 
serine and threonine phosphorylation, but the exact regulation and function of these 
modifications remain currently unclear. 
9. Concluding remarks and future directions
The aim of this thesis was to unravel the ubiquitination and deubiquitination of the ERBB 
receptors, in particular ERBB2 and ERBB4. Although we attempt to clarify the mechanisms 
whereby ERBB receptors become ubiquitinated and deubiquitinated, still a lot of questions 
remain. Our results indicate that EGFR, ERBB2 and ERBB4 become ubiquitinated in either 
the presence or absence of ligand. Furthermore, we show that EGFR and ERBB2 are 
K63-polyubiquitinated by CBL, while ERBB4 is K48-polyubiquitinated by CBL and K63-poly-
ubiquitinated by ITCH (figure 1). The molecular mechanisms underlying the difference 
between CBL-mediated K48- and K63-polyubiquitination is subject for further studies. It 
will be very important to unravel the E2’s and other E3 ligases that are involved in ERBB 
ubiquitination, since this will lead to a better understanding of the mechanisms underlying 
Figure 1   Schematic hypothetical model summarizing the role of various E3 ligases  
and DUB enzymes in EGFR (A), EGFR-ERBB2 (B) and EGFR-ERBB4 (C) lysosomal 
degradation. 
Thickness of the arrows indicate the relative amount of activated receptors in recycling versus 
lysosomal degradation. D, table summarizing the results described in this thesis. The blank cells 
represent the yet undiscoverd enzymes responsible for this (de)ubiquitination.
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Summary
The ERBB receptors are critical regulators of normal development, but are also frequently 
involved in the formation of solid tumors, which result from enhanced, prolonged or li-
gand-independent ERBB signaling. Attenuation of ERBB receptor signaling is mediated by 
the clathrin-dependent pathway of receptor-mediated endocytosis and subsequent 
sorting of the activated ligand-receptor complex via the MVB pathway to lysosomes for 
degradation. It has been demonstrated that the EGFR is more efficiently downregulated 
than the other ERBB receptors, which in turn display enhanced recycling compared to the 
EGFR. Accumulating evidence suggests that endosomal trafficking and lysosomal 
targeting are mediated in part by ERBB receptor ubiquitination. The concerted action of 
E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin 
ligases is responsible for the attachment of ubiquitin to activated ERBB receptors. Most 
studies have been performed on the EGFR, for which ligand-induced ubiquitination by 
the E3 ligase Cbl is suggested to play an important role in ligand-induced EGFR internal-
ization and lysosomal targeting. Knowledge about the ubiquitination and deubiquitina-
tion of the ERBB receptors may help us to elucidate more information about the ERBB 
downregulation pathway. 
 The work described in this thesis was aimed to unravel the ubiquitination and deu-
biquitination of the ERBB receptors. Since already a lot is known about the EGFR, we 
focused in particular on ERBB2 and ERBB4. To allow a direct comparison between the 
receptors, we used chimeric receptors containing the extracellular and transmembrane 
domain of the EGFR and the cytoplasmic tail of ERBB2 or ERBB4. Our data confirmed that 
in comparison with EGFR the EGFR-ERBB2 chimeric receptor shows decreased receptor 
downregulation, as well as decreased EGF degradation and enhanced recycling (chapter 
4). We further demonstrated that the EGFR-ERBB4 CYT-2 chimera shows decreased 
ligand-induced downregulation and EGF degradation, as well as enhanced EGF recycling, 
when compared to EGFR-ERBB4 CYT-1 (chapter 5). It has been suggested that poor 
downregulation of ERBB2 and ERBB4 compared to the EGFR is due to decreased 
recruitment of Cbl. Our data show that replacement of the EGFR Cbl binding site by that 
of ERBB2 or ERBB4 does not affect Cbl recruitment, receptor-ubiquitination, -degradation, 
-downregulation or ligand degradation (chapter 2), indicating that poor downregulation 
of ERBB2 and ERBB4 is not due to sequence variations in the CBL binding site of these 
receptors. 
 We further investigated the function of the naturally occurring CBL binding sites in 
EGFR, ERBB2 and ERBB4. We demonstrated that the EGFR is K63-polyubiquitinated by CBL. 
In addition, we showed that the CBL binding site in ERBB2 is functionally active in the 
context of a chimeric EGFR-ERBB2 receptor and that stimulation of this receptor by EGF 
leads to efficient CBL recruitment, CBL tyrosine phosphorylation and CBL binding 
site-dependent K63-poly-ubiquitination (chapter 3). We further demonstrated that the 
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manner (chapter 6). Our findings demonstrate that USP8 is a target for the post-transla-
tional serine and tyrosine phosphorylation, most likely characterized by low abundant 
tyrosine phosphorylation on multiple residues, and high abundant serine phosphoryla-
tion on a limited number of specific residues. Understanding the post-translational 
modifications of USP8 might give more insight in the regulatory mechanisms governing 
USP8-mediated deubiquitination.
Y1103 CBL binding site of ERBB4 is functionally active and leads to CBL recruitment and 
K48-poly-ubiquitination of CYT-1 and CYT-2, while the PPXY1056 ITCH binding site is 
responsible for K63-poly-ubiquitination of CYT-1 (chapter 5). However, the molecular 
mechanisms underlying the apparent discrepancy between K48- versus K63-polyubiquiti-
nation by CBL will require further studies. 
 We also investigated how endosomal trafficking of the EGFR, ERBB2 and ERBB4 is 
related to the level of tyrosine phosphorylation of the ESCRT-0 subunit HRS and deubiq-
uitination by the HRS-associated K63-specific DUB AMSH. We demonstrated that li-
gand-dependent recycling of EGFR, ERBB2 and ERBB4 is associated with impaired HRS 
tyrosine phosphorylation and decreased deubiquitination by AMSH (chapter 4 and 5). In 
the case of ERBB2, this enhanced recycling, impaired HRS tyrosine phosphorylation and 
decreased deubiquitination by AMSH of EGFR-ERBB2 chimeras is primarily due to the 
presence of ERBB2 sequences or the absence of EGFR sequences C-terminal to the CBL 
binding site (chapter 4). Our results support a model  whereby recycling receptors are not 
efficiently incorporated in the MVB pathway implying that the decision for recycling of 
receptors is made during an early stage of endosomal sorting and prior to interaction with 
the ESCRT-0 complex. 
 We also demonstrated that ligand-dependent recycling of EGFR and stimulation of 
ERBB2 and ERBB4 is associated with decreased deubiquitination by AMSH (chapter 4 and 
5). However, EGFR, ERBB2 and ERBB4 CYT-1 are deubiquitinated by the ESCRT-0 and 
ESCRT-III interacting DUB USP8 under both ligand-dependent and –independent 
conditions (chapter 3 and 5). Our results suggest that USP8 is involved in removing 
mono-ubiquitin from the receptors. Interestingly, ERBB receptors display constitutive in-
ternalization and recycling in the absence of ligand, but the E3 ligase that is responsible 
for the ubiquitination of ERBB receptor in the absence of ligand has not been identified 
yet. In conclusion, we propose a model whereby  AMSH is responsible for removing 
ligand-induced K63-polyubiquitin chains from EGFR upon entering the MVB lysosomal 
sorting pathway, while USP8 might be effective in removing mono/oligo-ubiquitin chains 
from EGFR, ERBB2 and ERBB4 under both ligand-dependent and –independent conditions 
upon entering the MVB lysosomal sorting pathway. Other deubiquitination enzymes may 
also participate in the removal of K48- and K63 polyubiquitin chains from ERBB receptors 
during recycling and/or lysosomal targeting.
 Finally, we investigated posttranslational modifications of USP8. We demonstrated 
that USP8 is efficiently tyrosine phosphorylated upon EGF stimulation of EGFR, ERBB2 and 
ERBB4 CYT-1 and we made an attempt to unravel the tyrosine phosphorylation sites in 
USP8. Mutation of a single tyrosine did not result in the detection of the phosphorylated 
residue, suggesting that multiple tyrosines become phosphorylated. Alternatively, only a 
small fraction of USP8 may become tyrosine phosphorylated. Our data show that USP8 is 
phosphorylated on multiple serines, including the S680 14-3-3 binding site, and we 
confirmed that USP8 binds to 14-3-3 proteins in a phosphorylated S680-dependent 
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De ERBB groeifactor-receptoren zijn belangrijke regulators van de normale ontwikkeling 
van weefsels en organen in de mens, maar zij zijn ook vaak betrokken bij de vorming van 
solide tumoren, als gevolg van verhoogde, langdurige of groeifactor-onafhankelijke  sig-
naaltransductie. Beëindiging van de ERBB receptor-signalering vindt plaats door middel 
van de clathrine-afhankelijke route van receptor-gemedieerde internalisatie (endocytose) 
gevolgd door sortering van het geactiveerde groeifactor-receptor complex via de MVB 
route naar de lysosomen waar beide worden afgebroken. Het is al eerder aangetoond dat 
de EGFR (ERBB1) efficiënter wordt geïnternaliseerd en afgebroken dan de andere ERBB 
receptoren (ERBB2-4), die op hun beurt na internalisatie beter recyclen naar het 
plasmamembraan. Er is steeds meer bewijs dat de endosomale routering en lysosomale 
afbraak worden bewerkstellingd door de aanhechting van ubiquitine eiwitten aan de 
ERBB receptoren (ubiquitinering). De samenwerking tussen E1 ubiquitine activerende 
enzymen, E2 ubiquitine conjugerende enzymen en E3 ubiquitine ligases is verantwoor-
delijk voor de uiteindelijke ERBB receptor ubiquitinering. De meeste studies zijn verricht 
aan de EGFR, waarbij is aangetoond dat groeifactor-geïnduceerde ubiquitinering door de 
E3 ligase CBL een belangrijke rol speelt in groeifactor-geïnduceerde internalisatie en 
lysosomale afbraak. Kennis over de ubiquitinering en deubiquitinering van the ERBB 
receptoren kunnen bijdragen aan meer duidelijkheid over de regulatie van de ERBB 
internalisatie en afbraakroute. 
 Het werk dat in deze thesis wordt beschreven, had als doel meer duidelijkheid te 
verkrijgen over de ubiquitinering en deubiquitinering van de ERBB receptoren. Omdat 
eerdere studies voornamelijk waren gericht op EGFR (de-)ubiquitinering, hebben wij ons 
met name gefocust op (de-)ubiquitinering van ERBB2 en ERBB4 receptoren. Om een 
eerlijke vergelijking te kunnen maken tussen de verschillende ERBB receptoren, hebben 
wij gebruik gemaakt van chimere receptoren die de extracellulaire en transmembraan 
domeinen van de EGFR bevatten en de cytoplasmatische staart van ERBB2 en ERBB4. We 
konden op deze wijze eerder onderzoek bevestigen dat EGFR-ERBB2 een verlaagde 
receptor downregulatie en een verlaagde EGF afbraak en verhoogde EGF recycling laat 
zien, vergeleken met de EGFR (hoofdstuk 4). Verder tonen we aan dat EGFR-ERBB4 CYT-2 
chimera een verlaagde groeifactor-geinduceerde downregulatie en EGF-degradatie 
ondergaat, alsmede een verhoogde recycling vergeleken met EGFR-ERBB4 CYT-1 
(hoofdstuk 5). Eerder is al gesuggereerd dat de verminderde downregulatie van ERBB2 en 
ERBB4 vergeleken met de EGFR veroorzaakt wordt door verlaagde binding van CBL. In 
deze studie tonen wij aan aan dat vervanging van de EGFR CBL bindingsplaats door die 
van ERBB2 of ERBB4 geen effect heeft op CBL recruiting, receptor -ubiquitinering, 
-degradatie, -downregulatie of groeifactor-degradatie (hoofdstuk 2). Deze resultaten 
tonen aan dat de veminderde downregulatie van ERBB2 en ERBB4 mogelijk niet wordt 
veroorzaakt door sequentie-variaties in the CBL bindingsplaats van deze receptoren. 
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sorteringsroute. Andere deubiquitinerende enzymen zouden een rol kunnen spelen in 
het verwijderen van K48- en K63-polyubiquitine ketens van ERBB receptoren tijdens 
recycling en/of MVB sortering. 
 Ten slotte hebben wij de posttranslationele modificaties van USP8 onderzocht. Onze 
studies tonen aan dat USP8 efficiënt wordt gefosforyleerd op tyrosines na stimulatie door 
EGF van EGFR, ERBB2 en ERBB4 CYT-1. Wij hebben een poging ondernomen om 
duidelijkheid te krijgen over de specifieke tyrosine fosforyleringsplaatsen in USP8. Mutatie 
van een individuele kandidaat tyrosines leidde niet tot de identificatie van een specifiek 
tyrosine residue dat gefosforyleerd wordt, hetgeen suggereert dat meerdere tyrosines 
gefosforyleerd worden. Een alternatieve hypothese is dat maar een kleine fractie van de 
USP8 moleculen wordt gefosforyleerd op tyrosine. Wij tonen verder aan dat USP8 op 
meerdere serines gefosforyleerd is, waaronder de S680 14-3-3 bindingsplaats, en 
bevestigen dat USP8 aan 14-3-3 eiwitten bindt op een S680 fosfo-serine afhankelijke 
manier (hoofdstuk 6). Onze bevindingen laten zien dat USP8 een doelwit is van posttrans-
lationele serine en tyrosine fosforylering, resulterendin een laag niveau van tyrosine 
fosforylering op meerdere residuen en een hoog niveau van serine fosforylering op een 
gelimiteerd aantal specifieke residuen. Het begrijpen van de posttranslationele 
modificaties van USP8 kan meer inzicht geven in de regulatiemechanismen van USP8-
gemedieerde deubiquitinering. 
 Vervolgens hebben wij de functie van de natuurlijk voorkomende CBL bindingsplaats 
van de EGFR, ERBB2 en ERBB4 nader onderzocht. Wij tonen aan dat ubiquitinering van de 
EGFR met K63 poly-ubiquitine ketens afhankelijk is van de EGFR Y1045 CBL bindingsplaats. 
Verder laten wij zien dat de Y1091 CBL bindingsplaats van ERBB2 functioneel actief is in de 
context van de chimere EGFR-ERBB2 receptor. Stimulatie van deze receptor leidt tot 
efficiënte CBL binding, CBL tyrosine fosforylering en CBL bindingsplaats afhankelijke K63-
polyubiquitinering (hoofdstuk 3). Verder laten wij zien dat de Y1103 CBL bindingsplaats 
van ERBB4 functioneel actief is en leidt tot CBL binding en K48-polyubiquitinering van de 
ERBB4 splice varianten CYT-1 en CYT-2, terwijl de PPXY1056 ITCH E3 ligase bindingsplaats 
verantwoordelijk is voor K63-polyubiquitinering van ERBB4 CYT-1 (hoofdstuk 5). De 
moleculaire mechanismen die aan dit verschil tussen K48- en K63-polyubiquitinering 
door CBL ten grondslag liggen, zijn vooralsnog niet duidelijk en onderwerp voor verdere 
studies. 
 Wij hebben ook onderzocht hoe de endosomale route van de EGFR, ERBB2 en ERBB4 
gerelateerd is aan het niveau van tyrosine fosforylering van de ESCRT-0 subunit HRS en 
deubiquitinering door de HRS-geassocieerde K63-specifieke DUB AMSH. Wij laten zien dat 
groeifactor afhankelijke recycling van de EGFR, ERBB2 en ERBB4 geassocieerd is met sterk 
verlaagde of afwezige HRS tyrosine fosforylering en verlaagde deubiquitinering door 
AMSH (hoofdstuk 4 en 5). In het geval van ERBB2 wordt deze verhoogde recycling met 
name veroorzaakt door de aanwezigheid van ERBB2 sequenties of de afwezigheid van 
EGFR sequenties C-terminaal van de CBL bindingsplaats (hoofdstuk 4). Onze resultaten 
ondersteunen een model waarbij receptoren die gerecycled worden naar de 
plasmamembraan niet efficiënt in contact komen met eiwitten die functioneren binnen 
de MVB route. Deze resultaten suggereren dat de beslissing voor recycling van receptoren 
wordt gemaakt gedurende een vroeg stadium van endosomale sortering en dus voordat 
er interactie plaatsvindt met het ESCRT-0 complex. 
 Wij laten ook zien dat TGFa-afhankelijke recycling van de EGFR en EGF geïnduceerde 
stimulatie van EGFR-ERBB2 is geassocieerd met verlaagde deubiquitinering door AMSH 
ten opzichte van EGF gestimuleerde EGFR (hoofdstuk 4 en 5). EGFR, ERBB2 en ERBB4 CYT-1 
worden wel gedeubiquitineerd door de DUB USP8, die interacties aangaat met ESCRT-0 
en ESCRT-III, zowel onder groeifactor-afhankelijke als –onafhankelijke condities (hoofdstuk 
3 en 5). Onze resultaten suggereren dat USP8 betrokken is bij het verwijderen van mono-
ubiquitine van de receptoren. ERBB receptoren ondergaan continu internalisatie en 
recycling in de afwezigheid van groeifactor, maar de E3 ligase die verantwoordelijk is voor 
de ubiquitinering van ERBB receptoren in de afwezigheid van groeifactor is (nog) niet 
geïdentificeerd. Concluderend stellen wij een model voor waarbij AMSH verantwoordelijk 
is voor het verwijderen van groeifactor-geinduceerde K63-polyubiquitine ketens van 
EGFR tijdens de MVB lysosomale sorterings route, terwijl USP8 effectief zou kunnen zijn bij 
het verwijderen van mono/oligo-ubiquitine ketens van EGFR, ERBB2 en ERBB4 onder 
zowel groeifactor-afhankelijke als –onafhankelijke condities tijdens de MVB lysosomale 
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door te gaan. Nog steeds blijf ik het ongelofelijk vinden dat je altijd het juiste artikel in al 
die stapels papier terug kon vinden. 
 Walter, helaas kun je deze dag niet meer meemaken. Je hebt een enorme bijdrage 
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